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ABSTRACT 
 
Nasopharyngeal carcinoma (NPC) is endemic in Southern China and South East 
Asia, causally linked to Epstein-Barr virus (EBV) infection, and frequently shows 
dysregulation in a number of stem cell maintenance signalling pathways. This thesis 
has endeavoured to investigate the status of one of these pathways; the Hedgehog 
(HH) signalling pathway, in NPC tumours, and reveals the novel finding that EBV is 
able to active the HH signalling pathway through autocrine induction of the SHH 
ligand in the C666.1 authentic EBV-positive NPC-derived cell line and latently 
infected epithelial carcinoma cell lines. This study demonstrates that constitutive 
engagement of the HH pathway in EBV-infected epithelial cells in vitro induces the 
expression of a number of stemness-associated genes and imposes stem-like 
characteristics. Using epithelial cells expressing individual EBV latent genes, this 
study also investigates the viral protein responsible for HH dysregulation 
demonstrating that EBNA1, LMP1 and LMP2A are all capable of inducing SHH ligand 
and activating the HH pathway, but only LMP1 and LMP2A are able to induce 
expression of stemness-associated marker genes. These findings not only identify a 
role for dysregulated HH signalling in NPC oncogenesis but also provide a novel 
rationale for therapeutic intervention. 
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CHAPTER ONE: INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
“As ideas are preserved and communicated by means of words, it necessarily follows 
that we cannot improve the language of any science, without at the same time 
improving the science itself; neither can we, on the other hand, improve a science 
without improving the language or nomenclature which belongs to it.” 
— Antoine-Laurent Lavoisier 
Elements of Chemistry (1790), trans. R. Kerr, Preface, xiv-v. 
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1.1 Introduction to cancer 
The earliest evidence of human cancer is found in 1.5 million year old hominid 
remains (Capasso, 2005). Whilst examples of neoplasms are rare in ancient 
populations, early Egyptian mummification has preserved cases of what has been 
interpreted as nasopharyngeal carcinoma (NPC), a disease which is the subject of 
this thesis (Strouhal, 1978). It is estimated that approximately 15% of all 
malignancies endemic to Dynastic Egypt were NPC, a cancer linked to Epstein-Barr 
virus (EBV) infection and exposure to chemical carcinogens, factors that are strongly 
associated with the development of this disease today (Capasso and Mariani-
Costantini, 1994, Capasso, 2005). There are written accounts of possible cancerous 
tumours and growths from many ancient cultures worldwide, dating from a few 
centuries BC back to the Babylonian Code of Hammurabi (1750 BC) (Javier and 
Butel, 2008, David and Zimmerman, 2010). However, our scientific understanding of 
cancer as a disease only began during the early 19th century. The discovery that 
infectious agents, in particular viruses, were linked to the development of certain 
types of cancer led ultimately to the discovery of the first human DNA tumour virus, 
Epstein-Barr virus (EBV), in the 1960s (Epstein et al., 1965). 
 
1.2 The biology of cancer 
Cancer is a disease of deregulated cell growth caused by the accumulation of 
mutations in the cellular genome. These events are generated through heritable 
changes in DNA sequence or epigenetic modification, a process that involves post-
translational modification of histone proteins and gene silencing through DNA 
methylation. Alterations in expression of non-coding RNAs, or cellular microRNAs, 
also regulate gene expression (Sandoval and Esteller, 2012). Collectively, these 
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changes alter the expression of genes regulating cell growth and differentiation, the 
consequence of which is aberrant or uncontrolled cell proliferation. There are over 
200 types of cancer and tumour subtypes identified in humans alone, with tumours 
falling into five categories: carcinoma, sarcoma, leukaemia, lymphoma and myeloma. 
The discovery of oncogenes and tumour suppressor genes, which, when mutated or 
inactivated, lead to a dominant gain or a suppressive loss of function respectively, 
has increased our understanding of the mechanisms involved in deregulated cell 
proliferation (Vogelstein and Kinzler, 2004). It is now well established that multiple 
genetic alterations are responsible for the acquisition of a fully malignant phenotype. 
This multi-step process is supported by the observation that cancer incidence does 
not have a linear relationship with age. Many cancers display an age dependent 
increase in incidence that would suggest the presence of around five rate-limiting 
steps which must be overcome before malignant transformation is achieved (Miller, 
1980, Stephens et al., 2012). In their 2000 review, Hanahan and Weinberg identify 
six classic cellular processes whose dysregulation is required for cell transformation 
and ultimately malignant progression. Cells must achieve self-sufficiency in growth 
signals and insensitivity to anti-growth signals; they must be able to evade apoptosis; 
acquire limitless reproductive potential; invade tissue and become metastatic, and 
hijack adipogenesis to provide sufficient nutrients for continued cell growth (Hanahan 
and Weinberg, 2000). Additional hallmarks are now known to include deregulation of 
cellular genes and the ability to avoid immune destruction, whilst genome instability 
and mutation, and tumour-promoting inflammation and microenvironment can also 
promote oncogenic progression (Hanahan and Weinberg, 2011). The acquisition of 
such mutations and characteristics often occurs spontaneously and sequentially, 
allowing cells with a malignant phenotype to develop over time. 
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1.3 The role of infectious agents in cancer 
The link between infectious agents and cancer has been appreciated for over a 100 
years. Chronic infection with certain strains of mycoplasma, bacteria and viruses has 
been associated with increased cancer risk (Huang et al., 2001, Mager, 2006, Talbot 
and Crawford, 2004). Persistent infection with low virulence mycoplasmas, such as 
Mycoplasma penetrans and Mycoplasma fermentans, is associated with significant 
alterations in host cell gene expression and malignant transformation (Tsai et al., 
1995). Similarly, infection with certain strains of bacteria is linked to increased cancer 
risk, presumably as a result of chronic inflammation and the production of bacterial-
derived metabolites that act as carcinogens. Chronic inflammation and its association 
with a predisposition to cancer development was first observed by Virchow (1858b), 
who suggested chronic irritation could give rise to cellular proliferation and the 
development of cancer (Virchow, 1863). Chronic inflammation gives rise to an 
environment that inhibits apoptosis, induces angiogenesis and compromises cell 
mediated immunity, which is believed to be a pre-requisite for malignant 
transformation (Macarthur et al., 2004). However, the role of inflammation in the 
development of cancer is not clear cut, and acute inflammation has been seen to 
cause tumour regression. Observations by Bruns, in 1866, of an erysipelas bacterial 
infection that cured multiple skin sarcomas led to experiments to show artificial 
erysipelas bacterial infection of sarcoma and carcinoma could cause tumour 
regression (Bruns, 1988, Fehleisen, 1882). Similarly Coley et al., (1991) found that 
repeated infection of malignant tumours with erysipelas bacteria lead to tumour 
regression. Despite these findings it is still recognised that inflammation can be 
tumour promoting, and the recruitment of inflammatory cells can induce cancer cell 
proliferation, invasion and angiogenesis (Grivennikov et al., 2010). 
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1.4 Viruses and cancer 
The link between viruses and cancer was first described by Ellermann and Bang 
(1908) following the discovery that filtered extracts from chicken leukaemia cells 
could pass the disease to healthy non-infected chickens. Similarly, work by Peyton 
Rous in 1909 showed that cell free filtrates purified from chicken fibrosarcomas, were 
able to produce sarcomas when injected into healthy chickens (Rous, 1911). It was 
later discovered that the filterable agent responsible was an RNA retrovirus, 
subsequently named Rous sarcoma virus (RSV). The viral transforming gene 
responsible for promoting sarcoma development (Martin et al., 1979) was 
subsequently identified as v-Src, a constitutively active form of the human c-Src 
proto-oncogene (Martin, 2004). This discovery led to the identification of cellular 
oncogenes, as it was later discovered that many acutely transforming retroviruses 
had acquired cellular proto-oncogenes involved in growth regulation. 
 
The discovery of RSV led to the identification of the first mammalian tumour viruses 
in the 1950s. For a timeline of oncogenic virus discovery please see Figure 1. 1. 
However, it was not until 1960s that the first human tumour virus was discovered by 
Tony Epstein and Yvonne Barr following the visualisation of herpesvirus-like particles 
in a cell line derived from a Burkitt’s Lymphoma (BL), reviewed by (Javier and Butel, 
2008). Human tumour viruses are now known to include the double stranded DNA 
(dsDNA) viruses Epstein-Barr virus (EBV), Hepatitis B virus (HBV), Kaposi-sarcoma 
associated virus (KSHV), high risk Human papillomaviruses (HPV), and the RNA 
retrovirus human T-cell lymphoma virus type I (HTLV-I). Viruses that are associated 
with human cancer are summarised in Table 1. 2 (adapted from McLaughlin-Drubin 
and Munger, 2008). Collectively, these viruses are responsible for an estimated 10-
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20% of cancer incidence worldwide (zur Hausen, 1991, Eckhart, 1998, Kalland et al., 
2009). Table 1. 1 shows the infection-attributed cancer incidence of 2008. For a 
recent review on human oncogenic viruses see (Moore and Chang, 2010). 
 
 
 
Table 1. 1 Infection-attributed cancer incidence (2008)  
(modified from de Martel et al., 2012)  
 
Agent Developing 
countries 
(%) 
Developed 
countries 
(%) 
World (%) 
Hepatitis B virus (HBV)/ Hepatitis C 
virus (HCV) 
32.0 19.4 29.5 
Human papillomavirus (HPV) 30.2 29.2 30.0 
H. pylori 28.9 46.2 32.5 
Epstein-Barr virus (EBV) 5.9 3.9 5.4 
Kaposi sarcoma herpesvirus (KSHV) 2.4 1.0 2.1 
Human T cell lymphotropic virus 1 
(HTVL-1) 
0.0 0.4 0.1 
Liver flukes 0.1 0.0 0.1 
Schistosomes (bladder) 0.4 0.0 0.3 
Total (n) 1.6M 0.41M 2M 
Total for all new cases (%) 22.9 7.4 16.1 
 
 
  
1909
1908
1933
1936
1961
1966 1976
1980
1983
2008
First link between viruses and cancer
Ellerman and Bang demonstrated cell-free 
transmission of avian viral leukaemia
Transmission of avian sarcoma
Rous showed cell free lysates from 
fibrosarcomas could transmit sarcomas. 
Discovery of the first 
mammalian tumour 
virus
Richard Edwin Shope
discovered the cottontail 
rabbit papillomavirus.
Mouse mammary 
tumour virus discovered
John J. Bittner identified an 
extrachromosomaal factor 
transmitted among lab 
mice by breast feeding.
SV40 discovered
Hilman, Sweet, and Eddy 
discover SV40 that was later 
shown to cause tumours in 
hamsters.
Nobel Prize awarded 
Baruch Blumberg’s mid 1960s work 
isolating and characterising Hepatitis B 
wins the Nobel prize in Medicine or 
Physiology.
Discovery of the first oncogene
Identifcation of the Src gene from a 
chicken reterovirus.
HPV16 and HPV18 discovered
Zur Hausen and team discovered two strains of the HPV 
responsible for approx. 70% of cervical cancers. 
HIV described
Luc Montagnier and team discover HIV.
EBV identified as the first 
human tumour virus
Epstein, Barr and Achong identify 
EBV from Burkitt’s lymphoma cells.
HTLV-1 discovered
First human retrovirus, HTLV-1, was 
discovered by Poiesz and Gallo, and 
Mistuaki.
HCV discovered
Houghton and Bradley discover HCV, which has 
since been identified as a major contributor to 
hepatocellular carcinoma.
Nobel Prize awarded
Bishop and Varmus awarded the Nobel Prize in. 
Phisiology or Medicine for therirdiscovery into the 
cellular origin of retroviral oncogenes.
Polyomavirus isolated by 
DTS
Chang and Moore develop 
digitial transcriptome
substraction and isolate 
Merkel cell polyomavirus
fragments.
1953
Murine polyomavirus
isolated
Ludvik Gross isolated the murine
polyomavirus causing salivary 
gland and other tumours in 
newborn mice.
Discovery of first mammalian 
leukaemia virus
Ludvwik Gross reported the first 
murine leukaemia reterovirus.
1951
1962
Adenovirus shown to 
induce tumours
Trentin and colleagues shown 
adenovirus 12 can induce 
tumours in rodents.
Nobel Prize awarded
Nobel prize in Medicine or Physiology awarded to Temin, 
Baltimore and Dubecco for work describing reverse 
trnscription of virus genome.
1967
1970
1975
1979
1981 1984
1988
1992 2006
EBV immortalisation of 
primary lymphocytes
Henle and Henle demonstrate EBV 
infection is sufficient to 
immortalize B lymphocytes
First anti-cancer vaccine
HBV linked to hepatocellular
carcinoma and the HBV 
vaccine was FDA approved.
EBV genome sequenced
The B95.8 EBV genome was sequence, 
comprising 10% of the NCBI database at the 
time.
Discovery of reverse 
transcription 
Baltimore and Temin  
discovered viral 
polymerase and 
evidence of reverse 
transcription.
Discovery of the p53 tumour 
suppressor gene
Identification of p53 protein 
associated with the T antigen of SV40.
Discovery of herpesvirus homologues 
of cellular oncogenes
Analysis of herpesvirus samiri genome 
identifies homologues of cellular 
oncogenes.
HPV anti-cancer vaccine
FDA approve HPV VLP-based anti-
cancer vaccine to reduce the 
incidence of cervical cancer.
Tumour viruses target retinoblastoma 
protein and p53
SV40 and HPV shown to target the retinoblastoma 
protein, HPV p53 associated also identified.
HBV discovered
Brauch Bleumberg
discovered HPV which 
was described as cause 
of hepatitis.
1965
1964
Nobel Prize awarded
The Nobel Prize in Physiology or 
Medicine awarded to Rous and 
Huggins for his work in 1909.
1989 1994
KSHV discovery
Moore and Chang identify KSHV  virus 
sequences leading to the identification of this 
virus as the ‘KS agent’ in Karposi sarcoma and 
related cancers.
 
Figure 1. 1 Timeline of oncogenic virus discovery showing key events in human oncogenic virus research 
Key date in the discovery of oncogenic viruses relating to human cancer. Abbreviations used SV40; Simian Virus 40, EBV; Epstein-Barr 
Virus, HBV; Herpes B Virus, HTLV-1; Human T-cell Lymphotropic Virus, HPV; Human Papilloma Virus, HCV; Herpes C Virus, KSHV; 
Kaposi Sarcoma Herpesvirus. 
Adapted from Moore and Chang (2010) 
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Table 1. 2 Human tumour viruses 
(adapted from McLaughlin-Drubin and Munger, 2008) 
Virus Family Genome Human Tumours 
HUMAN ONCOGENIC VIRUSES 
Hepatitis C virus  
(HCV) 
Flaviviridae dsRNA Hepatocellular carcinoma 
Hepatitis B virus  
(HBV) 
Hepadnaviridae 
Partially 
dsDNA 
Hepatocellular carcinoma 
Epstein-Barr virus  
(EBV) 
Herpesviridae dsDNA 
Nasopharyngeal carcinoma (NPC), 
gastric carcinoma (EBV-aGC), Burkitt’s, 
Immunoblastic Hodgkin’s, post-transplant 
and NK/T-cell lymphomas 
Kaposi’s Sarcoma 
herpesvirus (KSHV) 
Herpesviridae dsDNA 
Kaposi’s sarcoma (KS), primary effusion  
lymphoma, Castleman’s disease 
Human  
papillomavirus (HPV) 
Papillomaviridae dsDNA 
Cervical, oropharynx and other  
anogenital cancers 
Merkel cell virus  
(MCV) 
Papillomaviridae dsDNA Skin cancer 
Human T cell  
lymphotropic  
virus 1 (HTLV-1) 
Retroviridae ssRNA Adult T-cell leukaemia (ATL) 
Human 
immunodeficiency  
virus (HIV-1) 
Retroviridae ssRNA 
Indirectly associated with: 
B-cell lymphoma, Kaposi’s sarcoma 
 
1.4.1 Viruses implicated in cancer 
Whilst oncogenic viruses which express viral oncogenes can contribute directly to 
carcinogenesis, there are a number of viruses that may contribute indirectly to 
oncogenic transformation. For instance, cutaneous HPV types have been implicated 
in the aetiology of skin cancer but there is insufficient mechanistic evidence 
suggesting that they are directly carcinogenic (Bouvard et al., 2009). Human 
immunodeficiency virus (HIV) causes CD4+ T cell depletion which contributes to 
increased cancer risk due to decreased immune surveillance (Tuttleton et al., 2011). 
 
In the polyomaviridae family, the ubiquitous and wide spread JC virus (JCV) and BK 
virus (BKV) have been implicated in the aetiology of human cancer; however, their 
role in carcinogenesis is still debated (Sarid and Gao, 2011). Similarly a potential 
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indirect role for retroviruses in human cancer has been proposed. Human 
endogenous retroviruses (HERVs) have been reported to contribute to a range of 
cancers,  including breast, ovarian, prostate and melanoma, whilst the human 
mammary tumour virus (HMTV) has been implicated in the development of breast 
cancer (McLaughlin-Drubin and Munger, 2008). While current knowledge suggests 
the contribution of these viruses to human cancer is indirect, the future discovery of 
viral oncogenes within cancer cells may point toward a direct role for these viruses, 
and others, in cancer. 
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1.4.2 DNA and RNA viruses 
DNA and RNA viruses are classified into seven categories in the Baltimore 
classification system (Baltimore, 1971). The Baltimore classification and examples of 
human viruses in each group are shown in Table 1. 3. There are 21 different families 
of virus that have vertebrate hosts. This variety and the sheer number of different 
viruses that populate the viral family and sub-family classes demonstrate the success 
of these infectious agents. 
 
Table 1. 3. The Baltimore classification system including examples of human 
viruses 
 
Group Type Example: Family e.g. Genus – species 
I dsDNA viruses 
Herpesviridae e.g. Lymphocryptovirus - 
human herpesvirus 4 (a.k.a. Epstein-Barr virus; 
EBV) 
II ssDNA viruses 
Parvoviridae e.g. Erythrovirus - parvovirus 
B19 
III dsRNA viruses 
Reoviridae e.g. Orthoreovirus – mammalian 
reovirus 
IV 
Positive sense 
ssRNA viruses 
Flaviviridae e.g. Hepacivirus - hepatitis C virus 
V 
Negative sense 
ssRNA viruses 
Paramyxoviridae e.g. Morbillivirus – measles 
virus 
VI 
Reverse 
Transcribing 
RNA viruses 
Retroviridae e.g. Lentivirus - human 
immunodeficiency virus 1 
VII 
Reverse 
Transcribing 
DNA viruses 
Hepadnaviridae e.g. Orthohepadnavirus -
hepatitis B virus 
 
1.4.3 RNA tumour viruses 
RNA viruses, such as HCV, RSV and murine leukaemia virus, mostly contain a single 
stranded (ss) RNA sequence; however, many possess double stranded genomes. 
ssRNA viruses can be classified as positive sense, negative sense or ambisense 
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whereas dsRNA possess both sense and antisense strands (Nguyen and Haenni, 
2003). Positive sense viruses have RNA that can be immediately translated into 
protein whereas negative sense viral RNA has to first be transcribed to positive 
sense (often by a viral encoded RNA polymerase), ambisense viral RNA has regions 
of both positive and negative sense. Retroviruses also possess a ssRNA genome, 
however, these viruses are not classed as ssRNA viruses by the Baltimore 
classification system as they replicate following integration of viral DNA, produced by 
a viral reverse transcriptase, into the host genome (Coffin, 1992). 
 
RNA viruses are associated with a number of human tumours. HCV is a positive 
ssRNA flavivirus that has been associated with some lymphomas and hepatocellular 
carcinomas (Choo et al., 1989), whilst HTLV-I, a positive ssRNA retrovirus, is 
associated with adult T-cell leukaemia (ATL) (Poiesz et al., 1980).  
 
1.4.4 DNA tumour viruses 
The DNA tumour viruses contain viral genomes in the form of DNA. As with the RNA 
viruses there are dsDNA, ssDNA and reverse transcribing DNA viruses (King et al., 
2011). DNA viruses are most often double stranded, replicating using a 
DNA-dependant DNA polymerase. Like reverse transcribing RNA viruses, which 
replicate through a DNA intermediate, there exist DNA viruses that replicate through 
an RNA intermediate. These viruses, including HBV, are classified in a separate 
group, VII, by the Baltimore classification system (Baltimore, 1971). 
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DNA viruses that have been associated with malignant transformation include 
high-risk HPV, EBV, KSHV, and HBV (Inman et al., 2001).  
 
1.4.5 Herpesviruses family 
The Herpesviridae is a large family of DNA viruses that infect vertebrate hosts, and 
are responsible for both human and animal disease. Within this family there are three 
subfamilies: alphaherpesvirinae, betaherpesvirinae, and gammaherpesvirinae. 
 
The alphaherpersvirinae includes the Simplexvirus and Varicellovirus genera. 
Examples of viruses in this subfamily are the human herpes simplex virus (HSV)-1, 
HSV-2 and varicella zoster virus. These viruses are neurotropic, replicate in the 
musocal epithelium, and establish latency in the sensory ganglia of the nervous 
system (reviewed by Smith, 2012). The betaherpesvirinae genera are the 
cytomegalovirus, roseolovirus, and muromegalovirus. Viruses in this subfamily 
include human herpesvirus (HHV)-6 and HHV-7, and murine cytomegavirus (CMV) 
and establish latency in the secretory glands (Chen and Hudnall, 2006). The 
gammaherpesvirinae genera are lymphocryptovirus and rhadinovirus. Viruses in this 
last subfamily include EBV, Herpesvirus saimari (HVS), and KSHV (Damania, 2004). 
Oncogenic herpesviruses, and the human disease with which they are associated, 
can be found in Table 1. 2. 
 
1.5  Epstein-Barr virus (EBV) 
EBV was identified in 1964 (Epstein et al., 1964), following the visualisation of a 
novel herpesvirus-like particle in an electron micrograph of lymphoid cells grown from 
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a Burkitt’s Lymphoma (BL) (Epstein et al., 1965, Henle and Henle, 1966). EBV was 
later associated with other malignancies such as nasopharyngeal carcinoma (NPC) 
where, like endemic BL, NPC patients showed elevated antibodies to immediate 
early and late EBV antigens (Henle et al., 1970). The consistent presence of EBV 
DNA in the neoplastic cells of both BL and NPC implicates a causative role for EBV 
in the pathogenesis of both tumours (zur Hausen et al., 1970, Klein et al., 1974).  
 
Establishment of EBV as a human tumour inducing virus involved experiments on 
marmoset and owl monkeys in which inoculation with EBV was sufficient to induce 
lymphoma in some animals (Epstein et al., 1973, Shope et al., 1973). Additionally, 
EBV is associated with a number of other human malignancies including Hodgkin’s 
lymphoma (HL), lymphoproliferative disorders in immunocompromised individuals, T-
cell lymphomas and EBV-associated gastric carcinoma (EBV-aGC) (Okano, 1998). 
 
1.5.1 The EBV genome 
The EBV genome is a linear, double-stranded 172kb DNA which encodes nearly 100 
viral genes (Kieff and Rickinson, 2007). Upon release from the EBV capsid in the 
host nucleus (Pellet and Roizman, 2007) a covalently closed episome is generated 
through fusion of terminal repeat (TR) sequences (Adams and Lindahl, 1975, Kintner 
and Sugden, 1979, Raab-Traub and Flynn, 1986). The linear form of EBV DNA has 
variable numbers of these direct tandem 0.5kb repeats at each terminus, as well as 
3kb internal repeat sequences which in combination serve to effectively divide the 
genome into unique long and short regions (Hayward et al., 1980). There are two 
major EBV types, Type-1 (prevalent worldwide) and Type-2 (common in parts of 
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Africa), which are distinguished by their EBV nuclear antigen 2 (EBNA2) sequences 
(Tzellos and Farrell, 2012). 
 
The prototype EBV strain B95-8, which has a 11.8kb deletions compared to other 
EBV stains (Parker et al., 1990), was the first human herpesvirus genome to be fully 
cloned and sequenced (Baer et al., 1984), and regions of the EBV genome were 
designated by their position on a BamHI restriction endonuclease map (Murray and 
Young, 2001) (Figure 1. 2). The expression pattern of EBV genes in NPC, and the 
role of expressed latent proteins in the manipulation and dysregulation of cellular 
signalling are covered later in this chapter.  
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Figure 1. 2. The EBV Genome 
(A) Showing the EBV dsDNA episome. Exons encoding EBV latent proteins are 
marked, under respective promoters, with direction of transcription. The terminal 
repeat region (pink) is required from LMP2 gene transcription and is generated 
through re-circularisation of the EBV genome upon terminal repeat fusion. OriP 
(orange) is the origin of EBV replication. (B) B95-8 EBV prototype BamHI restriction 
endonuclease map showing the location of the EBV latent proteins open reading 
frames. Fragments labelled A-Z in descending size order. 
 
Figure from: Young, L.S. & Rickinson, A.B. (2004)  
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1.5.2 EBV biology 
EBV is a ubiquitous virus infecting the vast majority (greater than 90%) of the world’s 
population asymptomatically (Babcock et al., 1998, Cohen, 2000). Infection of naïve 
individuals occurs early in childhood and is usually asymptomatic; however, infection 
in developed countries often occurs following early adolescence and is associated 
with symptomatic disease presenting with clinical features of infectious 
mononucleosis (IM) (Vetsika and Callan, 2004).  
 
As with other herpesviruses, EBV demonstrates a biphasic life cycle, adopting both 
lytic and latent forms of infection. Latent infection in B-cells is complex and linked to 
the state of B-cell differentiation. To date, at least four latency states have been 
identified (Young and Rickinson, 2004). In latently infected memory B-cells, the site 
of long-term persistence, expression of viral transcripts is severely restricted to the 
non-coding RNAs; the so-called Latency 0 program. The lack of expression of EBV 
protein products allows the virus to evade the host immune system (Rickinson and 
Kieff, 2007). Viral latency states are discussed in section 1.7. Replication of the virus 
requires lytic induction with the expression of over 80 viral protein products that leads 
to the production and release of new, infectious viral particles. This lytic induction 
appears in both the B-cells and epithelial cells (Kieff and Rickinson, 2007); indeed, 
there is evidence that the epithelial tissue is EBV’s natural site of replication, 
occurring even in healthy individuals, and is believed to have a role in virus 
amplification prior to shedding (Stetler-Stevenson et al., 1997). Peripheral infected B 
lymphocytes will undergo periodic reactivation when circulating through the 
oropharynx producing new virions, by amplifying the genome more than 100-fold 
(Contreras-Brodin et al., 1991). These virions are shed into the saliva, allowing for 
Introduction 
17 
 
Chapter 1 
the spreading of infection through person-to-person contact (Kieff and Rickinson, 
2007). The transmission of EBV through the saliva, as the main vehicle for 
transferral, is followed by a symptomatic disease in naϊve individuals which is 
affectionately known as “The Kissing Disease”. EBV can also be transmitted via 
organ and bone marrow transplantation (Cen et al., 1991, Haque et al., 1996, Teira 
et al., 2006). 
 
Lytic replication is induced by the simultaneous expression of BamHI Z fragment 
leftward open reading frame 1 (BZLF1) and BamHI R fragment leftward open reading 
frame 1 (BRLF1), two immediate-early (IE) genes that encode transcription factors 
Zta and Rta respectively (Baer et al., 1984). These two transactivators are both 
required for lytic DNA replication; however, they can both induce lytic reactivation 
(Feederle et al., 2000). Lytic induction triggers the temporal, and ordered cascade of 
viral gene expression; early (E) genes, required for viral DNA replication and 
nucleotide metabolism, and subsequent late (L) viral genes, which support viral DNA 
amplification and produce the structural components required for viron packaging 
(Pellet and Roizman, 2007, Kieff and Rickinson, 2007). 
 
The induction of lytic replication appears to be differentiation dependent, induced in 
vivo in B lymphocytes by the differentiation of memory cells into plasma cells 
(Laichalk and Thorley-Lawson, 2005) and in squamous epithelial cells, where virus 
replication is linked to the keratinocyte differentiation programme. Indeed, in situ 
hybridisation (ISH) for EBV DNA in oral hairy leukoplakia (OHL), a benign 
hyperproliferative disease caused by opportunistic EBV infection in 
immunosuppressed acquired immunodeficiency syndrome (AIDS) and post-
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transplant patients, is found only in the upper, terminally differentiated layers of the 
tongue (Niedobitek et al., 1991). Furthermore, OHL demonstrated differentiation 
associated BZLF1 expression (Young et al., 1991). In vitro studies using the 
differentiation-competent SCC12F cell line showed that the BZLF1 promoter was 
found to contain an differentiation-specific response element that was activated in 
response to terminal differentiation (Karimi et al., 1995). 
 
1.6 EBV infection of B-cells and epithelial cells 
1.6.1 EBV infection of B-cells in vitro 
Infection of B-cells and epithelial cells in vitro occurs through distinct mechanisms. 
EBV infection of B-cells requires binding of the major capsid glycoprotein gp350, to 
the known EBV receptor CR2 (CD21) on the B-cell surface. Membrane fusion is then 
initiated through the binding of gp42 to major histocompatibility complex (MHC) class 
II molecules (Iizasa et al., 2012). 
 
Much of our understanding of the biology of EBV relates to its interaction with 
B-lymphocytes. Indeed, the B-lymphotropic nature of EBV is borne out by findings 
that EBV can readily infect and transform normal resting B-lymphocytes in vitro into 
lymphoblastoid cell lines (LCLs), which are capable of indefinite proliferative growth 
(Henderson et al., 1977, Miller, 1984). 
 
1.6.2 EBV infection of epithelial cells in vitro 
Whilst the generation of EBV infected B-lymphocytes is a relatively easy process, 
infection of epithelial cells in culture is problematic, attributed in part to the lack of the 
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known EBV receptor, CR2 (CD21) (Nemerow et al., 1985). In contrast to B-cells, 
epithelial cell infection appears to be gp350/220 independent and therefore does not 
require CR2. Studies with cell free infectious virus show infection requires the binding 
of BMRF2 to cell surface integrins; binding of gH/gL to αvβ5 initiates fusion with the 
plasma membrane. Interestingly, gp42 actually impedes epithelial cell infection 
(reviewed in Odumade et al., 2011). Whether the same molecules play a role in 
B-cell to epithelial cell “transfer” infection is currently unknown.  
 
However, epithelial cells stably expressing CR2, although amenable to infection, 
quickly lose the virus, perhaps reflecting a propensity of this cell type to adopt a lytic 
rather than a latent form of infection in vitro (Knox et al., 1996, Li et al., 1992). In 
recent years it has become possible to stably infect a range of epithelial cell lines 
with recombinant forms of EBV (rEBV) through co-cultivation with Akata BL cells 
replicating EBV or primary B-cells coated with EBV particles (Imai et al., 1998, 
Shannon-Lowe et al., 2006). However, the fact that only a small proportion of cells 
are amenable to infection, whilst most lose the EBV genome upon cell line 
generation, suggests that only a sub-population of cells can support a stable latent 
infection (Li et al., 1992). These findings support the existence of distinct populations 
of cells within these cell lines, which differ in their biological properties relating to their 
ability to support stable latent infection (Li et al., 1992). Furthermore isolated EBV 
infected clones have been shown to be slowly cycling and fail to respond to inducers 
of terminal differentiation (Tsao et al., 2012). 
 
Additional methods of infection are likely to exist in vivo; studies involving EBV 
infection of gastric carcinoma cell lines, which are negative for the CR2 receptor, 
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showed these cells are amenable to infection through a mechanism independent of 
CR2 (Yoshiyama et al., 1997). It was thus discovered that cell-cell contact has an 
important role in the infection and spread of the virus in epithelial cells. Studies by the 
Takada lab, in 1998, showed that co-cultivation of epithelial cells with recombinant 
EBV producing B-cells, produced low level infection at rates roughly 800 times that of 
non-co-cultivated cells. However, few of these acutely infected cells could give rise to 
EBV positive cell lines and of the cell lines produced only one showed NPC-like 
latency II viral protein expression whilst the other showed LCL-like latency 
expression program III (Imai et al., 1998). 
 
It has been postulated that EBV may only be able to establish a stable latent infection 
in an undifferentiated or more primitive epithelial cell environment. This is supported 
by studies showing that only undifferentiated NPC or adenocarcinoma cell lines give 
rise to stable EBV infection highlighting the need for an undifferentiated cellular 
environment for the establishment of persistent latent infection (Knox et al., 1996, 
Tsao et al., 2012). NPC tumour cells are found to express B-cell lymphoma 2 (BCL2), 
∆Np63 and B lymphoma Mo-MLV insertion region 1 homolog (BMI1) (Lu et al., 1993, 
Song et al., 2006, Fotheringham et al., 2010), a phenotype reminiscent of the cells 
residing in the basal layer of stratified squamous epithelium. It has thus been 
hypothesised that the population of cells originally establishing a latent infection in 
undifferentiated NPC, and gastric carcinoma, are either the adult stem cell pool or 
cells that harbour a stem cell/basal cell like phenotype. The possibility that stem cells 
could undergo malignant transformation into tumour initiators in cancer goes partway 
to explaining the activity of diverse developmental signalling pathways, increased 
DNA repair and ABC transporter-mediated drug efflux. It would seem possible that 
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instead of acquiring these attributes over time, slowly converting a differentiated cell 
towards a phenotype more commonly associated with stem cells, the generation of 
oncogenic potential may happen in a cell which already has these properties. 
 
1.6.2.1  EBV infection and persistence in vivo 
To establish long-term latency in the infected host, EBV has evolved a strategy to 
exploit the B-cell differentiation programme. EBV adopts a number of latency 
programmes which facilitate entry of EBV-infected B-cells into the long-lived memory 
B-cell pool; the site of long-term persistence (Babcock and Thorley-Lawson, 2000).  
 
During initial infection, virus enters lymphoid tissue within the Waldeyers ring 
(pharyngeal lymphoid tissue), where it crosses the surface epithelium to infect naïve 
B-cells, activating them into proliferating blasts through the expression of the 
so-called “growth program”. This latency program (Latency III), is associated with the 
expression of 10 viral genes, which include two non-translated RNAs; EBV encoded 
RNA 1 and 2 (EBER1/2), six nuclear proteins; EBNA1, 2, 3A, 3B, 3C, LP, three 
membrane proteins; latent membrane protein 1, 2A and 2B (LMP1, LMP2A/2B), 
BamH1-A reading frame 1 (BARF1) early lytic gene and a family of microRNAs 
encoded within the BamH reading frame 1 (BHRF1) and BamA rightward transcripts 
(BARTs) (Riley et al., 2012). Transit of these blasts into the germinal centre allows 
cells to undergo a germinal centre reaction and the antigen-driven somatic 
hypermutation of their immunoglobulin genes. In the germinal centre, latently infected 
cells switch to the so-called “default program” where viral gene expression is 
restricted to EBNA1, LMP1, LMP2A/2B and expression of the non-coding EBER1/2 
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and BHRF1 and BART miRNAs. Upon exiting the germinal centre as memory B-cells, 
latently infected cells either express EBNA1 and the non-coding EBER1/2, and 
BHRF1 and BART miRNAs (the EBNA1 only programme) or the non-coding 
EBER1/2, and BHRF1 and BART miRNAs in the absence of any viral proteins 
(Latency 0). The latter is considered to be the site of long-term persistence as these 
latently infected cells are quiescent and invisible to the immune system. A proportion 
of latently infected B-cells are induced into lytic cycle in response to terminal 
differentiation signals, with cells differentiating into plasma cells. At this stage, 
transient infection of squamous pharyngeal epithelium is thought to occur, amplifying 
the release of infectious virus. Whether, latent infection of epithelium plays a role in 
EBV persistence is still unknown (reviewed by Thorley-Lawson and Gross, 2004). 
The EBV latency programs and the gene products expressed in these states are 
shown in Table 1. 2 (Young and Rickinson, 2004). Also included are the known EBV-
associated malignancies and the latency states adopted in these cancers. 
 
Table 1. 4. Types of EBV latency and associated malignancies 
 
Latency 
Type 
Latent Products Expressed Associated Malignancies 
I 
EBNA1 expression mediated 
through the Qp promoter, EBERs, 
and BART RNAs 
Burkitt’s lymphoma 
II 
Default 
EBNA1 (Qp), LMP1, LMP2A, 
LMP2B , EBERs, and BART 
RNAs 
Nasopharyngeal Carcinoma, 
Hodgkin’s and EBV-positive T-
cell lymphomas 
III 
Growth 
EBNA1-6 mediated through 
Wp/Cp, LMP1, LMP2A, LMP2B, 
and EBERs. 
Post-transplant 
lymphoproliferative disorders 
0 
EBERs and BART RNAs. 
Perhaps additional expression of 
LMP2 and EBNA1 
Proposed to occur in peripheral 
resting memory B-cells 
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1.7 Latency programs in EBV-associated malignancies 
The latency program adopted in EBV-associated malignancies is most likely dictated 
by the state of cell differentiation and controlled by tissue and/or cell-type-specific 
transcription factors. With the exception of post-transplant lymphoproliferative 
disorder (PTLD), all known EBV-associated malignancies display a restricted form of 
EBV latency, with the majority displaying a Latency II or default latency program. The 
latency I program is characteristic of endemic BL, where viral gene expression is 
limited to Qp promoter-driven expression of EBNA1, and expression of EBER1/2 and 
BHRF1 and BART-encoded miRNAs. Latency II, also referred to as the default 
programme, is characteristic of NPC, EBV associated gastric carcinoma (EBV-aGC), 
Hodgkin’s disease and certain EBV-positive T-cell lymphomas. Here viral gene 
expression is restricted to Qp-driven EBNA1 and variable expression of LMP1 and/or 
LMP2A/2B and expression of EBER1/2 and BHRF1 and BART-encoded miRNAs. 
The latency III, or growth programme, as exemplified in vitro by LCLs, is also 
observed in PTLD. Here, the full complement of latent genes are expressed, with 
Cp/Wp-driven EBNA1, 2, 3A, 3B, 3C and LP, high levels of LMP1 and LMP2A/2B, 
and expression of EBER1/2, and BHRF1 and BART-encoded miRNAs. Whilst these 
classifications work as a general rule of thumb there are exceptions; an additional 
“Wp-restricted” latency has been reported in a subset of BL tumours, which harbour 
an EBNA2 deletion (Kelly et al., 2002). 
 
The function of products seen in a type II latency program, the expression profile 
which is associated with NPC, will be discussed later in this chapter. 
 
Introduction 
24 
 
Chapter 1 
1.7.1 EBV associated lymphoma malignancies 
EBV infection is implicated in the aetiology of B-cell lymphomas; BL, Hodgkin’s 
lymphoma (HL), PTLD and immunoblastic lymphoma, and an T/NK-cell malignancy 
that is caused by the expansion of transformed EBV-positive T-cells (Epstein et al., 
1964, Ziegler et al., 1982, Weiss et al., 1989, Shapiro et al., 1988, Jones et al., 
1988).  
 
1.7.1.1 Burkitt’s lymphoma (BL) 
EBV was first discovered in a case of BL, a lymphatic cancer (Epstein et al., 1964). 
BL is a non-Hodgkin’s lymphoma which is classified into three forms: endemic, 
sporadic and AIDS-associated. The endemic form is seen in equatorial Africa and 
displays a strong association with EBV infection and the geographical distribution of 
malaria. Endemic BL shows typical symptoms of rapid aggressive swelling of the jaw 
and facial bone. The sporadic form is less associated with EBV, between 10-20% are 
EBV positive, and more commonly involves distal ileum, cecum, ovaries, kidney or 
the breast (Epstein and Achong, 1979). BL is also associated with HIV infection, the 
AIDS-associated form of the disease that occurs in the early stages of HIV 
immunosuppression (Beral et al., 1991), as well as acute lymphoblastic leukaemia, 
and is seen in post-transplant patients owing to an impaired immune system. All 
forms of BL contain a chromosomal translocation that results in oncogenic cMYC 
deregulation (Rickinson and Kieff, 2007, Gutierrez et al., 1992). Around 70-80% of 
patients demonstrate the hallmark t(8;14)(q24;q32) translocation causing the 
juxtaposition of the MYC gene to enhancer element of the heavy chain 
immunoglobulin gene. Other translocations seen in this disease, t(2;8)(p:12;q24) and 
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t(8;22)(q24;q11), place MYC under the kappa and lambda light chain enhancer 
element control respectively (reviewed in Molyneux et al., 2012). 
 
1.7.1.2 Hodgkin’s lymphoma (HL) 
HL can be classified as one of four subtypes of which one, the mixed-cellularity 
subtype – a common form of this disease – is strongly associated with EBV infection. 
In 1966, MacMohon first proposed an infective aetiology for this disease (MacMahon, 
1966). Whilst the mechanism behind how EBV gives rise to oncogenic transformation 
in this disease is not fully understood, it is now known that EBV positive HL accounts 
for between 20-50% of cases in Europe and Northern America, and a substantially 
higher percentage of cases occurring in underdeveloped countries. Indeed, up to 
100% EBV positivity has been reported in tumours from populations within Kenya 
and Peru. Hodgkin’s lymphoma and its association with EBV are reviewed by (Flavell 
and Murray, 2000).  
 
1.7.1.3 Post-transplantation lymphoproliferative disorders (PTLDs) 
EBV is also associated with lymphomas which arise in immunosuppressed 
individuals as a result of impaired EBV-specific cellular immune responses. Most 
PTLDs are B-cell lymphoproliferative disorders associated with EBV infection; 
however rare T-cell lymphoproliferations, that are less commonly associated with 
EBV, are occasionally reported after renal transplantation (Frias et al., 2000). 
Approximately 90% of all PLTDs are reported to be EBV positive (EBV-PTLD), which 
demonstrate a type III latency program, expressing all EBV latent gene products, that 
is also seen in lymphoblastoid B-cell lines, and lymphomas occurring as a result of 
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congenital immunodeﬁciency or acquired immunodeﬁciency syndrome (AIDS) 
(Gottschalk et al., 2005). 
 
1.7.1.4 T and natural killer cell lymphomas 
EBV is primarily a B lymphotropic virus; however, it is also capable of infecting a 
number of other cell types including T-cells and epithelial cells. Whilst EBV is 
associated with a number of T-cell lymphomas, it is thought to be play an important 
role in the aetiology of peripheral angioimmunoblastic T-cell lymphoma (AITL) and 
extra nodal nasal type T/NK-cell lymphoma (Carbone et al., 2008). AITL is the most 
common peripheral T-cell lymphoma, accounting for around 1-2% of all non-
Hodgkin’s lymphomas (Jarrett et al., 2006), displaying EBV positive B-lymphocytes 
and B immunoblasts, and rarely non-neoplastic T-cells. EBV infection is seen only in 
a sub-population of cells in this lymphoma, and as such is believed to occur 
subsequent to oncogenic transformation, or is not required by and lost from 
malignant cells (Carbone et al., 2008). Nasal type T/NK-cell lymphoma are found in 
the nasal and upper aerodigestive passage and are strongly associated with EBV 
infection, demonstrating an NPC-like latency gene expression pattern and increased 
expression of EBV-induced genes (Chiang et al., 1996a, Huang et al., 2010b).  
 
1.7.2 EBV associated epithelial malignancies 
Whilst the association of EBV infection with tumours of lymphoid tissue is well-
established, the virus is also implicated in the aetiology of certain epithelial tumours; 
namely, undifferentiated NPC, a proportion of diffuse gastric adenocarcinoma 
(EBV-aGC) and a subset of rare lymphoepithelia-like carcinomas (LELC) of the 
Introduction 
27 
 
Chapter 1 
salivary gland, lung, thymus, gastric and intra-hepatic biliary epithelium (Hippocrate 
et al., 2011). However, unlike the situation in B lymphocytes, comparatively little 
known about the interaction between EBV and normal epithelial cells or the role that 
EBV plays in the transformation of these epithelial cell types.  
 
It is postulated that the establishment of latent EBV infection in epithelial tissue may 
promote malignant transformation (Herbst and Niedobitek, 2006). Whilst there is an 
obvious association of EBV with NPC, the links between EBV and gastric cancer, 
salivary gland and Lymphoepithelial-like carcinomas (LELC) are much weaker. Whilst 
both NPC and EBV-aGC carry monoclonal viral genomes (Raab-Traub and Flynn, 
1986, Imai et al., 1994), suggesting that EBV infection must have occurred prior to 
the expansion of the final malignant clone, the stage at which EBV participates in the 
carcinogenic process is currently unknown but is discussed in the context of NPC in 
the following section.  
 
1.7.2.1 Nasopharyngeal Carcinoma (NPC) 
NPC is a tumour of the mucosal epithelium of the nasopharynx (Regaud, 1921, 
Schmincke, 1921) that is associated with a number of genetic and dietary factors 
(e.g. preserved foods that are high in nitrosamines) (Yu and Yuan, 2002). While 
endemic to parts of South-East Asia and China, NPC displays medium incidence 
rates in parts of North Africa, the Mediterranean basin and Greenland, and overall 
has low worldwide incidence (Yu and Yuan, 2002) as seen in Figure 1. 3. It is 
estimated that 84,400 new cases of NPC occurred in 2008 with 51,600 deaths 
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(mortality to incidence ratio of 0.61) representing 0.7% of the global cancer burden 
and making NPC the 24th most common cancer worldwide (Jemal et al., 2011). 
 
 
 
Figure 1. 3. Global NPC incidence 
The GLOBOCAN2008 maps for NPC incidence in (A) male and (B) female. 
From Sun et al., (2011) 
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There are two main types of NPC as defined by the World Health Organisation 
(WHO); keratinising squamous cell carcinoma (Type I) and non–keratinising 
squamous cell carcinoma (differentiated; Type II, and undifferentiated; Type III) (Wei 
et al., 2011). It is non-keratinising Type II and III that show a strong association with 
EBV latent infection; EBV is not generally associated with Type I NPC (Neel et al., 
1983, Pathmanathan et al., 1995). 
 
NPC was first associated with EBV following the finding that the high antibody titres 
to the EBV-associated immediate early/late structural antigens are seen in 
serological studies from BL patients were also present in individuals with NPC (Old et 
al., 1966, Henle et al., 1970, Henle and Henle, 1976). This association was later 
confirmed with the discovery of clonal EBV genomic DNA in the neoplastic cells of 
NPC (Wolf et al., 1975, Andersson-Anvret et al., 1977). Furthermore, latent EBV 
infection, as detected by in situ hybridisation to the viral EBER RNAs, has been 
demonstrated in almost 100% of type II and type III tumours (Raab-Traub et al., 
1987). Latent infection with EBV is postulated to play a critical function in the 
aetiology of non-keratinising NPC, with tumour cells showing the presence of 
monoclonal EBV episomes indicating that EBV infection must have occurred prior to 
expansion of the final malignant clone (Raab-Traub and Flynn, 1986, Raab-Traub, 
2002). EBV is not normally found in histologically normal nasopharyngeal epithelium 
(Sam et al., 1993) and is also absent from the abundant lymphomal infiltrate seen in 
Type III undifferentiated NPC. 
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Undifferentiated carcinomas that show similar characteristics to Type III NPC exist as 
carcinomas of the tonsils, lungs, thymus, stomach, skin and cervix. These 
carcinomas are referred to as undifferentiated carcinomas of nasopharyngeal type 
(UCNT). EBV association with other UCNTs has been investigated and, whilst 
undifferentiated stomas carcinomas show a high degree of EBV infection (Shibata et 
al., 1991), other UCNTs are not seen to be consistently EBV positive (Fujii et al., 
1993, Raab-Traub et al., 1991, Weinberg et al., 1993, Dadmanesh et al., 2001). 
 
The role of EBV in the pathogenesis of NPC is still being elucidated; disease 
progression involves multiple mutational and epigenetic events, seen to occur 
frequently at progressive stages of the disease (reviewed by Lo, et al., 2013). These 
events can be seen in Figure 1. 4 (Young and Rickinson, 2004) where it is proposed 
that EBV latent infection occurs in a low-grade pre-invasive lesion that will support 
EBV latent infection, and leads to further cell deregulation and ultimately NPC.  
 
Genome wide alleleotyping has identified allelic deletions of numerous chromosomes 
implicated in NPC pathogenesis; of these, 3p, 9p and 14p are detected in 85% of 
primary tumours (reviewed by Lo et al., 2012). Tree models investigating the order of 
transformational events in NPC have identified the 3p deletion and chromosome 12 
gain as early event in NPC pathogenesis whilst also finding evidence that two 
pathways to cellular dysregulation may exist; the first involving loss of 9p and 13q 
with the gain of 1q, and the second loss of 14q, 16q, 9q and 1p (Shih-Hsin Wu, 
2006). Allelic imbalances allow the inactivation of tumour suppressor genes and 
overexpression of oncogenes; for instance commonly deleted regions 9p21 and 
3p21.3 contain tumour suppressors p15, p16 INK4/ARF and DAPK1, and RASSF1A 
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and RARβ2 genes respectively, whilst overexpression of cyclinD1, which is present 
in over 90% of NPC primary tumours, can be achieved through amplification of 
11q13.3 (Lo et al., 2012). 
 
Epigenetic inactivation of the RASSF1A and p16 tumour suppressors is also 
achieved through hypermethylation allowing progression towards dysplastic 
nasopharyngeal epithelium. Indeed, inactivation of p16 or overexpression of cyclinD1 
is believed to be required for cell proliferation and establishment of a stable latent 
EBV infection (Tsang et al., 2012). Hypermethylation of other genes including CHRF, 
RIZ1, WIFI, TIG1, THY1 and many more have been reported in NPC, of which the 
former three, in conjunction with p16 and RASSF1A hypermethylation, have been 
proposed as a means of early NPC detection (Hutajulu et al., 2011). 
 
Other early modifications that contribute to the initial establishment of a low-grade 
pre-invasive phenotype include BCL2 overexpression, telomerase dysfunction and 
nuclear factor kappa-light-chain-enhancer of activated B-cells (NFκB) activation. 
Whilst this cell signalling activation occurs via a 12p13.3 amplicon, further cell 
signalling dysregulation occurs following EBV infection with LMP1 and LMP2A driven 
proliferation and transformation (Lo et al., 2012). Figure 1. 4 shows the current theory 
behind NPC pathogenesis detailing the key events in oncogenic transformation. 
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Normal
epithelium
→ LMP1/ LMP2A driven clonal expansion and transformation
→ BMI1 induction via LMP1
→ Dysregulation of cellular signaling pathways                    
(Wnt/β-catenin, TFGβ, Notch and Hedgehog)
Latent EBV infection of dysplastic epithelial cells
→ LOH on chromosomes 3p and 9p
→ Chromosome 12 gain
→ BCL2 overexpression
→ Telomerase dysfunction
Low-grade
pre-invasive
High-grade
pre-invasive
Nasopharyngeal 
carcinoma
→ Hypermethylation of 9p21 (p16) and 3p21.3 (RASSF1A)
→ CyclinD1 overexpression
→ NFκB activation
Metastasis
→ Further allelic imbalances involving at 
chromosomes 1q, 7q, 11q, 12q, 13q, 14q, 
and 16q 19p and 19q.
→ Further aberrant promoter methylation
→ Inactivation of E-cadherin
→ p53 mutation
 
 
 
 
 
Figure 1. 4. Schematic showing the current theory behind NPC pathogenesis 
Multiple mutational and epigenetic modifications accompany EBV infection and cell 
signalling dysregulation in the onset of NPC. Mutational modifications include 
chromosomal imbalancing, the mutation of cell cycle modulators, cyclinD1 and p53, 
and other cell maintenance proteins, BCL2 and E-cadherin, and loss of telomerase 
function. Epigenetics modifications (presented in blue), involving the 
hypermethylation of gene promoter regions, and the dysregulation in multiple cell 
signalling pathways (green) is also observed. 
 
Adapted from Young and Rickinson (2004) and Lo, Chung and To (2012) 
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1.7.2.2 EBV-associated Gastric Carcinoma (EBV-aGC) 
Like NPC, gastric carcinoma (GC) is an epithelial malignancy that is frequently 
associated with EBV. It was estimated that 989,600 new cases of stomach cancer 
occurred in 2008, representing 8% of global cancer incidence and 10% of total 
deaths (mortality to incidence ratio 0.75) (Jemal et al., 2011). Whilst EBV positive 
gastric carcinoma (EBV-aGC) has been reported to account for around 10% of 
worldwide GC incidence (Strong et al., 2013), the number of cases of GC per year 
means there is a greater incidence of EBV-aGC than NPC.  
 
EBV-aGC is a non-endemic disease, with incidence throughout the world, but like 
EBV positive NPC EBV-aGC shows substantial geographic variation thought to be 
caused by ethnic and genetic differences (Lee et al., 2009, Murphy et al., 2009). The 
highest proportion of EBV-aGC to non EBV-aGC occurs in Germany and the USA, 
with 18% and 16% respectively (Takada, 2000). EBV-aGC was originally proposed to 
display the same latency II program as NPC; however, early studies were unable to 
demonstrate LMP1 expression, as such, viral gene expression was proposed to more 
closely represent a latency I program, as observed in Burkitt’s lymphoma, with 
occasional, additional expression of LMP2A at low levels (Imai et al., 1994, Sugiura 
et al., 1996). A more recent study of EBV expression in EBV-aGC was able to detect 
very low expression of LMP1, in addition to LMP2 and other EBV latent genes, and 
identified EBV positivity in 17% of 71 GC cases (Strong et al., 2013). Additionally this 
study identified two distinct forms of EBV infection; less than 200 EBV reads per 
sample and more than 30,000 EBV reads per sample, which the authors suggest 
should be considered functionally different in relation to therapeutic intervention and 
clinical responsiveness (Strong et al., 2013). Further regard for the EBV status of GC 
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is required to direct therapeutic intervention for EBV-aGC as a separate disease to 
EBV negative GC. EBV-aGC are more commonly hypermethylated, and 
demethylating agent inducing EBV lytic replication may result in the lysis of stable 
infected GC cells (for a review see Iizasa et al., 2012). 
 
1.7.2.3 Lymphoepithelioma-like carcinomas (LELCs) 
In addition to NPC and gastric cancer, EBV is also linked to the development of 
LELCs of the salivary gland, lung, thymus, and intra-hepatic biliary epithelium 
(Hippocrate et al., 2011). LELCs have histopathological features similar to 
undifferentiated NPC, but the low incidence of LELC at sites other than the 
nasopharynx and gastric epithelium means the EBV status and viral contribution to 
these cancers is still being investigated. Interestingly the EBV positivity of LELCs 
around the body appears to differ greatly; in a study of 32 cases of lung LELC in 
southern China 94% showed EBER positivity, compared to 0% of non-LELC lung 
cancers, suggesting a causal link between EBV and the disease (Han et al., 2000), 
whereas EBV in situ hybridisation was negative in all 35 cases of urinary tract LELCs 
(Mori et al., 2013). In breast cancer EBV positivity has been reported in between 10-
51% of tumour samples but with less than one in a thousand cells harbouring EBV 
the contribution of the virus to disease progression, if any, is likely to be very different 
from that seen in NPC or EBV-aGC (Hippocrate et al., 2011). 
 
1.8 EBV gene expression and the pathogenesis of NPC and EBV-aGC 
Unlike B-cells, EBV infection of epithelial cells is not associated with growth 
transformation. It is now generally accepted that epithelial cell infection with EBV is 
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associated with lytic replication and the loss of the viral genome. This is exemplified 
in studies on OHL in vivo and EBV: epithelial-cell infection systems in vitro 
(Greenspan et al., 1985, Tsao et al., 2012). It has been postulated that NPC or 
EBV-aGC development occurs as a result of EBV infection of initiated or pre-
neoplastic epithelia cells (Greenspan et al., 1985), which are impaired in their ability 
to differentiate. While evidence for this is still controversial, in vitro studies show that 
stable, latently EBV-infected clones of squamous differentiation-competent 
SV40-immortalised keratinocytes have lost their ability to differentiate (Li et al., 1992, 
Knox et al., 1996). 
 
Like other EBV-associated malignancies, with the exception of PTLD, viral gene 
expression is restricted in both lymphoid (BL, HL, T/NK) and epithelial malignancies 
(NPC, EBV-aGC), with tumours displaying a latency II or default programme. In this 
form of latency, viral gene expression is restricted to EBNA1, LMP1, LMP2A/2B, 
BARF1 and the non-coding EBER1/2 and BART-derived miRNAs. Numerous in vivo 
and in vitro studies have shown that all of these gene products can impact on 
epithelial cell biology (Frappier, 2012, Dawson et al., 2012, Takada, 2012, Lung et 
al., 2013). The biological properties of these proteins and RNAs are discussed in the 
following section. 
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1.9 EBV latent proteins 
1.9.1 Latent membrane protein 1 (LMP1) 
LMP1 is an approximately 62kDa, six membrane spanning, integral membrane 
protein that localises to lipid raft domains within the plasma membrane and to 
intracellular endosomes. LMP1 possesses a short cytoplasmic N-terminal and longer, 
200 amino acid, cytoplasmic C-terminal containing three functional signalling 
domains (CTAR1, CTAR2, and CTAR3) (the structure of LMP1 is reviewed in 
Meckes Jr and Raab-Traub, 2011). The structure and signalling domains of LMP1, 
and signalling proteins that engage with the dimerised form of this EBV latent protein 
are depicted in Figure 1. 5 (reproduced from Dawson et al., 2012). 
 
LMP1 was the first EBV latent protein found to possess oncogenic properties, 
transforming established rodent fibroblast cell lines in vitro and rendering them 
tumourigenic in vivo (Wang et al., 1985). LMP1 plays a critical role in B-cell 
transformation, as naive B-cells infected with a recombinant rEBV deleted for LMP1 
are not transformed in vitro (Kaye et al., 1993). And, with the exception of endemic 
BL, most EBV positive B-cell cancers express LMP1 (Young et al., 1989). This 
contrasts with NPC where expression appears to be both variable and 
heterogeneous (Tsao et al., 2002). Whilst early RT-PCR-based studies identified 
expression of LMP1 at the mRNA level in between 80-92% of NPC samples (Brooks 
et al., 1992; Chen et al., 1995), immunohistochemical (IHC) staining studies did not 
corroborate these findings, identifying expression of LMP1 at the protein level in 
anywhere between 20–100% of cases. Here, LMP1 expression can be uniform or 
patchy, and display low, intermediate or high levels of expression (Khabir et al., 
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2005, Chen et al., 2010). More recent studies support these early observations and 
show that LMP1 expression is extremely variable, in the range of 20-65% of samples 
(Lo et al., 2013, Chen et al., 2012). These findings have raised questions regarding 
the role that LMP1 plays in the pathogenesis of NPC 
 
LMP1 has pleiotropic effects when expressed in epithelial cells, inducing 
morphological change, a blockade in epithelial cell differentiation, blocking apoptosis, 
promoting migration and angiogenesis, reducing growth factor requirement, and 
altering cell cycle regulation, all of which can contribute to malignant transformation 
(Dawson et al., 1990, Lo et al., 2003, Everly et al., 2004, Dawson et al., 2008). LMP1 
has also been shown to induce cancer stem cell (CSC)-like characteristics and an 
epithelial-mesenchymal transition (EMT) in NPC cell lines (Kondo et al., 2011, 
Horikawa et al., 2011), and contributes to genomic instability by inhibiting DNA repair 
(Gruhne et al., 2009). 
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Figure 1. 5. Activation of cell signalling pathways by LMP1 
Signalling is achieved through three carboxyl terminal signalling domains, CTAR1, 
CTAR2 and CTAR3. Recruitment of signalling adapter proteins (TRAF, TRADD, 
RIP), and BS69 and Janus kinase (JAK)-3 proteins allows activation of the NFκB, 
JNK/SAPK, PI3K/Akt, ERK-MAPK, PLC/PKC and JAK/STAT signalling pathways. 
Signalling activation impacts on cell phenotype by influencing cell proliferation, 
survival, motility and invasion. 
 
Figure reproduced from Dawson et al., (2012) 
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These effects are achieved through activation of a multitude of cell signalling 
pathway that include NFκB, c-Jun N-terminal kinase/SAP kinase (JNK/SAPK), 
phosphatidyl inositol-3 kinase (PI3K)/Akt, extracellular signal-regulated 
kinase/mitogen activated protein kinase (ERK/MAPK), phospholipase C/protein 
kinase C (PLC/PKC) and Janus kinase/signal transducer and activator of 
transcription (JAK/STAT) (see Figure 1. 5). Collectively, activation of these pathways 
is required for various facets of LMP1-induced effects. These signalling pathways are 
also seen to be deregulated in other cancers of epithelial origin as discussed later in 
this chapter. 
 
1.9.2 Latent membrane protein 2 (LMP2) 
The LMP2 gene codes two mRNA products, LMP2A and LMP2B, initiated from two 
different promoters (Sample et al., 1989). These two proteins are highly similar in 
their structure containing 12 hydrophobic transmembrane domains, and a 
cytoplasmic C-terminal domain. Additionally, LMP2A possesses an N-terminal 
cytoplasmic domain, which is not present in LMP2B, containing motifs that bind 
tyrosine kinases Lyn, Syk, and the ubiquitin ligases Nedd4/Itchy (Dawson et al., 
2012). Original studies demonstrated that LMP2A acts to maintain viral latency by 
modulating signalling from the B-cell receptor (BCR) (Miller et al., 1994, Miller et al., 
1995). While LMP2B may also possess intrinsic signalling capabilities, it is currently 
thought to act as a competitive regulator of LMP2A (Rovedo and Longnecker, 2007).  
 
Like LMP1, LMP2A has been shown to act on multiple signalling pathways (Figure 1. 
6 reproduced from Dawson et al., 2012), and in carcinoma cells can activate 
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PI3K/Akt pathway and modulate STAT and NFκB signalling pathways (Scholle et al., 
2000, Stewart et al., 2004). The consequences of LMP2 expression in epithelial 
tissues range from inhibition of cell differentiation (Fotheringham et al., 2010) and 
increased migration (Allen et al., 2005, Fotheringham et al., 2012) to the induction of 
an epithelial to mesenchymal transition (EMT) in NPC cells (Kong et al., 2010). The 
role of LMP1 and LMP2 in the pathogenesis of NPC is reviewed in (Dawson et al., 
2012). 
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Figure 1. 6. Activation of cell signalling pathways by LMP2 
Signalling occurs through motifs in the amino terminus of LMP2A contains which bind 
tyrosine kinases Lyn, Syk, and the ubiquitin ligases Nedd4/Itchy. Activation of 
PI3K/Akt, JNK/SAPK, ERK-MAPK and WNT/β-catenin signalling pathways impacts 
on cell phenotype; influencing cell growth, inhibiting apoptosis and differentiation, and 
contributing transformation.  
 
Figure reproduced from Dawson et al., (2012) 
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1.9.3 Epstein-Barr virus nuclear antigen 1 (EBNA1) 
EBNA1 is a 641 amino acid nuclear phosphoprotein containing a glycine-alanine 
repeat region (Fischer et al., 1997), nuclear localisation sequence and DNA 
binding/dimerisation domain (Ambinder et al., 1991). EBNA1 transcription is driven 
from three viral promoters; Cp/Wp, Qp and Fp. The Wp promoter drives EBNA1 
expression upon initial infection B-cell infection, and is also active in a latency III 
transcription programme. In latency I and II programmes EBNA1 transcripts are 
initiated from the Qp promoter (Bakos et al., 2007) as the Cp promoter is silenced 
(Chen et al., 1999). The Fp promoter has been reported to drive EBNA1 expression 
upon entry into lytic cycle (Zetterberg et al., 1999). 
 
Like LMP1 and LMP2, EBNA1 is also seen to influence cell signalling pathways; 
modulating transforming growth factor β (TGFβ) and STAT1 signalling (Flavell et al., 
2008, Wood et al., 2007), inhibiting NFκB (Valentine et al., 2010), and destabilising 
p53 leading to cell immortalisation (Holowaty et al., 2003, Sheng et al., 2006). The 
immortalisation of EBV positive lymphomas is also promoted by EBNA1, via oxidative 
stress induced telomere dysfunction (Kamranvar and Masucci, 2011).  
 
EBNA1 influences cell biology through a number of mechanisms; by promoting 
tumourigenicity and chemotherapy resistance (Cheng et al., 2010), inducing 
metastasis (Kaul et al., 2007), disrupting PML bodies (Sivachandran et al., 2008, 
Sivachandran et al., 2010) and, in B-cells, conferring resistance to apoptosis (Lu et 
al., 2011) and enhancing migration (Murakami et al., 2005). EBNA1 also promotes 
genomic instability and, like LMP1, has been demonstrated to induce reactive oxygen 
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species in BL (Gruhne et al., 2009). EBNA1 additionally regulates viral Cp and LMP1 
promoters (Guha et al., 1990), and is required for the maintenance and replication of 
the EBV genome (Gregory et al., 1990). 
 
1.9.4 EBV-encoded RNAs (EBERs) 
EBERs are small non-coding non-polyadenylated RNAs that are expressed in all 
forms of EBV latency (Takada and Asuka, 2001). Although not essential for B cell 
transformation and viral replication in vitro (Takada, 2012), the EBER RNAs are 
thought to modulate innate immune responses (Takada, 2012). Due to their 
abundant expression, in-situ hybridisation (ISH) of the EBERs is commonly used as 
an indicator of stable latent infection with EBV (Takada, 2012). High resolution ISH 
has suggested a close association with the Golgi apparatus and rough endoplasmic 
reticulum (Takada, 2012). 
 
There are two EBER RNAs; EBER1 (167bp) and EBER2 (172bp), which have similar 
tertiary structures comprising multiple short stem-loops (Takada, 2012). Both EBER1 
and EBER2 are thought to contribute to the malignant phenotype of EBV lymphoid 
and epithelial cancers through modulation of innate immunity and induction of pro-
inflammatory cytokines (Iwakiri and Takada, 2010; Mrinal and Takada, 2010; 
reviewed by Takada, 2012). Indeed EBER is seen to induce type-1 interferons and 
activate NF-κB signalling. EBER also has a role conferring resistance to IFN and FAS 
mediated apoptosis and inhibiting PKR phosphorylation of eLF-2α so blocking its 
antiviral effects (Takada, 2012). 
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1.9.5 The EBV-encoded micro-RNAs (miRNAs) 
EBV has been found to encode 25 EBV miRNA precursors and 48 mature miRNAs 
from two transcripts; BHRF1 and the BamHI-A rightward transcripts (BARTs). Whilst 
the BHRF1-encoded miRNAs are restricted to B-lymphocytes (Pfeffer et al., 2004), 
BART miRNAs are detected in all types of latent infection and are highly expressed 
in NPC and EBV-aGC (Qiu et al., 2011). The BHRF1 transcript encodes the three 
miRNA precursors; ebv-miR-BHRF1-1, -2 and -3 that produce 4 mature miRNAs, and 
the BART region encodes the remaining 22 miRNA precursors producing 44 mature 
miRNAs. These mature BART miRNAs are produce from two clusters; cluster 1 
located between BART exon I and IB encodes ebv-miR-BART1, -BART3 to 6, and –
BART15 to 17, and cluster 2 located between exon IV and V encodes ebv-miR-
BART2-3p and 2-5p (Zhu et al., 2009, Lung et al., 2009, Cai et al., 2006, Grundhoff 
et al., 2006, Pfeffer et al., 2004). 
 
Recently it has become apparent that BHRF1 and BART miRNAs have a role in 
modulating cellular phenotype by targeting both cellular and viral genes. For 
instance, ebv-miR-BART22, which is highly expressed in NPC, targets LMP2A and 
has a role in immune evasion (Lung et al., 2009),  whilst  ebv-miR-BART5 modulates 
the expression of p53 up-regulated modulator of apoptosis (PUMA) promoting 
apoptosis resistance (Choy et al., 2008). Viral and cellular targets of the BART 
miRNAs, and associated cellular consequences, can be found in Table 1. 5. 
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Table 1. 5. BART miRNA viral and cellular targets and cellular consequence 
Modified from Lung et al., 2013. 
Target miRNA Cellular consequence 
BALF5 
DNA polymerase 
BART2-5p 
v-snoRNA22pp 
Maintain latency 
BHRF1 
DNA polymerase 
BART10-3p Unknown 
LMP1 
Signalling protein 
BART1-5p, 16, 17-
5p 
BART19-5p, 5 
BART9 
Anti-apoptotic 
Immune evasion 
Promotes NK/T cell growth 
LMP2A 
Signalling protein 
BART22 Immune evasion 
APC 
WNT inhibitor 
BART19-3p, 7, 17-
5p 
Pro-oncogenic 
Bim 
Proapoptotic protein 
BART cluster 1 Anti-apoptotic 
BRUCE 
Anti-apoptotic protein 
BART15 Pro-apoptotic 
CASP3 
Proapoptotic protein 
BART1-3p, 16 Anti-apoptotic 
CAPRIN2 
WNT-signalling 
enhancer 
BART13-3p Anti-apoptotic 
DICE1 
Tumour suppressor 
BART3 Pro-oncogenic 
DICER 
miRNA synthesis 
BART6-5p Unknown 
IPO7 
Nuclear importer 
BART3, BART16 Immune evasion 
MICB 
NK cell ligand 
BART2-5p Immune evasion 
NLK 
WNT inhibitor 
WNT inhibitor Pro-oncogenic 
NLPR3 
Inflammation regulator 
BART15 Immune evasion 
PUMA 
Proapoptotic protein 
BART5-5p Anti-apoptotic 
T-bet 
T-box transcription 
factor 
BART20-5p Anti-apoptotic 
TOMM22 
Mitochondrial Bax 
proapoptic receptor 
BART16 Anti-apoptotic 
WIF1 
WNT inhibitor 
BART19-3p Pro-oncogenic 
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1.9.6 BamH1-A reading frame-1 (BARF1) 
BARF1 located in BamHI-A fragment of the EBV genome and was originally 
identified as an early lytic protein being restricted to the lytic replication in B-cells (Lu 
et al., 2006). BARF1 is highly expressed in NPC and EBV-aGC tumours in the 
absence of spontaneous lytic induction (Takada, 2012). Although identified as a viral 
homologue of CSF1, BARF1 has been shown to possess oncogenic and 
immunomodulatory properties in epithelial cells and B-cells, and can immortalise 
fibroblasts and activate anti-apoptotic BCL2 production (Hoebe et al., 2012).  
 
1.10 The cancer stem cell hypothesis 
1.10.1 Stem cells 
Stem cells are undifferentiated progenitor cells with an infinite life span, high self-
renewal capacity, and the ability to generate differentiated cell progenitors of multiple 
cell lineages (Mimeault and Batra, 2006). In 1963, McCulloch and Till first described 
the regenerative capacity of transplanted mouse bone marrow cells identifying cells 
that had limitless self-renewal capabilities (Becker et al., 1963) having previously 
published the discovery of radiation sensitive cells of the marrow (McCulloch and Till, 
1960, Till and McCulloch, 1961). It is now known that many distinct stem cell types 
exist. ESCs, found in the foetal tissues and umbilical cord blood, are the only true 
totipotent cells capable of differentiating into multiple cell types. Multipotent adult 
stem cells share properties with totipotent ESCs; such as limitless self-renewal 
capacity, high proliferative capacity, high telomerase activity and slow rates of 
division (Sales et al., 2007, Harrison et al., 1978, Hoshino et al., 1967). These 
specialised cells exist in many adult tissues and organs such as the brain, skin, 
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heart, bone marrow, intestines, lungs kidneys, pancreas, liver and eyes. However, 
unlike the totipotent ESCs from which they are derived, adult stem cells have a 
restricted differentiation potential; as such they can only generate a limited number of 
lineage-restricted progenitor cells (Mimeault and Batra, 2006). Adult stem cells 
reside, quiescently, in specialized niches within organs and are responsible for 
normal tissue maintenance and repair, they are also essential in regeneration and 
repair of tissue after damage. 
 
Self-renewal of somatic stem cells produces daughter cells with the same 
self-renewal capacity, as well as a more differentiated transit amplifying (TA) cells, 
which have a lower self-renewal capacity but higher cycling speed (Clarke and Fuller, 
2006, Barker et al., 2007, Pastrana et al., 2011). These progeny TA cells are 
responsible for the generation of the bulk of the tissue by undergoing terminal 
differentiation. The current understanding of the epidermal stem cell niche is that a 
single stem cell and ~10 TA cells that undergo several rounds of amplification in the 
basal layer prior exiting the niche and terminally differentiating, switching between 
different keratin expression profiles as they differentiate up through the skin layers 
(reviewed in Fuchs, 2009a). This is also true of the intestinal epithelium, where stem 
cells reside at the base of the crypts and produce the TA cells which undergo several 
rounds of amplification prior to differentiation as they progress up to the lumen 
(reviewed in Simons and Clevers, 2011). 
 
The self-renewal capacity of stem cells is demonstrated by the self-renewal and 
differentiation of isolated cells in primary transplants such that they are able to 
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reconstitute the whole spectrum of differentiated cells from the tissue from which they 
are derived (Uchida et al., 2000). This process is then repeated in subsequent serial 
transplantations in which the same phenotype differentiation and self-renewal of the 
population is required. This has so far been demonstrated for adult stem cells 
residing in the hematopoietic system, bone marrow, and breast and prostate 
epithelium (Matsuzaki et al., 2004, Stingl et al., 2006, Krause et al., 2001, Shackleton 
et al., 2006, Leong et al., 2008). 
 
To investigate the properties of stem cells, ESC lines derived from the inner cell 
mass of the blastocyst in early embryo development, have been established 
(Thomson et al., 1998). Human ESCs express markers common to undifferentiated 
cells such as octamer-binding protein (OCT4), NANOG, SOX2, CD9 and CD24 
(Hoffman and Carpenter, 2005). When grown in simplified culture or transplanted in 
vivo ESC differentiate into all foetal and adult stem cells and progenitor cells found in 
the adult body (Evans and Kaufman, 1981). Hence human ESCs are potential tools 
for a range of applications, from regenerative medicine to drug discovery and 
toxicology, studies of human development and as unique model for cancer 
progression. For these applications it is necessary that we understand the molecular 
mechanisms of human ESC self-renewal, maintenance and differentiation. Our 
understanding of the signalling pathways involved in human ESC self-renewal is 
incomplete. Several signalling pathways are thought to be important in ESC 
maintenance and function including epidermal growth factor (EGF), fibroblast growth 
factor (FGF), TGFβ, hedgehog (HH), WNT/β-catenin, PI3K and NOTCH signalling 
pathways, which will feature in the later part of this introduction. 
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1.10.2 Cancer stem cells (CSCs) 
The role of CSCs in the initiation and maintenance of cancers is not a new concept. It 
has long been postulated that cancers arise from normal long-lived stem cell 
populations which acquire numerous genetic modifications. A cancer derived from a 
mutated stem cell would already possess limitless self-renewal capacities, 
subjugating the need for this property of cancerous cells. This idea is countered by a 
theory that supposes non stem cells can acquire stem cell “like” characteristics during 
genetic modification that precedes cancer cell formation (Pardal et al., 2003). 
 
Recamier was the first to propose that dormant embryonic cells residing in adult 
tissues could be the origin of cancer over 100 years ago in his treatise “Recherches 
sur le traitement du cancer” dated 1829. In this work he coined the term “métastase” 
as meaning the spread of cancer (Carr and Carr, 2005). This “embryonic rest 
hypothesis of cancer origin” was also proposed by Remak in 1854 (Remak, 1855) 
and Virchow in 1858 (Virchow, 1858a), and was later refined by Durante and 
Cohnhiem who described these embryonic cells in adult tissues as dormant until 
activated at the onset of cancer (Sell, 2004). The displacement and activation of 
germ cells as the origin of tumours was postulated by John Beard in the early 20th 
century, a theory that continues to receive support today (Ratajczak et al., 2010).  
 
The existence of CSCs had been proposed as early as 1829 (Carr and Carr, 2005), 
however it was not until 1994 that the first evidence for their existence came to light 
following the finding that a small sub-population of acute myeloid leukaemia cells 
could initiate leukaemia in immunodeficient mice (Lapidot et al., 1994). Isolation of 
CSCs from solid tumours has proved more technically difficult. However, cells with 
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the ability to initiate new tumours in non-obese diabetic/severe combined 
immunodeficient (NON/SCID) mice were first identified as a minor CD44 positive, but 
CD24 and lineage dependent marker negative (CD44+/CD24-/LOW/Lineage-) 
population of breast cancer cells in 2002 (Al-Hajj et al., 2003). Since this time CSCs, 
defined as a subpopulation of tumour cells capable of repopulating the phenotype of 
the tumour over serial passages and expressing a mixture of tissue dependent 
“CSC-markers”, have been identified in numerous solid tumours (Visvader and 
Lindeman, 2008).  
 
The CSC hypothesis states that only this subpopulation of cells is capable of 
regenerating the tumour, the bulk of the tumour does not have this capability. 
Furthermore, it is believed that the tumour mass comes from the differentiation of a 
CSC such that on differentiation the vast majority of the tumour cells lose their stem 
like properties. It is the similarity of the self-renewal and differentiation mechanisms 
between normal and CSCs that make this such an attractive theory (Reya et al., 
2001, Pardal et al., 2003). 
 
Whilst the origin of cancer is still debated, many tumours, including most NPC and 
EBV-aGC, display an undifferentiated phenotype (Niedobitek et al., 1992). This 
would occur if either the cancer develops from differentiated cells that acquires 
transforming mutations and dedifferentiates prior to expansion, or if an 
undifferentiated stem cell acquires multiple mutations allowing dysregulation of the 
cell towards a cancer like phenotype. The possibility that stem cells undergo 
malignant transformation into tumour initiators in cancers not only explains the 
acquisition of limitless self-renewal but goes partway to explaining activity of diverse 
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developmental signalling pathways, increased DNA repair and high rates of ABC 
transporter-mediated drug efflux, which would normally be associated with stem cells. 
It would seem possible that instead of acquiring these attributes over time, slowly 
converting a differentiated cell towards a phenotype more commonly associated with 
stem cells, the mutation may occur in a cell which already has these properties.  
 
1.10.3 Isolation of CSCs 
In recent years considerable progress has been made in identifying populations of 
cells within the proliferative compartments of both lymphoid and epithelial tissues that 
display characteristics of multipotent stem cells. The gold-standard for characterising 
stem cells is demonstrated by serial transplantation experiments involving the 
isolation of precursor cells, frequently sorted from the bulk population on the 
expression of putative stem cell markers, and transplantation into nude mice to form 
new tumours at which point the tumour is dissociated, cell are resorted and 
transplanted again (Uchida et al., 2000). In these studies putative stem cells will 
continue to regenerate tumours characteristic of the original tumour from which the 
cell was derived through these serial transplantations. However, other techniques for 
establishing the presence of a stem cell population have also been reported. Stem 
cells possess the ability to form tumourspheres in highly defined serum-free medium 
in the absence of an adhesive substrate (technique reviewed by Pastrana et al., 
2011), they are often slow cycling and so can be identified as the label retaining 
population in bromodeoxyuridine (BrdU) label retaining studies (reviewed by Fuchs, 
2009b), and various cancer stem cell populations have been shown to differentially 
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express markers on the cell surface although these markers are highly lineage 
dependent and as such many markers appear in the literature.  
 
Integrin profiling, particularly the expression of β1 integrin, has been used to 
characterise numerous putative stem cell populations from normal epithelial tissues 
(Jones and Watt, 1993, Schlotzer-Schrehardt and Kruse, 2005, Lathia et al., 2010); 
studies have demonstrated some stem cell populations express cell surface β1 
integrin at levels 2-3 fold higher than their transit amplifying progeny (Hotchin et al., 
1995). In epidermal keratinocytes overexpression of β1 integrins or constitutive 
activation of the MAPK kinase 1 (MEK) (an important effector protein downstream of 
integrins) leads to expansion of the stem cell pool (Zhu et al., 1999, Haase et al., 
2001) underscoring the importance of integrin signalling in the maintenance of the 
stem cell phenotype. Similarly depletion of this integrin in intestinal stem cells leads 
to an increase in differentiation due to an impaired HH signalling pathway (Jones et 
al., 2006), and β1 integrin has also been reported to modulate NOTCH signalling in 
the maintenance of an stem cell phenotype in breast and neural stem cells (Campos 
et al., 2006, Brisken and Duss, 2007).  
 
Isolation of putative CSC populations in neuroblastoma, glioblastoma, breast and 
lung cancer cell lines has been achieved by utilising the increased expression of the 
ABC transporter proteins, believed to confer cells with increased resistance to 
chemotherapy reagents (Hirschmann-Jax et al., 2004). Characterisation of putative 
stem cells, and the identification of extracellular markers, has allowed the isolation of 
subpopulations of cells by fluorescence activated cell sorting – a technique that has 
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proved invaluable in the characterisation of populations of cells that make up the bulk 
of the tumour.  
 
As previously mentioned, stem cell markers are highly tissue dependent however 
there are number of markers that consistently appear in the literature in relation to 
epithelial tumours. CD133 has been identified as a CSC in multiple tissues (Clevers, 
2011); in prostate cancer CD133, Trop-2 and α2β1 integrin are reported to mark 
CSCs (Trerotola et al., 2010), whilst in head and neck squamous cell carcinoma 
(HNSCC) and NPC markers such as CD133 and CD44 are reported to identify the 
CSC population (Sayed et al., 2011, Su et al., 2011, Zhuang et al., 2013).  
 
Stem cells can also be identified by expression of stem cell maintenance proteins 
such as the polycomb protein BMI1, homeobox protein NANOG, and transcription 
factors such as OCT4 and SOX2 (Chambers et al., 2003, Claudinot et al., 2005, Lee 
et al., 2006, Boyer et al., 2006). These markers of “stemness” are not only expressed 
or over-expressed in a range of undifferentiated carcinomas in vivo, but in vitro 
studies support a role for these proteins in maintaining an “undifferentiated” or stem 
cell-like phenotype (Park et al., 2003, Kashyap et al., 2009), indeed as few as four 
stem cell factors (OCT4, SOX2, NANOG and LIN28) are sufficient to reprogram more 
committed cells to adopt an undifferentiated state (Yu et al., 2007, Pardo et al., 
2010). Other novel proteins, such as the transcriptional repressor Zfp145 and 
MTS24, have also been reported as markers of stem cells (Claudinot et al., 2005). 
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Stemness related transcription factors expressed in the putative stem cell population 
of HNSCC cell lines have recently been investigated. Spheroid derived HNSCC cells, 
a subpopulation of cells capable of forming spheres in serum free medium, showed 
marked increase in the expression of SOX2, NANOG and OCT3/4 whilst also 
demonstrating increased expression of EMT related genes (Chen et al., 2011). This 
study also demonstrated an increased expression of aldehyde dehydrogenase 
(ADHD) in the sphere forming cells, which has been shown to identify CSCs in 
HNSCC and other epithelial cancers (Chen et al., 2009, Clay et al., 2010, Chen et al., 
2011). 
 
1.10.4 Evidence for CSCs in NPC 
As with other carcinomas of the head and neck, considerable interest has focused on 
the possibility that NPC may originate from a CSC population. The presence of CSC 
in NPC is supported by studies on biopsies of NPC tumours which demonstrate 
expression of ESC proteins such as BMI1, SOX2 and OCT4, and the isolation of 
tumour initiating cells from an undifferentiated NPC cell line, CNE2 (Song et al., 
2006, Wang et al., 2007, Zhang et al., 2010, Luo et al., 2013). A “side population” of 
cells enriched for putative CSCs has been isolated from the CNE2 cell line on 
differential efflux of Hoechst dye, a DNA binding drug exported by the ABC 
transporter (Wang et al., 2007). These cells were able to form tumour in non-obese 
diabetic/severe combined immunodeficient mice with 20 times fewer cells than the 
unsorted population. 
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In the NPC biopsies a small population of cells were found to express embryonic 
stem cell markers, OCT4 and SOX2, these cells also showed deregulated NOTCH1 
signalling which was proposed to regulate the NPC CSC population (Zhang et al., 
2010). Further interrogation of the role of NOTCH in the CSC-like population of NPC 
has demonstrated this signalling pathway is required for the self-renewal of the side 
population cells in CNE1 and CNE2 cell lines. Furthermore inhibition of NOTCH 
signalling reduced the ability for unsorted cells to form tumours (Yu et al., 2012).  
 
1.11 Deregulation of signalling pathways associated with “stemness” and 
cancer 
Various signalling pathways are associated with development and regulating normal 
cell growth. A number of these: HH, WNT/β-catenin, NOTCH, TGFβ, FGF, play 
essential roles in maintaining populations of stem cells within a defined stem cell 
“niche” (Katoh, 2007a). Aberrant regulation of these pathways is known to give rise to 
tumours, underscoring the importance of these pathways in oncogenesis. This 
section will briefly introduce some of the pathways known to influence stem cell self-
renewal, which are dysregulated in tumours with a particular emphasis on the HH 
signalling pathway. 
 
The HH signalling pathway is intrinsically entwined with the WNT, TGFβ, NOTCH 
and FGF transduction pathways, which together constitute a signalling network 
responsible for the maintenance of CSCs (Katoh and Katoh, 2006). Whilst there are 
many review papers on stem cell maintenance signalling pathways and their 
interactions, in relation to the HH signalling pathway and cancer, reviews by 
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Merchant and Takebe provide an overview of the stem cell signalling network 
relevant to this thesis (Merchant and Matsui, 2010, Takebe et al., 2011).  
 
In the maintenance of the embryonic stem cells, the TGFβ family of proteins act as 
growth and differentiation factors and direct embryonic stem cell fate commitment 
(Kitisin et al., 2007); the WNT pathway regulates stem-cell self-renewal, embryonic 
patterning and cell commitment (Alonso and Fuchs, 2003, Huelsken and Birchmeier, 
2001); MAPK signalling activates proliferation and induces differentiation (Orford and 
Scadden, 2008), and the NOTCH pathway directs differentiation to maintain cell fate 
commitment and the expansion of the stem cell pool (Stier et al., 2002, Chiba, 2006). 
 
Transcriptional profiling comparing the expression of genes in embryonic stem cells 
ESCs, neural stem cells (NSCs), and hematopoietic stem cells (HSC) has identified 
the upregulation of several members of the TGFβ family of proteins, as well as 
members of the JAK/STAT pathway, in all three types of stem cell, indicating the 
importance of activated TGFβ signalling in these populations (Ramalho-Santos et al., 
2002). Other pathways involved in ESC maintenance also influence adult stem cell 
systems; NOTCH signalling regulates the size of the stem cell compartment in 
multiple adult progenitor cells (Androutsellis-Theotokis et al., 2006) and regulates 
cellular-fate in mammary progenitor cells (Dontu et al., 2004), WNT signalling is seen 
to maintain self-renewal in stem cell populations not limited to breast, brain and the 
hematopoietic system (Reya and Clevers, 2005), while bone morphogenic protein 
(BMP) signalling suppresses WNT in intestinal precursor cells to inhibit this process 
(He et al., 2004). There are many examples of cross-talk between different stem cell 
signalling pathways; in the intestine an interplay between the WNT and NOTCH 
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pathways is involved in epithelial cell renewal and differentiation (Nakamura et al., 
2007b), and many signalling pathways have downstream targets that feature in other 
signalling pathways. These interactions of stem cell signalling pathways are poorly 
understood but it is likely that stem cell growth, differentiation and fate determination, 
and the maintenance of the stem cell pool, is highly dependent on the interactions of 
multiple signalling pathways.  
 
WNT5A regulates both the canonical and non-canonical WNT signalling cascades in 
a context dependant manner (Katoh, 2007b). Canonical signalling occurs through the 
frizzled receptor and LRP5/LRP6 co-receptor to activate the β-catenin, TCF/LEF, 
BCL9/BXL9L and PYGO1/PYGO2 nuclear complex and induce downstream targets 
such as MYC (He et al., 1998) and JAG1 (Katoh, 2006). Transcription of Dkk1 is also 
activated and implicated in negative feedback control on this pathway (Chamorro et 
al., 2005, Hirata et al., 2011). In contrast, the non-canonical WNT signalling is 
activated at the tumour stromal interface and is transduced through the Frizzled 
receptor and ROR2/RYK co-receptor inducing RhoA, JNK, PKC, NFAT and NLK 
signalling cascades (reviewed by Katoh, 2007a). The non-canonical WNT signalling 
pathway has roles in cellular polarity, adhesion and movement and is activated in 
tumour invasion and metastasis (Ling et al., 2009). 
 
1.11.1 The Hedgehog (HH) Signalling Pathway 
The HH signalling pathway is critical for stem cell maintenance; it plays an essential 
role in development, morphogenesis, and patterning, by dictating tissue patterning in 
multiple organs (reviewed by McMahon et al., 2003). The hh gene was discovered in 
Introduction 
58 
 
Chapter 1 
Drosophila as a secreted signalling protein expressed in stripes within the Drosophila 
embryo with a role in dictating embryonic segment polarity (Tashiro et al., 1993). 
There are three mammalian hh homologs desert hedgehog (DHH), Indian hedgehog 
(IHH) and sonic hedgehog (SHH). The indispensability of HH signalling is 
demonstrated by the severe congenital mutations and neonatal lethality seen in IHH 
and SHH targeted gene disruption mouse models (Chiang et al., 1996b, St-Jacques 
et al., 1999, Hayhurst and McConnell, 2003), and holoprosencephaly in humans, a 
developmental defect of the forebrain and midface caused by SHH mutation 
(Roessler et al., 1996). Additionally, in epidermal stem cell populations, SHH is 
required for normal proliferation as treatment with cyclopamine, a SHH inhibitor, 
decreased stem cell proliferation (Zhou et al., 2006). SHH has been shown to directly 
regulate the cell-cycle as human keratinocytes overexpressing SHH from a 
transfected vector no longer exit S and G2/M in response to calcium, an inducer of 
terminal differentiation (Fan and Khavari, 1999, Roy and Ingham, 2002). 
 
Activated HH ligand is produced by post translational modification of the HH 
precursor ligands; autocatalytic cleavage from 45kD to 19kD and a palmitoyl acid and 
cholesterol moiety addition at the N-terminus and C-terminal respectively (Pepinsky 
et al., 1998, Porter et al., 1996). 
 
Drosophila HH ligands function by binding to transmembrane receptors, Hip1, 
Patched 1 (PTCH1), and Patched 2 (PTCH2), relieving the tonic inhibition of receptor 
bound Smoothened (SMO). Once depressed, Smo activates HH signalling through 
the activation and nuclear transport of Ci, a Drosophila transcription factor, which 
regulates gene transcription. Whilst mammalian HH signalling functions in much the 
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same way, three vertebrate homologues of Ci exist, GLI1, GLI2 and GLI3, which may 
have independent and distinct repressor and activator activities that are cell context 
dependent (Ruiz i Altaba et al., 2002 and references there in).  
 
GLI1 and GLI2 act primarily as transcriptional activators, whereas GLI3 exists as both 
a transcriptional activator and repressor. In the absence of HH signalling, GLI3 is 
sequentially phosphorylated by protein kinase A (PKA), glycogen synthase kinase-3β 
and casein kinase 1 (CK1) prior to polyubiquitination via ubiquitin ligase β-TrCP and 
processing by the proteasome to produce an N-terminal fragment that acts as a 
transcriptional repressor. GLI2 also has an amino-terminal repressor domain and in 
the absence of SHH is phosphorylated and processed through interaction with β-
TrCP, however processing to the repressor form is inefficient and where it does 
happen largely leads to the degradation by the proteasome (reviewed in Simpson et 
al., 2009).  
 
In the presence of active HH signalling, SHH acts to inhibit the cleavage of GLI2 and 
GLI3 allowing the full length proteins to act as transcriptional activators. GLI1 cannot 
be processed and acts only as a strong transcriptional activator although does not 
appear to be essential as GLI1-/- mice are viable and exhibit a normal phenotype 
(Park et al., 2000). GLI1 and GLI2 have been shown to have overlapping functions 
and whilst some studies suggest low level GLI1 expression can rescue GLI2 mutants 
in vivo (Bai and Joyner, 2001), other studies have found a distinct, and essential, role 
for GLI2 in lung and hair follicle development, initial SHH responsiveness and ectopic 
activation which cannot be rescued by GLI1 (Bai et al., 2002, Mill et al., 2003).  
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Activated transcription factors are translocated to the nucleus where they activate 
downstream target transcription. The primary cilica and intraflagellar transport (IFT) 
proteins facilitate HH signalling; allowing the import and export of PTCH, SMO, and 
the GLI transcription factors via the Kif3 motor complex and retrograde dynein 
motors, and promoting GLI activation. Indeed mutations that disrupt the IFT proteins 
and Kif3a cause phenotypes associated with HH signalling defects (reviewed in Pan 
et al., 2013). A schematic of the HH signalling pathway can be seen in Figure 1. 7. 
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Figure 1. 7. Schematic of the HH Signalling Pathway 
Modified activated oligomeric HH ligand (yellow) is released from Dispatched (DISP) 
and secreted into the intracellular space where it is able to act in a paracrine or 
autocrine manner. HH ligand binds to Patched (PTCH) cell membrane receptor with 
assistance from GAS1, BCO and CDO which relieves inhibition of Smoothened 
(SMO). Activated SMO moves to the cilia where it promotes the activation of GLI2/3 
(GLI2/3A) and inhibits repressor of transcription GLI3R. Activated GLI transcription 
factors are translocated to the nucleus to activate downstream HH target expression. 
Arrow represents activation, flat headed arrow represents inhibition. 
 
From Pan et al., (2013) 
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1.11.2 Regulators of the HH Signalling Pathway 
Positive regulators of the HH pathway include Growth arrest-specific protein (GAS1), 
Hedgehog acyltransferase (HHAT), Caveolin1 (CAV1), CDO, BOC, Fused (FU) and 
ZIC2. Loss of HHAT leads to decreased HH secretion demonstrating this protein is 
needed for HH ligand modification (Dennis et al., 2012), CAV1 is also proposed to 
facilitate SHH ligand by assisting vesicular packaging for intracellular transport (Mao 
et al., 2009), whilst other studies have demonstrated a negative regulatory function 
for CAV1 (Capozza et al., 2012). GAS1 and BOC/CDO are theorised to be SHH co-
receptors for PTCH; however, an interaction between these proteins has remained 
elusive. GAS1 is negatively transcribed in relation to HH pathway activity, and both 
GAS1-/- and CDO-/- mutants show similar HH target expression profiles to those of 
SHH-/- mice and display severe defects in regard to notochord and craniofacial 
defects that partially recapitulate those seen in SHH-/- mice (Allen et al., 2007). 
CDO/GAS1 and CDO/BOC double mutants also exhibit severe defects, although the 
viability of BOC-/- mice suggests this protein has a similar function to CDO which is 
compensating for its loss (reviewed in Pan et al., 2013).   
 
FU, also known as STK36, is a positive regulator of the GLI transcription factors and 
its expression, like GLI1, has been demonstrated to rescue lymphoma cells grown in 
the presence of cyclopamine (Dierks et al., 2007). ZIC2 is also reported to positively 
regulate GLI transcription by increasing nuclear retention of GLI1 (Chan 2011). 
 
Multiple negative regulators of the HH signalling pathway exist and inhibit the 
pathway at different points. Suppressor of fused (SUFU) negatively regulates the 
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modification of GLI3 into its repressor or activator forms (Humke et al., 2010) and 
RAB23 has been identified through epigenetic studies, with RAB23/GLI2 double 
knockout mice, to inhibit with the processing of GLI2 into a transcriptional activator 
(Eggenschwiler et al., 2006). DAZ interacting protein 1 (DZIP1) promotes GLI 
turnover, a process that is regulated by the phosphorylation of DZIP1 by casein 
kinase 2 and inhibited by B56-containing protein phosphatases (Jin et al., 2011). 
Additional regulation of the HH pathway involves the expression of GLI1 and PTCH1, 
HH pathway components, as downstream targets (Lee et al., 1997, Goodrich et al., 
1996). 
 
1.11.3 Targets of activated GLI transcription factors 
The three vertebrate GLI proteins bind conserved target sequences to activate 
downstream target transcription (Villavicencio et al., 2000), of note is the common 
GLI1 and GLI2 DNA binding motif, GACCACCCA, which allows for some functional 
redundancy between these two proteins (Yan et al., 2011). Classical transcriptional 
targets of an activated HH pathway include FOXM1 (Teh et al., 2002), BCL2 (Regl et 
al., 2004, Bigelow et al., 2004) and Cyclin D proteins, CyclinD1 and CyclinD2 (Mill et 
al., 2003), additionally activated GLI proteins target HH pathway components, 
PTCH1 (Ågren et al., 2004) and GLI1 (Dai et al., 1999), creating a positive feedback 
loop (Katoh and Katoh, 2006). In addition to the BCL2 and Cyclin D proteins, which 
have a role in cell proliferation and survival, other direct targets of GLI transcription 
influence cellular phenotype by regulating cell cycle (Cyclin E and cMYC), 
adipogenesis (vascular endothelial growth factor VEGF, and angiopotetins-1 and 2), 
epithelial to mesenchymal transition (SNAIL and MUC5A) and self-renewal (BMI1, 
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SOX2, PAX3) (Perrot et al., 2012). Recently gene expression profiling and chromatin 
immunoprecipitation have allowed the identification of many putative GLI targets, 
however these have yet to be confirmed as global transcriptional targets in all human 
cell types (Vokes et al., 2007, Lee et al., 2010, Vokes et al., 2008). 
 
1.11.4 Interaction of HH signalling pathway with other stem cell maintenance 
pathways 
The HH pathway feeds into other stem cell maintenance pathways via downstream 
targets that feature in the WNT family, such as WNT5A (Mullor et al., 2001, Cohen, 
2003, Cohen, 2010), and TGFβ family, and BMPs, such as BMP4 (Astorga and 
Carlsson, 2007). These signalling pathways may function to regulate one another; 
indeed, co-expression of HH and BMP -2,-4 and -6 suggests interaction between 
these two pathways (Bitgood and McMahon, 1995) and TGFβ has been shown to 
induce SHH ligand expression (Chung and Fu, 2013). Additionally, TGFβ  can induce 
the expression of GLI1 in a GLI2 dependent manner, and this induction is also 
SMAD3 dependent (Javelaud et al., 2012).  
 
Ligand independent activation of the HH pathway is also achieved through the TNF-α 
(Wang et al., 2012c) and WNT pathways (Borycki et al., 2000), and via mutant KRAS 
(Collins et al., 2012), whilst the NFκB signalling pathway may contribute to SHH 
ligand induction (Nakashima et al., 2006, Kasperczyk et al., 2009). The PI3K/Akt 
pathway regulates (Ramaswamy et al., 2012) also positively regulate HH, whereas 
NOTCH, GsPCR and PTEN signalling downregulate GLI1 transcription (Katoh and 
Katoh, 2009b, Schreck et al., 2010, Xu et al., 2008) and Akt-GSKβ3 signalling, 
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initiated by osteopontin, influences GLI1 distribution and activation (Das et al., 2013). 
Finally crosstalk and co-operation between the HH and EGF (Palma and Ruiz i 
Altaba, 2004, Bigelow et al., 2005), and WNT signalling pathways has also been 
described (Yang et al., 2008a). The consequences of an activated HH signalling 
pathway in relation to tumourgenesis are outlined in Figure 1. 8 (reviewed by Kar et 
al., 2012). 
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Figure 1. 8. Consequences of an activated HH signalling pathway 
Schematic showing cellular consequences of activated HH signalling pathway downstream targets and other cell maintenance pathways 
with which the HH signalling pathway interacts. 
Adapted from Kar S, et al., (2012) 
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1.12 The HH signalling pathway in cancer 
HH signalling is seen in both the ESC and adult stem cell compartments (Lai et al., 
2003, Palma and Ruiz i Altaba, 2004) as well as being implicated in numerous 
cancers (Xie and Epstein, 2011) such as basal cell carcinoma (BCC), a tumour 
arising in the undifferentiated epidermal stem cell population (Grachtchouk et al., 
2011), and glioblastoma multiforme (GBM) (Dahmane et al., 2001, Bar et al., 2007). 
Indeed, GLI1 was first identified from its overexpression in malignant glioma (Kinzler 
et al., 1987) and is identified as an oncogene due to its ability to transform primary 
cells in concert with adenovirus E1A (Ruppert et al., 1991). Overexpression of GLI1 
has been identified in many cancers including BCC (Dahmane et al., 1997, Ghali et 
al., 1999), B-cell lymphoma (Rao et al., 1998), meduloblastoma, glioma and other 
brain tumours (Kinzler et al., 1987, Salgaller et al., 1991, Reifenberger et al., 1996, 
Pasca di Magliano and Hebrok, 2003) and childhood sarcomas (Roberts et al., 1989, 
Khatib et al., 1993) in which the scale of upregulation is correlated with tumour grade 
(Stein et al., 1999). GLI1 overexpression is also associated with breast cancer and 
can predict early relapse (ten Haaf et al., 2009, Li et al., 2012), whilst the expression 
of GLI2 is correlated with poor prognosis in hepatocellular carcinoma (Zhang et al., 
2013). Furthermore, the chromosomal location of the GLI gene is frequently 
rearranged or amplified in human cancers (Stein et al., 1999). 
 
1.12.1 Mechanisms of HH signalling pathway activation 
HH activation in BCC is largely the consequence of frequent UV-induced mutations in 
PTCH and SMO leading to constitutive HH signalling (Villavicencio et al., 2000, 
Daya-Grosjean and Couve-Privat, 2005, Daya-Grosjean and Sarasin, 2005). Indeed 
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more than 90% of sporadic BCC has a mutation in a single PTCH allele and 10% 
display activating mutations in SMO (Roewert-Huber et al., 2007). As such HH 
pathway activation in the initiation and maintenance of BCC is ligand independent; 
mutations occur downstream of the HH ligand, this is also true of meduloblastoma 
which most commonly involves mutations in PTCH or SMO receptors (Thompson et 
al., 2006).  
 
The HH signalling pathway can also become aberrantly activated by overexpression 
of SHH, which in transgenic mice and human fibroblasts is sufficient to induce the 
onset of BCC (Grachtchouk et al., 2000, Oro et al., 1997, Fan et al., 1997). Similarly 
GLI1 RNA injected into the epidermis is also capable of inducing BCC formation 
(Dahmane et al., 1997), however expression of an activated mutant form of SMO 
was insufficient for the induction of BCC (Grachtchouk et al., 2003), and studies 
using mutated SMO in pancreatic cancer have since identified a paracrine nature of 
HH signalling such that oncogenic SMO induces HH activation in the stromal cells 
(Tian et al., 2009). Tumour cells in this paracrine HH ligand-dependent model are 
responsible for HH signalling activation in the stromal cells that feeds back inducing 
alternative signalling pathway to maintain the tumour (Tian et al., 2009). Whilst this 
study does not rule out the existence of ligand independent mechanisms for 
pancreatic cancer initiation and maintenance, indeed constitutively activating 
mutations are associated with this cancer (Kar et al., 2012), it highlights the complex 
interaction between the stroma and tumour cells that is responsible for HH stimulated 
tumourgenesis in at least a subset of this disease.  
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A paracrine HH ligand dependent nature has been demonstrated in a number of 
other human cancers including those of the breast, colon, prostate and ovaries which 
demonstrate HH activity in the adjacent stroma in response to tumour produced 
ligand (O'Toole et al., 2011, Yauch et al., 2008, Teglund and Toftgard, 2010). 
Additional autocrine signalling mechanisms have been suggested for prostate, lung, 
ovarian, colon and upper gastrointestinal cancers (Teglund and Toftgard, 2010, Kar 
et al., 2012). It would appear that in a number of cancers HH signalling may act 
through both autocrine and paracrine mechanisms, for instance prostate cancer 
where the former is implicated in tumour initiation and the latter in establishing 
communication with the stroma and cancer progression (Kar et al., 2012).  
 
While it would be unwise to dismiss autocrine HH signalling entirely, further support 
of a paracrine mechanisms for HH signalling in pancreatic and colon cancer follows 
the findings that proposed autocrine HH signalling in these tumours may be 
inadequate when considering the off target effects of cyclopamine at high doses and 
lack of cyclopamine induced growth inhibition at SMO specific levels (Varnat et al., 
2009, Pasca di Magliano et al., 2006, Kolterud et al., 2009), and the low levels of HH 
activity in tumour cells (Yauch et al., 2008, Berman et al., 2003).  
 
Interestingly whilst it would appear that in certain cancers HH activity in the stroma 
may be more important than in the tumour cells themselves. Yauch et al. (2008) 
noted that this does not rule out a role for HH activity in the stem cell population. 
Future studies may tease out further intricacies in the HH signalling pathway that 
might well support multiple methods of HH activation within the tumour cell and 
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stroma at different stages of tumourgenesis and subsequent maintenance that are 
likely to be highly tumour dependent. 
 
1.12.2 Targeting the HH signalling pathway in tumour therapy 
The involvement of HH in the initiation and maintenance of numerous cancers has 
encouraged research into the therapeutic application of HH pathway inhibitors. 
Cyclopamine is a plant alkaloid that directly inhibits the HH signalling pathway 
through its interaction with SMO. Multiple SMO inhibitors have been produced that 
act by a variety of mechanisms (interacting with SMO directly to prevent processing 
into its active form or inhibiting SMO transport to the cilia) and have progressed into 
clinical trials (reviewed in Onishi and Katano, 2011). Vismodegib is a cyclopamine-
competitive SMO inhibitor that has recently been approved by the US Food and Drug 
Administration’s (US FDA). Whilst many of these inhibitors have been demonstrated 
to disrupt HH signalling, continued use of Vismodegib and other SMO inhibitors is 
associated with mutations in the SMO receptor leading to drug resistance (Sandhiya 
et al., 2013).  
 
In tumours dependent on SHH ligand overexpression, aberrant HH signalling can be 
disrupted through with use of SHH blocking antibody 5E1 or the small molecular SHH 
inhibitor, robotnikinin (Merchant and Matsui, 2010). However, therapies relying on 
ligand targeting to inhibit the pathway may induce PTCH or SMO mutations, leading 
to resistance. In order to decrease the development of drug resistance and to target 
tumours resulting in downstream HH pathway mutations, such as meduloblastomas 
that arise in SUFU-/- mice (Lee et al., 2007a), the HH pathway must be inhibited 
Introduction 
71 
 
Chapter 1 
downstream of SMO. Multiple downstream pathway inhibitors of HH exist (e.g. 
GLI-antagonists GANT58 and GANT61, zerumbone, arcyriaflavin C and physalin F) 
which inhibit GLI transcription, whilst small molecular HH protein inhibitors (HPIs) act 
to block components of the HH signalling cascade downstream of SMO (Hyman et 
al., 2009). With the identification of HH signalling dysregulation in an increasing 
number of cancers, the future of targeted cancer therapies will likely involve HH 
inhibitors. 
 
This thesis investigates the contribution of a dysregulated HH signalling pathway in 
NPC, interrogates the relationship between EBV and HH dysregulation, and attempts 
to establish the cellular consequences of EBV induced HH activation.  
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CHAPTER TWO: MATERIALS AND METHODS 
 
 
 
 
 
 
 
 
 
 
There is one thing even more vital to science than intelligent methods; and that is, 
the sincere desire to find out the truth, whatever it may be.  
— Charles Sanders Peirce 
Pragmatism as a Principle and Method of Right Thinking (1997), 266.  
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2.1 Cell culture 
2.1.1 Basic media 
Tissue culture media purchased is outlined below. Supplements added through 0.2 
µm syringe filters (PALL Life Sciences, US). All media were stored at 4 oC. Antibiotics 
added to all media unless stated in method. 
RPMI 1640: Liquid in sterile 500ml bottles (Sigma Aldrich, US). Supplemented with 
2 mM L-glutamine, 25 mM Hepes and adjusted to pH 7.0.  
Dulbecco’s Modified Eagle’s Medium (DMEM): Liquid in sterile 500ml bottles (Sigma 
Aldrich, US). Supplemented with 2 mM L-glutamine, 25 mM Hepes and adjusted to 
pH 7.0.  
Keratinocyte serum-free medium: Liquid in sterile 500 ml bottles from (Gibco®, 
Invitrogen, US). Supplemented with 25 mg bovine pituitary extract. 
 
2.1.2 Supplements and sterile solutions 
Foetal Calf Serum (FCS): Liquid in sterile 500ml bottles pre-screened for viral and 
mycoplasma contamination (Gibco®, Invitrogen, US). Stored as 50 ml aliquots at 
-20 oC. 
Penicillin/Streptomycin: Liquid in sterile 100 ml bottles containing 10,000 units/ml 
penicillin and 10 mg/ml streptomycin (Sigma Aldrich, US). Used at 2.5 ml/500 ml 
media. Stored at 4 oC. 
Ciprofloxacin: Liquid in sterile 250 ml bottles of concentration 200 mg/ml (Bayer, 
Germany). Used at 2.5 ml/500 ml media. Stored at room temperature. 
Fibronectin: Solution of 0.1% from human plasma. Supplied at 1 mg/ml in 1-5 ml 
bottles (Sigma Aldrich, US). Stored at 4 oC. 
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TrypLE™ Express Stable Trypsin Replacement: 1x solution in 100 ml sterile bottles 
containing EDTA buffer and phenol red (Gibco®, Invitrogen, US), stored at 4 oC. 
Geneticin disulphate salt (G418): Powder (Sigma Aldrich, US). 5 g powder dissolved 
in 100 ml SDW producing a stock solution of 50 mg/ml. Stored as filter sterilised 5ml 
aliquots at -20 oC. 
Phosphate Buffered Saline (PBS): 100 tablets of 0.8 g NaCl, 0.02 g KCL, 0.115 g 
Na2HPO4, 0.02 g KH2PO4 (Oxid LTD). 100 tablets dissolved in 10 litres distilled 
water. Stored as 50 ml aliquots following 20 min autoclave sterilisation at 15 psi and 
120 oC. 
Ethylenediaminetetra acetic acid (EDTA): Powder (Difco™, BD Biosciences, US) 
0.02% autoclaved solution made up by dissolving 0.5 g in 2.5 litres PBS and 
adjusting to pH 7.0, stored at 4 oC. 
Dimethyl Sulphoxide (DMSO): Liquid in 500 ml sterile bottle (Fisher Scientific, US), 
stored at room temperature. 
 
2.2 Cell lines 
All cell lines were maintained at 37 oC and 5% CO2 in complete growth medium (5% 
FCS, antibiotic supplemented RPMI unless otherwise stated). 
C666-1: subclone of stable EBV positive cell line derived from a human 
undifferentiated nasopharyngeal carcinoma (NPC) xenograft of Southern Chinese 
origin (Cheung et al., 1999). Maintained in 10% FCS supplemented RPM1. Plastic 
tissue culture dishes were treated with 10% fibronectin in PBS for an hr at 37 oC prior 
to use. 
Primary Tonsil Keratinocytes: human, normal primary oral keratinocytes, maintained 
in keratinocyte media. 
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OKF6: human, retroviral hTert-immortalised, normal oral epithelial cell line (Opitz et 
al., 2001), maintained in keratinocyte media. 
NP460: human, Chinese derived, hTert-immortalised normal nasopharyngeal cell line 
(Li et al., 2006), maintained in keratinocyte media. 
YCCEL1: human, Korean derived, naturally EBV positive gastric carcinoma cell line 
(Seo et al., 2013). 
CNE2: human EBV negative cell line isolated from undifferentiated NPC biopsy. 
Original EBV status unknown (Sizhong et al., 1983).  
CNE1: undifferentiated, human, EBV negative NPC derived cell line (Sizhong et al., 
1983). 
SUNE1: poorly differentiated, human, EBV negative NPC derived cell line (Chen et 
al., 1998). 
H103: EBV negative, human squamous cell carcinoma derived cell line (Prime et al., 
1990). Maintained in 10% FCS supplemented RPMI. 
HONE1: EBV negative cell line derived from an EBV-positive undifferentiated 
Chinese NPC biopsy (Glaser et al., 1989). 
ADAH: EBV negative, human, immortalised cell line derived from an adenocarcinoma 
of the nasopharynx (Takimoto, 1979). 
AGS: human, tumourigenic immortalised cell line derived from an undifferentiated 
gastric carcinoma (Barranco et al., 1983). 
CNE2, SUNE1, CNE1, HONE1, AGS and ADAH rEBV: cell line stably infected with 
recombinant Akata strain of EBV containing neomycin resistance cassette. 
Maintained under neomycin drug selection. 
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HONE1 NEO, EBNA1, LMP1, LMP2A and LMP2B: cell lines generated from 
individual clones of parental HONE1 transfected with EBV gene or neomycin control 
plasmid, maintained under neomycin drug selection. 
 
2.2.1 Maintenance of cell lines 
Adherent epithelial cells were grown on plastic tissue culture flasks in humid 
incubators at 37 oC with 5% CO2. Adherent cells were grown to 80% confluence, 
pre-confluence log phase growth prior to passage. Subculture involved gently 
washing cells once in 1x PBS and incubating for a maximum of 10-15 min in a 
covering of trypsin replacement solution at 37 oC. Once detached cells were 
recovered in an excess of FCS containing complete growth medium, and pelleted by 
centrifugation at 1,000rpm for 5 min at room temperature. Supernatant was 
discarded and cells resuspended in 5 ml of supplemented growth medium ready for 
re-plating at required density in fresh growth media as established by 
haemocytometer counts. 
 
2.2.2 Cryopreservation of cell lines  
Pre-confluent cells, in log phase of growth, were trypsinised and pelleted as above 
prior to resuspension in 1ml of freezing medium. Freezing medium contained 50% 
supplemented growth medium, 40% FCS and 10% DMSO cyroprotectant. Aliquots of 
1 x106 cells were dispensed into freezing ampoules (Nunc, Denmark) and placed into 
a cryopreservation container (Mr Frosty, Nalgene, US). The container was then 
placed into 80 oC freezer for at least 4 hr before the ampules were transferred to 
liquid nitrogen for long term storage. 
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2.2.2.1 Recovery of cryopreserved cells 
Frozen ampoules were rapidly thawed in a 37 oC water bath. Cells were transferred 
to sterile universal (Sterilin, Thermo Scientific, US) and warm supplemented growth 
medium was added drop wise. Cells were left for 5-10 min prior to centrifugation at 
1,500rpm for 5 min at room temperature. The supernatant containing the DMSO was 
removed and cells resuspended in supplemented growth medium before plating out. 
 
2.3 Generation of EBV positive cell lines 
Generation of SUNE1, CNE1 and H103 cell lines was necessary for this thesis. All 
other cell lines had previously been generated. A cross linked Akata Burkett’s 
lymphoma (Akata BL) cell line was utilised to infect epithelial cells with neomycin 
cassette containing wild type EBV (Stewart et al., 2004). Akata cells were pelleted 
and resuspended at 2 x106 cell/well in fresh 10% BL media, to which 1 µl/ml anti 
Human IgG cross linker was added. Cells were incubated for 2-3 hr in a 9 cm dish 
prior to recovery of cell suspension and resuspension at 2 x106 cell/ml in fresh media. 
Cells were left for 72-96 hr prior to plating at 3 x105 B-cells with 1x105 epithelial 
cells/well (3:1 ratio), in a 12 well plate. Epithelial cells attached over the following 48-
72 hr at which point the Akata cells were washed off and EBV infected, polyclonal 
population of epithelial cells was selected for by G418 treatment. 
 
2.4 Bacterial cell culture for the production of plasmid DNA 
2.4.1 Preparation of competent cells 
E.coli strain XL1-Blue cell aliquots were stored at -80 oC in 20% (v/v) glycerol. 
Aliquots were recovered onto LB media plates containing 15 g bacto-agar per litre of 
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LB media, and incubated overnight at 37 oC. Isolated colonies were removed into 2ml 
SOB and placed back at 37 oC until the cell density rose to 5 x107 cells/ml (OD600 = 
0.5). Cells pelleted by centrifugation at 2,500 x g at 4 oC for 10 min (Sorvall SS-34 
centrifuge, Du Pont Instruments, US) prior to resuspension in 50 ml pre-chilled RF1 
(100 mM RbCl, 50 mM MnCl2, 10 mM potassium acetate pH 5.8, 10 mM CaCl2, 15% 
(w/v) glycerol) 
 
2.5 Generation of SHH plasmid 
Plasmids were supplied (Addgene, US) as bacterial colonies in agar, and bulked up 
overnight in 400 ml broth (shaking at 37 oC) prior to plasmid extraction using purelink 
plasmid miniprep system (Invitrogen, US) according to manufacturer’s instructions. 
DNA resuspended in DEPC water at 1 µg/µl. FastDigest® (Thermo Scientific, US), 
Fast simultaneous plasmid vector linearization and dephosphorylation reaction 
mixtures are presented in Table 2.1 and 2.2 respectively. Reactions were incubated 
at 37 oC for 5 min. 
 
Table 2. 1 Reaction mixture for plasmid digestion 
 
Reagent Volume (µl) 
13996 pBS hShh CT#401 
(Addgene, US) (1µl/µl) 
2 
10x FastDigest® buffer 
(Thermo Scientific, US) 
4 
FastDigest® enzyme 2 
Nuclease free water 32 
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Table 2. 2 Reaction mixture for plasmid linearization and dephosphorylation. 
 
Reagent Volume (µl) 
Plasmid DNA 1 
10x FastDigest® buffer 2 
FastDigest® enzyme 1 
FAST AP™ 
Thermosensitive Alkaline 
Phosphate 
1 
Nuclease free water 15 
 
 
Backbone pBABE-puro plasmid (1764, Addgene, US) was digested with EcoRI and 
alkaline phosphatase. pBS hShh CT#40 (113996, Addgene, US) plasmid was 
digested with EcoRI prior to loading into an agarose gel. Plasmid maps of pBS hShh 
and pBABE puro are shown in Figure 2.1 A and B respectively. The SHH insert gene 
was excised from the agarose gel under UV and purified with a GeneJet Gel 
Extraction Kit (Thermo Scientific, US). Linear DNA sample concentrations were 
analysed on a Nanodrop (Fisher Scientific, UK) prior to ligation. Rapid DNA ligation 
(Fermentas, US) protocol was used to ligate 10-100 ng of linearised vector DNA with 
SHH insert DNA at a 3:1 molar excess using 4µl of 5x rapid ligation buffer 
(Fermentas, US) and 1 µl of 5 µg/µl T4 DNA ligase made up to 20 µl with H2O. Cells 
were heat shocked prior to plating on ampicillin plates (20 ml agar/LB broth 
containing 100 µg/ml ampicillin). Cells were plated at 2 densities using 5 and 10 µl of 
reaction mixture on two plates alongside a control pBABE and control complement 
cell plate, and left at 37 oC overnight. Colonies were picked and put in 3 ml LB broth 
containing 100 µg/ml ampicillin and left shaking at 37 oC overnight. 1.5 ml LB culture 
used for miniprep (QIAprep Spin Miniprep Kit, Qiagen, US) according to 
manufacturer’s protocol, prior to diagnostic digest with bglII and HindIII restriction 
enzymes. Remaining LB culture containing correct plasmid construct was bulked up.  
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2.5.1 Visualisation of digest products 
Digest products of pBS hShh were visualised in a gel from which the SHH gene, 
1567bp, was excised (Figure 2. 2). Following ligation of pBABE-puro and SHH insert 
were bulked up and purified. Insert presence and orientation was established by 
analytical digestion using BglII and HindIII enzymes sites for which both appear once 
in the pBABE SHH plasmid. Digestion of pBABE SHH in the correct orientation would 
give bands at 5kb and 1.5kb, where as a SHH insert in the wrong direction would 
give rise to a 6Kb and 560bp bands. Digestion was seen to produce linearised 
products of the pBABE puro backbone without insert in 4 of the 5 ligations tested, 
and produced two ligation products in the remaining digest. Lane 3 of Figure 2. 2 
shows the two digestion products present at 5kb and 1.5kb in addition to undigested 
plasmid present at 6.5Kb. 
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Figure 2. 1 Plasmid Maps of (A) pBABE-puro target backbone and (B) pBS 
hShh 
EcoRI, HindIII enzymatic sites utilised in the generation of pBABE-puro hShh are 
located either side of the SV promoter (green arrow). SHH gene insert can be 
extracted by EcoRI restriction enzyme digestion (figures from addgene.org/13996/ 
and addgene.org/1764/). 
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Figure 2. 2 Generation of the SHH expression plasmid  
(A) Digestion of Addgene plasmid 13996: pBS hShh with EcoRI to generate 1576bp 
fragment for excision. (B) BglII and HindIII diagnostic digestion of DNA isolated from 
five bacterial colonies grown on ampicillin plates. Colony three contains the desired 
fragment sizes. 
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2.6 Luciferase reporter assay 
Dual-Luciferase Reporter Assay System (Promega, US) was used to sequentially 
measure a single transfection for luciferase activity of firefly (Photinus pyralis) for the 
reporter of interest, and Renilla (Renilla reniformis) acting as an internal cell viability 
and transfection control. Cells were seeded at 0.5-2 x105, depending on individual 
cell proliferative rates, in a 12-well plate and allowed to reach 70% confluence.  
 
Table 2. 3 Preparation of transfection media 
 
Reagent (Supplier) 
Control plasmid 
transfection 
(µl/well) 
Reporter plasmid 
transfection 
(µl/well) 
Optimem (Life 
technologies, US) 
250 250 
Plasmid of interest  0.5 
Control plasmid 0.5  
Renilla  0.5 0.5 
Plus™ reagent 
(Invitrogen, US) 
1 1 
 5 min at RT 
LTX (Invitrogen, US) 3 3 
 30 min at RT 
Add 255 µ transfection media per well  
 
Per well 0.5-1 µg of plasmid DNA was diluted in 250 µl Optimem and complexed with 
1 µl Plus™ reagent (Invitrogen, US) for 5 min at room temperature to increase 
transformation efficiency. Lipofectamine™ LTX reagent (Invitrogen, US) was added 
to the DNA complex and left for a further 30 min whilst the medium on the cells was 
replaced with 745 µl complete growth medium, without the addition of antibiotics. 
255 µl transfection media was added to each well (Table 2. 1). Cells were incubated 
for 6-12 hr, and lysed in 500 µl 1x Passive Lysis Buffer for 30 s with agitation prior to 
freezing at -20 oC. Plasmids used for luciferase are summarised in Table 2. 2. 
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Table 2. 4 Plasmids utilised in this thesis 
 
Plasmid Control Source 
8xGLI-BS-Luc pGL2-basic 
Kindly provided by Dr. Steven Cheng, Nanjing 
Medical University, China 
pSHH pBABE-puro 
Generated in this thesis, see Materials and 
Methods, section 2.5  and Chapter 3, section 3.6.1 
 
2.7 Stimulation and inhibition of cells 
A number of cytokines, pharmacological and chemical inhibitors were used in this 
thesis (Table 2.3). Cells were plated at appropriate densities, in complete media, and 
allowed to attach, prior to replacement with media containing 0.5% FCS for 12-24 hr. 
Cytokines and inhibitors were added at appropriate concentrations in 0.5% serum 
media and incubated for an assay dependent length of time. 
 
Table 2. 5 Cytokines and inhibitors utilised in this thesis 
 
Reagent (supplier) 
Standard 
concentration 
Nature and target pathway  
SHH  
(Peprotech, US) 
0.5 μg/ml Soluble HH pathway ligand 
5E1  
(Developmental Studies 
Hybridoma Bank, 
University of Iowa) 
10 μg/ml Anti-SHH antibody 
Cyclopamine (Miltenyi 
Biotech, Germany) 
25 μM HH pathway agonist SMO inhibitor 
GANT58  
(Tocris, US) 
25 μM 
HH transcription factor GLI1 chemical 
inhibitor (Lauth et al., 2007) 
GANT61  
(Tocris, US) 
12.5 μM 
HH transcription factor GLI1 and GLI2 
chemical inhibitor (Lauth et al., 2007). 
 
2.8 5E1 and conditioned media 
5E1 (anti-SHH mAb) or C651.6 (anti Notch2 mAb) hybridoma cells were grown to 
80% confluence and then switched to medium (RPMI1640) containing 0.5% FCS and 
allowed to condition the medium for 48 hr. The medium was aspirated and 
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centrifuged to remove cells, prior to filtration through a 0.2 micron filter and storage at 
4oC. In SHH stimulation/inhibition experiments, conditioned medium was diluted 1:1 
with complete growth medium prior to incubation.  
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2.9 Molecular biology 
2.9.1 Isolation of RNA 
Cells were plated onto 10 cm2 dishes and grown to 80% confluence prior to total 
RNA extraction. 500 ml Trizol Reagent (Invitrogen, US) was used to lyse cells and 
processed as per manufacturer’s instructions. A scraper was used to transfer lysed 
cells to a 1.5 ml eppendorf and shaken for 2 min to homogenise sample. Cell lysates 
were frozen overnight to ensure complete cell fragmentation. Defrosted samples 
were incubated at room temperature for 5 min prior to the addition of 100 µl 100% 
chloroform. Tubes were shaken vigorously for 15 s and incubated at room 
temperature for 2-3 min before centrifugation at 3,000 rpm for 30 min at 4 oC. The 
upper phase, containing the RNA, was transferred to a fresh eppendorf being careful 
to leave the participated interphase, containing the DNA, behind. The interphase and 
phenol was set aside when protein extracts were also to be isolated.  
 
250 µl 100% isopropanol was added to the upper aqueous phase, inverted to mix, 
and incubated for 10 min at room temperature. Centrifugation at 3,000 rpm for 30 min 
at 4 oC pelleted the RNA which was washed in 0.5 ml 75% ethanol and incubated 
overnight at -20 oC. Ethanol was removed from the RNA pellet, which was allowed to 
air dry for 5 min before resuspension in max 200 µl DEPC treated water in a fresh 
eppendorf. Complete dissolution was insured by incubation at 55 oC for 10 min. RNA 
concentration and quality was analysed using a spectrophotometer (Nanodrop, 
Thermo Scientific, US) and diluted to 0.5 µg/µl with DEPC treated water then stored 
at -80 oC. 
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2.9.2 cDNA synthesis 
First strand cDNA synthesis was achieved using SuperScript III Reverse 
Transcriptase (Invitrogen, US) as per manufacturer’s instructions. Table 2. 6 lists the 
reagents and volumes used.  
 
Table 2. 6 Reaction mixture A for initial cDNA synthesis reaction 
 
Reagent Volume (µl) 
Random Primers (250 ng/µl) 1 
dNTP mix (10 mM) 1 
RNA (0.5 µg/µl) 2 
SDW 9 
 
The reaction mix A was heated to 65oC for 5 min and subsequently kept on ice for 
5 min. Reaction mixture B, in Table 2. 7, was added to each reaction followed by 
incubation at 50 oC for 1 hr then 72 oC for 15 min. cDNA was stored at -20 oC. 
 
Table 2. 7 Reaction mixture B added to initial cDNA synthesis reaction 
 
Reagent Volume (µl) 
First strand buffer (5x) 4 
DTT (0.1 M) 1 
RNaseOUT (40 U/µl) 1 
SuperScript III RT (200 U/µl) 1 
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2.9.3 Reverse transcriptase-polymerase chain reaction (RT-PCR) 
RT-PCR was carried out using cDNA generated as described above. The reaction 
mixture for the amplification of a known gene is listed Table 2. 8 
 
Table 2. 8 RT-PCR reaction mixture 
 
 Reagent Volume (µl) 
DreamTaq (Thermo Scientific, US) 25 
5’ Forward Primer (100 pmol/μl) 1 
3’ Reverse Primer (100 pmol/μl) 1 
DEPC-water 22 
cDNA 1 
 
The general thermal cycler conditions used are depicted in Table 2. 9. The number of 
cycles and annealing temperature were optimised for the specific primer set 
presented (Sigma Aldrich, US). 
 
Table 2. 9 General PCR thermal cycler conditions 
 
Step Temperature Time (min) 
1. 95 oC 5 
2. 95 oC 1 
3. Annealing 
Temperature 
0.5 
4. 72 oC 2 
Repeat step 2 to 4 for specified cycle no. 
5. 72 oC 5 
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 Table 2. 10 Primer DNA sequences 
Gene Primers 
Annealing 
Temp (oC) 
No. of 
Cycles 
Product 
Size 
SHH 
FWD: GCGGACAGGCTGATGACTC 
REV: CGAGTTCTCTGCTTTCACCG 
62 40 248 
IHH 
FWD: CTGAACTCGCTGGCTATCTC 
REV: CCCACTCTCCAGGCGTAC 
57 35 305 
GLI1 
FWD: GTGTGGGGACAGAAGGAC 
REV: GAGATGACCGTAGGAGCC 
60 40 248 
GLI2 
FWD: GTGTCCCGTTTCTCCAGC 
REV: GCTTGTTCTGGTTGGTGTCA 
58 40 424 
GLI3 
FWD: CACTACCACCCTCCTCATC 
REV: GTATTCTGCTGGCTGAC 
56 35 337 
SUFU 
FWD: GCGGACAGTGCCTATTGCT 
REV: GAGGGTTGATTGGTGGAAGG 
60 30 320 
SFRP1 
FWD: AGCGAGTTTGCACTGAGGAT 
REV: GGGCACTCATGGTTTTTCAT 
58 35 307 
STK36 
FWD: GAGCAAGAGGACAAGACCAGC 
REV: GCAGGATGTGGGAAGCAC 
60 35 444 
PTCH1 
FWD: CACTGTGGTCCATCCCGA 
REV: GTGATGGGCTGGCAGTAGC 
62 40 306 
SMO 
FWD: CCCTGGTCTCCAACCCATTC 
REV: ACCACAAGCTCTGCATACCC 
62 40 481 
FOXM1 
FWD: CCACTCAGCCTCCAGGACTC 
REV: AACCTGTCGCTGCTCCAG 
59 30 308 
WNT5A 
FWD: TGGCTTTGGCCATATTTTTC 
REV: CCGATGTACTGCATGTGGTC 
57 35 220 
BMP2 
FWD: CCTGAAACAGAGACCCACC 
REV: GCATTCTGATTCACCAACCT 
56 56 417 
BCL2 
FWD: CGGGAGATAGTGATGAAGTAC 
REV: AGCGGCGGGAGAAGTCGTCG 
62 35 288 
SNAI1 
FWD: CCACATCAGCCCCACA  
REV: CATAGTTAGTCACACCACGT 
58 35 321 
SIP1 
FWD: GCAAACAAGCCAATCCCAGG  
REV: TGCATTCTTCACTGGACCATCT 
58 35 299 
CD133 
FWD: CGTAGCAGGTATCAAAAGGG 
REV: AGTGCCGTAAGTGCCTCTATT 
56 40 583 
P75NTR 
FWD: CGAGTGCGAGGAGATCCC 
REV: ACAACCACAGCAGCCAGG 
56 40 234 
LRIG1 
FWD: GACCTGCCCTCCTGGAC 
REV: CAAATGCTCCCAACTCCA 
58 35 358 
EZH2 
FWD: TAGGGCGGTGGAAGATGAA 
REV: TTTAGTTCTTCTGCTGTGCC 
58 40 355 
BMI1 
FWD: CATTCCTTCTGTAAAACGTGTATTTA 
REV: TCATCTGCAACCTCTCCTC 
56 30 254 
SOX2 
FWD: AGAACCCCAAGATGCACAAC 
REV: ATGTAGGTCTGCAGCTGGT 
61 40 455 
CD44v6 
FWD: TCCAGGCAACTCCTAGTAGT 
REV: CAGCTGTCCCTGTTGTCGAA 
60 32 129 
OCT4 
FWD: CCTGGGGGTTCTATTTGGG 
REV: GCCTCTCACTCGGTTTCG 
60 35 219 
NESTIN 
FWD: CTGGAAGGTCGGCAGCAG 
REV: CACCCTGTGTCTGGAGCAG 
56 35 415 
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NANOG 
FWD: CAGAGAAGAGTGTCGCAAAAA 
REV: ATCCCTGCGTCACACCATT 
55 38 267 
cMYC 
FWD: AACCAGAGTTTCATCCGACCCG 
REV: TTGTGCTGATGTGTGGAGACGTGG 
62 35 591 
CXCR4 
FWD: GGTGGTCTATGTTGGCGTCT 
REV: TGGCGTGTGACAGCTTGGAG 
60 40 228 
EPCAM 
FWD: GAATGTGTCTGTGAAAACTAC 
REV: CAGTGTCCTTGTCTGTTCTTC 
55 30 318 
EBNA1 
FWD: GATGAGCGTTTGGGAGAGCTGATTCTG  
REV: TCCTCGTCCATGGTTATCAC 
56 40 320 
LMP1 
FWD: CCCCCACTCTGCTCTCAAA 
REV: CCGTGGGGGTCGTCATCAT 
56 32 488 
GAPDH 
FWD: GCCTCCTGCACCACCAACTG 
REV: CGACGCCTGCTTCACCACCTTCT 
52 25 351 
EBV primers used for characterisation of HONE1 cell lines 
EBNA1 
Qp 
FWD: GTGCGCTACCGGATGGCG  
REV: CATTTCCAGGTCCTGTTACCT 
52 35 236 
EBNA1 
Wp 
FWD: TGGCGTGTGACGTGGTGCAA  
REV: CATTTCCAGGTCCTGTTACCT 
53 35 265 
LMP1 
2.8Kb 
FWD: ACACACTGCCCTGAGGATGG  
REV: ATACCTAAGACAAGTAAGCA 
45 35 381 
LMP1 
3.7Kb 
FWD: GCGTTACTCTGACGTAGCCG  
REV: ATACCTAAGACAAGTAAGCA 
45 35 460 
LMP2A 
FWD: ATGACTCATCTCAACACATA  
REV: CATGTTAGGCAAATTGCAAA  
44 35 280 
LMP2B 
FWD: CAGTGTAATCTGCACAAAGA  
REV: CATGTTAGGCAAATTGCAAA 
46 35 324 
BamH1 
A1/2 
FWD: CCTTCGATATCGAGTGTCTG  
REV: ATGGCCGGAGCTCGTCGACG 
50 35 163 
BamH1 
A3/4 
FWD: AGAGACCAGGCTGCTAAACA  
REV: AAGCAGCTTTCCTTTCCGAG 
53 35 232 
EBER1 
FWD: AGGACCTACGCTGCCCTAGA  
REV: AAAACATGCGGACCACCAGC 
55 35 166 
EBER2 
FWD: GCCGTTGCCCTAGTGGTTT  
REV: GGGATTAGAGAATCCTGACTT 
50 35 130 
BZLF1 
FWD: ATTGCACCTTGCCGCCACCTTTG  
REV: CGGCATTTTCTGGAAGCCACCCGA 
46 35 731 
BARF1 
FWD: GGCTGTCACCGCTTTCTTGG  
REV: AGGTGTTGGCACTTCTGTGG 
56 35 202 
BHRF1 
FWD: GTCAAGGTTTCGTCTGTGTG  
REV: TTCTCTTGCTGCTAGCTCCA 
51 35 650 
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2.9.4 Agarose gel electrophoresis 
Gel electrophoresis was used to separate PCR product dependent on the size of the 
DNA fragment. Electrophoresis gel at 0.5% - 2.0%, dependant on fragment size, was 
made by dissolving ultrapure DNA grade agarose (Sigma Aldrich, US) in 1x TBE 
buffer (containing 10.8 g Tris, 4.5 g orthoboric acid and 0.74 g EDTA per 1 litre SDW) 
with aid of a microwave oven. The solution was poured into a casting gel around an 
appropriate gel comb and allowed to solidify at room temperature. Amplified PCR 
produces were loaded into the gel in a gel electrophoresis tank containing 1x TBE 
alongside a molecular weight ladder (1 Kb and 100 bp ladder, Invitrogen, US). DNA 
was visualised and photographed with a GeneFlash bio imaging system (GeneFlow, 
UK). 
 
2.10 Real-time quantitative PCR (QPCR) 
Expression of viral mRNAs was performed on cDNA generated as in section 2.9.2. 
TaqMan® primer and probe sets for EBNA1, LMP1 and LMP2A, Table 2. 11; 
sequences from Bell at al., (2006), were labelled with a 6-carboxyfluorescein 
phosphormaidite (FAM™) reporter dye at the 5’ end and 6-
carboxytetramethylrhodamin (TAMRA™) at the 3’ end. Expression of mRNA of 
interest was normalised against a commercially available huGAPDH primer/probe set 
containing a VIC™ labelled probe (4310884E, Applied Biosciences, US) as an 
internal control. The reaction mixture is described in Table 2. 12. 
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Table 2. 11 TaqMan primer/probe sequences for EBV transcript detection 
Sequences from Bell et al., (2006) 
 
Gene Oligonucleotide sequence EBV coordinates  
EBNA1 
5’        GTGCGCTACCGGATGGC 
3’        CATGATTCACACTTAAAGGAGACGG 
Probe TCCTCTGGAGCCTGACCTGTGATCG 
62440-62456 
107952-107941 
67563-67587 
LMP1 
5’        AATTGCACGGACAGGCATT 
3’        AAGGCCAAAAGCTGCCAGAT 
Probe TCCAGATACCTAAGACAAGTAAGCACCCGAAGAT 
169102–169083 
168893–168912 
168951–168965 
LMP2A 
5’        CGGGATGACTCATCTCAACACATA 
3’        GGCGGTCACAACGGTACTAACT 
Probe CAGTATGCCTGCCTGTAATTGTTGCGC 
166870–166893 
166870–166893 
66–92 
 
Table 2. 12 QPCR reaction mixture 
 
 Reagent Volume (µl) 
Gene of interest primer and probe 
(10 pmol primer, 5 pmol probe) 
1 
huGAPDH primer and probe 0.5 
1x TaqMan universal mastermix 
(Applied Biosystems, US) 
10 
DEPC-water 3.5 
cDNA (5 ng/µl) 5 
 
Thermal-cycling conditions were based on those described in Bell et al., (2006). All 
reactions were performed in triplicate and analysed on an ABI 7500 Fast RT-PCR 
machine (Applied Biosystems, US) using the 2-ΔΔCt method described in Livak and 
Schmittgen (2001). Cycle threshold (Ct) values were determined by identifying the 
value at which amplification exceeded background levels for each reaction, Primers 
for the gene of interest were then normalised to the internal GAPDH control giving a 
ΔCt value which were averaged to produce a mean ΔCt value for each gene of 
interest. Normalisation of all value to the control cell line resulted in a ΔΔCt value 
from which fold changes relative to the control could be calculated using the 2-ΔΔCt 
formula. 
 
Materials and Methods 
93 
 
Chapter 2 
2.11 Immunoblotting 
2.11.1 Solutions and buffers 
RIPA Buffer 50 mM: Tris-HCl (pH 8.0), 150 mM NACl, 1% NP40, 0.5% deoxycholate, 
0.1% SDS. 40 μl/ml complete protease inhibitors (Roche, Switzerland), 0.5 mM 
sodium orthovanadate (S6508, Sigma Aldrich, US) and 1 mM PMSF (P7626, Sigma 
Aldrich, US). 
3x SDS sample buffer: 197.5 mM Tris-HCl (pH 8.0), 6% w/v SDS, 30% glycerol, 
0.03% w/v bromophenol blue. 
Resolving Gel Buffer: 500 ml solution of 1.5 M Tris-HCl (pH 8.8) made by dissolving 
90.86 g Tris in SDW containing 0.4% w/v SDS and 0.24% w/v TEMED. 
Stacking Gel Buffer: 500ml solution of 0.25 M Tris-HCl (pH 6.8) made by dissolving 
15.14 g Tris in SDW containing 0.2% w/v SDS and 0.12% w/v TEMED. 
1x Running Buffer: 10x solution made up of 30g Tris-HCl, 144 g glycine, and 10 g 
SDS. Made up to 10 litres with SDW. Diluted 1 in 10 with SDW before use. 
1x Transfer Buffer: Solution made up of 30g Tris and 144g glycine in 8 litres of SDW 
and 2 litres of 100% methanol. 
10x Tris Buffered Saline-Tween (TBS-T): Stock solution made up of 60.5 g Tris-HCl, 
200 g NaCl, 25 ml Tween-20 made up to 10 litres with SDW. Diluted 1 in 10 with 
SDW before use. 
Blocking Buffer: 5% non-fat milk powder in 1% TBS-T 
Stripping Buffer: Solution made up of 100 mM Tris-HCl pH 6.8, 2% w/v SDS, 50 mM 
2-mercaptoethanol, in 500 ml SDW 
Ammonium Persulphate (APS): 20% stock made up by dissolving 2 g APS in 10 ml 
and aliquoted at 1 ml in 1.5 ml eppendorfs. 
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2.11.2 Preparation of whole cell extracts 
Cells were plated onto 10cm2 dishes and grown to 80% confluence prior to protein 
extraction. Cells were washed once in PBS and lysed with 50ml ice-cold RIPA 
supplemented with a complete protease inhibitor tablet (Roche, Switzerland). A 
scraper was used to transfer lysed cells to a 1.5 ml eppendorf and sonication for 10 s 
on a 50% setting. Cellular debris was removed by centrifuging at 13,000 rpm for 
5 min at 4 oC and the transferring the supernatant to a new eppendorf. 
 
The DC protein assay kit (Bio-Rad, US) was used to determine protein concentration 
of lysates as per manufacturer’s instructions. 5 µl of protein standard and sample 
lysates were aliquoted in triplicate into a 96 well plate and to this added 25 µl of 
reagent A and 200 µl of reagent B per well. The plate was placed on a plate shaker 
at 200 rpm for 3 min prior to reading on a microplate automated plate reader (Biotek, 
US) at 620 nm. A standard curve of the BSA standards allowed for protein 
concentration to be calculated.  
 
Equal amounts of cell sample lysates were suspended in 3x sodium dodecyl sulphate 
sample buffer and incubated to 100 oC for 5 min. Boiled lysates were returned to ice 
prior to loading on appropriate percentage poly-acrylamide gel next to PageRuler 
protein standard marker (Fermentas, Fisher Scientific, US). 
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2.11.3 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
Mini-PROTEAN 3 electrophoresis kit (Biorad, US) was used to cast an appropriate 
concentration of SDS-polyacrylamide gel. Table 2. 13 shows the reagents used to 
make up a single 10% polyacrylamide gel.  
 
Table 2. 13 Reagents for 10ml of 10% resolving gel 
 
Reagent Volume (ml) 
SDW 4.0 
30% acrylamide mix 3.3 
Resolving Buffer 2.5 
20% APS 0.1 
0.8% N,N-bis acrylamide (v/v) 0.004 
 
To assist with a level gel being cast, once poured the gel was overlaid with 100% 
ethanol and allowed to polymerise at room temperature. The ethanol was then 
poured off and the gel washed with SDW. Stacking gel, detailed in Table 2. 14, was 
then poured on top, a gel comb inserted and allowed to polymerise. 
 
Table 2. 14 Reagents for 5ml of 10% stacking gel 
 
Reagent Volume (ml) 
SDW 3.2 
30% acrylamide mix 0.83 
Resolving Buffer 0.84 
20% APS 0.05 
0.8% N,N-bis acrylamide (v/v) 0.005 
 
Prior to loading the wells were washed with SDW. Equal amounts of protein samples 
were loaded into the wells and accompanied by a full range molecular weight marker 
(10,000-250,000 bp) (Amersham Biosciences, UK). Electrophoresis was carried out, 
cooled by a constant cold water flow, at 90 V for 90 min or until the loading dye had 
reached the bottom of the running gel. 
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2.11.4 Western blot analysis 
Membranes were blocked in 5% milk powder in Tris buffered saline-Tween 20 
(TBST) for a minimum of 30 min and incubated in primary antibody overnight on a 
nutator at 4 oC. Antibodies used are shown in Table 2.13. 
 
Following three 5 min washes in TBST, the membranes were incubated in 
horseradish peroxidise-tagged secondary antibody (1:1,000; Dako, US) for 1 hr at 
room temperature on a nutator. After three 5 min washes in TBST, membrane were 
incubated with enhanced chemiliuminescence (ECL) detection reagents (Amersham 
International, UK) for 5 min, rinsed with TBST and exposed to X-ray film (Kodak, US).  
 
Following electrophoresis, the resolved soluble proteins were transferred onto a 
nitrocellulose membrane (Geneflow, UK). The gel and membrane were sandwiched 
between two layers of 3MM filter paper (Whatman, UK) which were pre-soaked in 
transfer buffer. Proteins were transferred from the gel onto the membrane using the 
Mini-transblot apparatus (Biorad, UK), at 90 V for 90 min on ice. Non-specific binding 
sites on the membrane were blocked in blocking buffer for 1 hr at room temperature 
with gentle agitation. The membrane was then placed into blocked buffer containing 
the relevant primary antibody (Table 2. 15) and incubated overnight at 4 oC with 
gentle agitation. The membrane was rinsed in TBS-R followed by 3 x 5 min washes 
in TBS-T and subsequently incubated with the appropriate horse radish peroxidise 
(HRP) conjugated secondary antibody (Dako, US) at room temperature for 1 hr with 
gentle agitation. Following incubation with the secondary antibody, the membrane 
was rinsed in TBS-T followed by 3 x 5 min washes in TBS-T. The complex bound to 
the protein of choice was detected and visualised by enhanced chemiliuminescence 
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(ECL) detection reagents (Amersham International, UK). Briefly, the membrane was 
incubated in a 1:1 solution of reagent A and reagent B for 5 min at room temperature 
with no agitation. The membrane was rinsed in TBS-T to removed excess ECL 
reagent and covered in saran wrap. The membrane was exposed to X-ray film 
(Kodak, US) for different time periods depending on the strength of the 
chemiluminescent signal. X-ray films were developed in a compact automatic film 
processor x2 (Xograph Ltd., UK). 
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Table 2. 15 Antibodies and conditions used for western blot analysis, 
immunofluorescence staining, and FACS analysis 
(Abbreviations: ab; Abcam, SC; Santa Cruz, C; Cell Signalling, M; Miltenyi, AC; 
Merck Millipore, Sig; Sigma, -MM; mouse monoclonal, RM; rabbit monoclonal, RP; 
rabbit polyclonal, H; from human serum, WB; western blot analysis, IHC, 
immunohistochemistry, IF; immunofluorescence, FACS; flow activated cell sorting) 
 
Protein Antibody Nature WB IHC IF/FACS 
SHH ab53281 RM 1:500 1:200 1:100 
PTCH ab53715 RP 1:500 1:400 1:200 
SMO ab38686 RP 1:1000 1:50 1:50 
GLI1 ab49314 RP 1:400 - 1:100 
GLI1 SC20687 RP - 1:50 - 
GLI2 ab26065 RM 1:250 1:100 1:50 
GLI3 ab6050 RP 1:500 1:800 1:50 
FOXM1 SC500 RP 1:250 - 1:50 
FOXM1 ab83907 RP - 1:25 - 
SUFU ab52913 RM 1:1000 1:50 - 
BMP2 ab14933 RP 1:200 - - 
WNT5A ab30436 MM 1:1000 - - 
CD133 C24B91 RM - - 1:10 
CD133macs M293C3pure MM - - 1:50 
P75NTR ab8874 RM - - 1:100 
CD44v6 ab30436 MM 1:1000 - 1:100 
CD44 ab51037 RM 1:5000 - - 
NESTIN ab22035 MM 1:1000 - - 
BMI1 SC10745 RP 1:200 - - 
EZH2 AC22 MM 1:1000 - - 
SIP1 ab25837 RM 1:500 - - 
SNAIL1 SC28199 RM - - 1:50 
SNAIL1 ab177321 RM 1:500 - - 
BZLF1 BZ12 H 1:500 - - 
EBNA1  R43 H 1:5000 - 1:1000 
β-Actin ab3280 MM 1:10000 - - 
1Discontinued 
2Monoclonal human antibody provided in house, acknowledgements to Dr. Martin 
Rowe 
3A kind gift from Prof. L. Frappier 
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2.12 In situ immunofluorescence staining 
2.12.1 Immunofluorescence staining solutions 
4% Paraformaldehyde (PFA): 20 g PFA was dissolved in 500 ml SDW, dissolved by 
stirring overnight at 42 oC. Once dissolved, five Dulbecco A tablets (Sigma Aldrich, 
US) were added and the bottle was covered in tin foil and stored at room 
temperature. 
20% HINGS: Heat inactivated normal goat serum diluted to 20% in PBS and stored 
at -20 oC. 
0.5% Triton X-100: 2.5 ml Triton X-100 dissolved in 497.5 ml 1 x PBS and stored at 
4 oC 
DABCO: 90 ml 100% glycerol was mixed with 10 ml 1x PBS and 2.5 mg DABCO 
powder (Sigma Aldrich, US). The solution was adjusted to pH 8.6, covered in silver 
foil, and stored at room temperature. 
 
2.12.2 in –situ immunofluorescence staining procedure 
Cells of interest were seeded on to Teflon coated microdot slide (Henley, UK) at 
1 x104 cells in 50µl complete growth medium. Slides were kept in a sterile petri dish 
with 2ml PBS, and incubated overnight at 37 oC in a humidified incubator containing 
5% CO2 to allow the cells to adhere. Two staining protocols were used. 
Protocol 1: Cells were washed and fixed in 4% PFA for 10 min and permeabilised in 
0.5% Triton X-100 for 5 min for the detection of intracellular proteins. Non-specific 
binding sites were blocked by incubation with 50 µl 20% HINGS in PBS for 1 hr in a 
wet box at room temperature. Slides were incubated for 1 hr with primary antibody 
(see table 2. 13) diluted in 20% HINGS, in a wet box at room temperature. Following 
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3 x 5 min washes in PBS, cells were incubated for 1 hr in a wet box at room 
temperature with secondary antibody (1:1000 in 20% HINGS) containing DAPI 
nuclear stain (1:1000) for 1 hr. Slides were washed again 3 x 5 min prior to mounting 
with DABCO anti-fading agent. Slides were stored at -20 oC until being viewed on a 
fluorescence microscope. 
 
Protocol 2 (for the detection of cell surface markers without fixation): Cells were 
washed and maintained at 4 oC throughout this protocol. Cells were blocked in 50 µl 
20% HINGS in PBS with the addition of 0.1% sodium azide (from a stock solution of 
10% sodium azide) for 30 min. Primary antibody (20% HINGS, 0.1% sodium azide in 
PBS) was incubated for 1 hr, cells washed trice for 5 min in PBS, and secondary 
antibody (20% HINGS, 0.1% sodium azide in PDBS) incubated for a further hr. Slides 
were washed a further 3 times prior to fixation in 4% PFA for 10 min. 
 
2.13 FACS analysis 
Cells harvested using accutase reagent (Innovative Cell Technologies, US) to 
maintain cell surface protein integrity, plated into a v-bottomed 96 well plate at 5 x105 
cell per well and maintained at 4 oC on ice for the staining procedure. Cells were 
spun down prior to addition of primary antibody (see table 2. 13) diluted in 20% 
HINGS for 1 hr. Cells were washed with 1% FCS three times by resuspension and 
re-centrifugation, prior to addition of appropriate secondary antibody Alexa Flour 488 
(Invitrogen, US) for 60 min. Following three further washes, cells were fixed in 1% 
PFA and analysed on XL-MCL Flow Cytometer (Beckman Coulter’s Epics, US) or 
Accuri C6 (BD Biosciences, US). 
 
Materials and Methods 
101 
 
Chapter 2 
2.14 IHC staining 
2.14.1 IHC staining solutions 
EDTA buffer/Tween: 10x solution supplied by Abcam, UK (ab64216) Diluted 1:10 
prior to use 
2.14.2 IHC pre-treatment and staining procedure 
Formalin-fixed, paraffin-embedded blocks of NPC and normal tonsil tissue were 
obtained from the Pathology Department of the Cancer Centre at Sun Yat-Sen 
University (Guangzhou, Guangdong, China) in 2007 were sectioned, heated at 60 oC 
for 60 min, and pre-treated by sequentially placing sides into xylene, 100% IMS, and 
0.3% hydrogen peroxide in water for 5 min.  
 
The ALTER (Agitated Low Temperature Epitope Retrieval) method was used prior to 
staining by heating slides to 65 oC in 1 litre of diluted pH 8 EDTA buffer/Tween, and 
leaving stirring for 16 hr. EDTA/Tween buffer was removed from the hotplate and 
placed under a running tap until the liquid reached room temperature.  
 
Slides were washed in PBS and non-specific antibody binding blocked by applying 
serum for 10 min, with use of a wax pen, prior to staining. Primary antibody was 
added at serial dilutions in PBS for 1.5 hr, and slides washed with PBS/Tween prior 
to the addition of secondary antibody for 30 min. DAB chromagen was used to 
visualise antibody as a brown stain for a defined time (10 s to 2 min). Slides were 
washed prior to counter stain with Haematoxylin for 40 s, washed again in warm tap 
water for 5 min, de-hydrated in IMS for 5 min, washed in xylene, and left to dry before 
mounting in DPX mountant (Sigma Aldrich, UK). 
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Following optimisation, staining for proteins of interest was performed on tissue 
arrays, containing cores from 50 NPC tumour samples and 20 normal counterparts, 
using the optimised antibody concentrations and conditions. Scores for protein 
expression (values 0-9) were obtained using a semi-quantitative scoring system by 
multiplying staining intensity (negative = 0, weak = 1, moderate = 2, or strong = 3) by 
the proportion of positive cells (< 30% = 1, 30-70% = 2, > 70% = 3) (Hu et al., 2012).  
 
2.15 Cell proliferation ELISA, BRDU (colorimetric) 
This colorimetric immunoassay was purchased as a kit from Roche, Switzerland 
(catalogue no. 11 647 229 001) and used according to manufacturer’s instructions. 
Briefly cells, in exponential grown phase, in a 96 well plate were incubated with 
diluted BDRU labelling reagent for 4-6 hr, depending on proliferative rate of the 
individual cell lines. Cells were fixed with FixDenat solution according to instructions, 
and anti-BRDU-POD solution applied, to bind incorporated BRDU, prior to washing. 
Anti-BRDU-POD was detected using a tetrametyl-benzidine colorimetric substrate 
reaction allowing for spectrophotometric detection on a Victor™ plate reader 
(PerkinElmer, US). 
 
2.16 Anchorage independent growth assay 
2.16.1  Anchorage independent growth assay solutions 
2x RPM1 acquired from Fisher Scientific, US. 
10% agarose: made up with dH2O and autoclaved for sterilisation. Agarose was 
re-liquefied prior to use by briefly heating in a microwave and allowing to cool to 
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37 oC in a water bath. All solutions made with agarose were kept at 37 oC to prevent 
their solidification. 
 
2.16.2 Anchorage independent growth assay protocol 
This assay measures proliferative ability by assessing the tendency of a single cell 
suspension to form colonies. Cells were plated out at 1 x102-103 cells per well in full 
complement 5% FCS media containing 0.3% agarose. This was achieved by first 
layering the bottom of a 12 well plate with 0.5ml of 5% FCS/1% RPMI/1% agarose 
and allowing the agarose to set at 4 oC, before transferring briefly to -20 oC. A cell 
line dependent number of cells were seeded in 1ml per well 5% FCS/1%RPMI/0.3% 
agarose, and allowed to set in pre-layered and cooled plates before transferring to 
the incubator. GANT treatment was applied at 25-50 µM total volume of well in 50 µl 
every 3-4 days for 2-4 weeks. All colonies greater of equal to 25 µm in size were 
counted and four representative images of each well, in triplicate, were taken to allow 
scoring of maximal diameter using calibrated AxioVision software (Zeiss, Germany). 
 
2.17 Sphere forming assay 
2.17.1 Sphere forming assay solutions 
Assay as with colony forming replacing FCS with restricted supplements as follows: 
N2® supplement (Invitrogen, US); used at 1% total agarose containing media, B27® 
supplement (Invitrogen, US); used at 2% total agarose containing media, FGF (10 
ng/ml) and EGF (100 ng/ml). 
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2.17.2 Sphere forming assay protocol 
Cell set up as with the colony forming assay in restricted supplement 1% RPM1/0.3% 
agarose on a layer of restricted supplement 1% RPM1/1% agarose. Cells seeded at 
a higher concentration 5 x102-103 depending on proliferative potential of the cell line. 
GANT treatment was applied at 25-50 µM total volume of well in 50 µl every 3-4 days 
for 2-4 weeks. All colonies greater of equal to 25 µm in size were counted and three 
representative images of each well, in triplicate, were taken to allow scoring of 
maximal diameter using calibrated AxioVision software (Zeiss, Germany). 
 
2.18 Statistics 
Unless otherwise stated, statistical significance was determined using a Student’s 
t-test preceded by an f-test to establish the equality of variance. 
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CHAPTER THREE: DYSREGULATION OF THE HEDGEHOG 
SIGNALLING PATHWAY AND ITS RELATION TO 
STEMNESS IN NASOPHARYNGEAL CARCINOMA. 
 
 
 
 
 
 
 
 
 
 
"Science and art belong to the whole world, and the barriers of nationality vanish 
before them." 
– Johann Wolfgang Goethe 
Remark to a German historian, 1813. From the series Great Ideas of Western Man.
Results 
106 
 
Chapter 3 
3.1 Introduction 
A number of signalling pathways have been found to be consistently dysregulated in 
NPC. These include the TGFβ, WNT, EGF, MAPK, PI3K/Akt, NOTCH and NFκB 
signalling pathways (Sriuranpong et al., 2004, Zeng et al., 2007b, Shi et al., 2006, 
Morrison et al., 2004, Lee et al., 2007b, Liu et al., 2009, Zhang et al., 2009a). Whilst 
these pathways function to regulate various aspects of cellular growth and 
differentiation, they also play an essential role in the growth, renewal and cell fate 
commitment of both ESC and adult stem cells (Rochon et al., 2006, Ramalho-Santos 
et al., 2002). Adult stem cells, like ESC, have properties of limitless self-renewal and 
multi-lineage differentiation, while residing life-long in adult organs and tissues. 
These specialised cells have the role of generating transit amplifying (TA) cells and 
terminally differentiated cells of the tissue in which they reside during normal growth 
and under situations of wound healing or tissue repair (Prockop et al., 2003, Lehrer 
et al., 1998, Alison et al., 2002). 
 
Many cancers, including NPC, exhibit dysregulation of one or more signalling 
pathways implicated in stem cell maintenance. Additionally, certain malignancies 
contain small populations of cells that share characteristic properties with stem cell 
populations such as limitless self-renewal and multiple lineage differentiation capacity 
(Reya et al., 2001). Furthermore, isolation of cell sub-populations has provided 
evidence that these “stem-like” cells display increased tumour forming properties 
compared to non “stem-like” cells (Wang et al., 2007). The ability of cells to form 
tumours upon serial transplantation is the gold standard for identification of CSCs 
(Visvader and Lindeman, 2008).  
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Two opposing theories exist as to the process of CSC generation. In the first 
scenario, CSCs are produced through acquired mutations in normal stem cells; the 
second proposes that stem cell-like characteristics are acquired in more committed 
cells through genetic and/or epigenetic changes. Regardless of their mechanism of 
generation, it is now recognised that most, if not all, solid tumours and 
haematological malignancies possess a sub-population of CSCs. These 
undifferentiated cells are responsible for generating more committed malignant cells 
that make up the bulk of the tumour (Tu et al., 2002, Bjerkvig et al., 2005). The 
presence of CSCs, which are inherently more resistant to chemotherapy and 
radiotherapy (Costello et al., 2000, Dean et al., 2005, Guzman et al., 2002), are 
believed to be at least partly responsible for the return of malignancies following 
periods of regression. Evidence for this comes from the finding that tumour 
responses to chemotherapeutic drugs, as measured by shrinkage of the tumour 
mass rather than the eradication of the CSC population, does not always correlate 
with increased survival (Reya et al., 2001, Al-Hajj et al., 2004, Wicha et al., 2006). 
This is true of head and neck malignancies, which often respond poorly to 
chemotherapy, resulting in high rates of recurrence (Prince and Ailles, 2008). In 
comparison, drug targeting of CSC populations in addition to conventional therapies 
are often more effective therapies (Tozer et al., 2005). Whilst CSC targeted therapies 
may not induce rapid tumour shrinkage, these therapies can increase tumour 
remission times and overall survival (Hirsch et al., 2009, Beier et al., 2008).  
 
Like many other solid tumours sub-populations of cells displaying CSC-like 
characteristics have been isolated from NPC. One means by which NPC CSCs have 
been isolated is based on their ability to exclude Hoechst DNA binding dye through 
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upregulation of multidrug transport proteins (Wang et al., 2007). Both normal stem 
cell and CSC populations express high levels of multidrug transporters, which act to 
exclude potentially damaging chemicals that could impinge on the stability of the 
cellular genome. Expulsion of drugs protects these cell populations allowing them to 
exist stably for periods of time greater than that of more differentiated cells and the 
expression of these multidrug transporters is associated with increased 
chemotherapy resistance (Doyle and Ross, 2003). Hoechst dye expulsion used in 
conjunction with rhodamine 123 (Wolf et al., 1993) or detected with dual fluorescence 
emission (Goodell et al., 1996) has facilitated the purification of “side population” 
(SP) cells from numerous tissues (reviewed by Hadnagy et al., 2006). SP sorted cells 
contain populations which will undergo long-term repopulation, and differentiate to 
regenerate the lineages of cells of the tissue from which they were generated. 
Tumour-derived SP cells will additionally demonstrate increased tumour forming 
potential compared to non SP cells and may show abnormal cell maintenance 
pathway activity such as NOTCH, PI3K/Akt, and HH (Dontu et al., 2004, Fan et al., 
2006, Bleau et al., 2009, Bar et al., 2007). 
 
Hoechst dye has been used to identify sub populations of cells displaying increased 
expression of these multidrug transporters from the EBV-negative NPC cell line 
CNE2. Cells isolated through their ability to exclude Hoechst dye, displayed 
increased proliferative potential, could differentiate to recapitulate the whole cell 
population from which they were isolated, and showed increased tumour formation in 
non-SCID mice. This sub population also demonstrated greater resistance to a 
number of drugs, X-rays and radiation. However, sensitivity to radiation could be 
restored in response to cyclopamine treatment, a HH pathway inhibitor. These 
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abilities suggest that the Hoechst dye excluding cells were, or included, a stem cell 
population that was, at least partially, dependent on HH signalling pathway activity 
(Wang et al., 2007). 
 
Tissue specific CSC markers have been used to identify populations of 
tumour-initiating cells from a variety of tumours. The isolation of cells expressing 
putative CSC markers has also been performed from NPC cell lines. CD44 positive 
cells (CD44+), isolated from the EBV negative NPC cell line SUNE1, displayed 
increased proliferative capacity compared to CD44- or unsorted counterparts. CD44+ 
cells also displayed increased expression of stem cell-associated genes, BMI1 and 
OCT4, and were less sensitive to radiation and the chemotherapy reagent cisplatin. 
This is consistent with the theory that CSCs are refractory to genotoxic assault in 
response to chemo or radiotherapy and repopulate the tumour following remission 
(Su et al., 2011). Further studies used small interfering RNAs (siRNAs) to inhibit 
CD44 expression, were found to significantly impact on tumour volume by inhibiting 
progression from G0/G1 to S phase in the EBV negative NPC cell line CNE-2L2 (Shi 
et al., 2007). 
  
CD44 has many splice variants; different isoforms have been identified in many 
epithelial carcinomas (Gunthert et al., 1991, Ghatak et al., 2010, da Cunha et al., 
2010). In breast carcinoma, isoform switching has been shown to be essential for an 
EMT (Brown et al., 2011) and also correlates with tumour subtypes and CSC marker 
expression (Olsson et al., 2011). CD44 expression has also been shown to influence 
cell phenotype in head and neck squamous carcinoma, whereas CD44 variant 
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expression, including variant 6 (CD44v6), correlated with tumour grade, migration, 
proliferation and cisplatin sensitivity (Wang et al., 2009). 
 
The expression of stem cell maintenance proteins has also been demonstrated in 
NPC. The BMI1 protein is required from stem cell maintenance and self-renewal in a 
variety of tissue types (Park et al., 2004) and is frequently upregulated in a wide 
variety of epithelial and even haematological malignancies (Kim et al., 2004, 
Bhattacharya et al., 2009, Bea et al., 2001). Expression of BMI1 in NPC is associated 
with poor prognosis (Song et al., 2006), and down regulation of BMI1 assists in 
growth inhibition (Wu et al., 2011). Another stem cell maintenance protein, EZH2, is 
often overexpressed in recurrent NPC, highlighting a correlation between an increase 
in the population of cells that express this marker and increased resistance to 
therapy (Alajez et al., 2010). 
 
Work presented in this chapter investigates the expression of putative stem cell 
markers, and stem cell associated proteins in NPC, and investigates the status of HH 
signalling in this disease. 
 
3.1.1 Hedgehog (HH) signalling pathway 
The HH signalling pathway was described in detail in section 1.11. Briefly, HH signal 
transduction involves HH ligand, of which there are three (SHH, DHH and IHH), 
binding to the membrane receptor PTCH. In the absence of HH ligand, PTCH inhibits 
the activity of SMO, a constitutively active serpentine receptor (Denef et al., 2000). 
HH ligand binding relieves PTCH inhibition of SMO (Ingham, 1998), which localises 
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to the membrane cilium and activates the GLI transcription factors (GLI1, 2 and 3) 
and the transcription of downstream targets.  
 
The HH signalling pathway is critical for stem cell maintenance; it plays an essential 
role in development, morphogenesis, and patterning (Ruiz i Altaba et al., 2002, 
Goodrich and Scott, 1998, Ingham and McMahon, 2001, Fournier-Thibault et al., 
2009, Huycke et al., 2012, Huang et al., 2010a, Dessaud et al., 2008). HH signalling 
is operational in both the embryonic stem cell and adult stem cell compartments (Lai 
et al., 2003, Palma and Ruiz i Altaba, 2004) as well as being implicated in the 
cancers including basal cell carcinoma (BCC) (Kasper et al., 2012), Glioblastoma 
Multiforme (GBM) (Braun et al., 2012), meduloblastoma (Berman et al., 2002), lung 
(Watkins et al., 2003), gastric (Berman et al., 2003), prostate (Karhadkar et al., 2004) 
and pancreatic carcinomas (Thayer et al., 2003). In common with primordial BCC, 
NPC WHO III displays an undifferentiated phenotype, raising the possibility that NPC 
is derived from less differentiated stem cell progenitors (Brennan, 2006). Activating 
mutations in the HH pathway, such as SMO, when targeted to the epidermis of 
transgenic murine models, is sufficient to induce BCC formation (Aszterbaum et al., 
1999, Mancuso et al., 2004), as is overexpression of the GLI2 transcription factor 
(Grachtchouk et al., 2000). Indeed the vast majority of BCC are the result of 
mutations most commonly in PTCH and less often in SMO (Johnson et al., 1996, Xie 
et al., 1998). 
 
The HH signalling pathway engages many downstream targets that intersect with 
other signalling pathways. These include WNT5A, which feeds into the WNT 
pathway, NOTCH, ACTIVIN and the BMPs, members of the TGFβ family of proteins, 
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which serve to modulate HH signalling and promote differentiation. Induction of the 
HH signalling pathway could, therefore, have a widespread and significant impact on 
a cellular signalling network responsible for stem cell maintenance, renewal and 
differentiation. In addition, the HH signalling pathway is itself a downstream target of 
other cell signalling pathways such as TGFβ/Activin/BMP, WNT and NOTCH, which 
are also dysregulated in NPC (Zeng et al., 2007a, Zeng et al., 2007b, Wang et al., 
2011, Man et al., 2012). 
 
Previous work in this laboratory has utilised gene expression profiling of 4 normal 
nasopharynx and 15 microdissected NPC biopsies along with the C666.1 cell line, to 
identify cell signalling pathways whose dysregulation is a feature of this disease. 
Whilst other NPC xenografts have been isolated C666.1 is the only authentic EBV 
positive NPC cell line that can be propagated in vitro. Derived from an NPC xenograft 
originating in Southern China, the C666.1 cell line is unique as it maintains the EBV 
genome. These data were interrogated for dysregulation of signalling pathways 
involved in stem cell maintenance and confirmed previous studies demonstrating that 
the TGFβ, BMP, ACTIVIN and WNT signalling pathways were indeed dysregulated in 
NPC (Zeng et al., 2007b, Zeng et al., 2007a, Wang et al., 2011, Man et al., 2012). 
Further interrogation has been performed on this data, which will be presented in this 
thesis and was indeed the initial finding which sparked further investigation into the 
condition of the HH signalling pathway in NPC. 
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3.2 Primary nasopharyngeal carcinoma and the C666.1 cell line are enriched 
for basal cell and putative stem cell markers 
3.2.1 Microarray expression data reveals increased expression of basal cell 
and putative stem cell markers in nasopharyngeal carcinoma tumour 
biopsies 
Initially, microarray expression data obtained from microdissected NPC tumours was 
mined for the expression of basal/stem cell markers and HH pathway components. 
Normal age-matched control nasopharyngeal epithelium and tonsil epithelium served 
as controls. Whilst the microarray analysis was not performed as part of this project, 
some understanding of the methodologies involving data collection, sample 
correlation, the methods of analysis employed, and results generated from this study 
should be mentioned.  
 
Global gene expression profiling was performed on total RNA extracted from laser 
microdissected purified cells (LMPCs) from 3 normal and 1 tonsil epithelium biopsies, 
along with 14 NPC tumours samples and the C666.1 cell line using Affymetrix 
Human Genome U133Plus 2.0 chips. Previously, a correlation heatmap of the four 
normal samples (MSTA, MBEZ, MHAU and T3) and 15 tumours (14 biopsies and 
C666.1 prototype NPC cell line) established that geographical and gender 
differences were not significant between samples and that C666.1 constitutes a good 
tumour model for NPC. It was also established that tonsil epithelium closely 
resembles nasopharyngeal epithelium, allowing for the inclusion of this tissue in 
subsequent immunohistochemical (IHC) validation. Additional gene expression 
profiling between the C666.1 cell line and the four normal biopsies demonstrated fold 
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changes in the same direction as those observed between the NPC tumours and 
normal biopsies, and established the C666.1 cell line as a good model for NPC (Hu, 
2010). 
 
Microarray data previous obtained in our laboratory (Hu, 2010) was interrogated for 
genes relating to epithelial cell ‘stemness’. The array data has been deposited in the 
GEO database, http://www.ncbi.nlm.nih.gov/geo, with accession number GSE34573 
(Hu et al., 2012). Initially the gene expression array data generated from the 16 NPC 
samples and 4 normal samples (three normal nasopharynx and one tonsil epithelium) 
were normalised and processed using Robust Multi-array Average (RMA) and Rank 
Product (RP) analyses to identify differentially expressed genes and the fold change 
in their expression. Affymetrix GeneChip Operating Software (GCOS) analysis was 
also performed allowing the present/absent status of the gene expression above 
background levels to be taken into account.  
 
Interrogation of the microarray data from the four normal nasopharyngeal/tonsil 
tissue samples, the 14 microdissected NPC samples and C666.1 cell line, identified 
increased expression of squamous epithelial cell basal cell markers in NPC tumours, 
consistent with the undifferentiated nature of NPC tumours. In addition, a number of 
putative stem cell markers were found to be upregulated in NPC specimens relative 
to control tissue. Table 3.1 shows the fold changes and statistical significance, from 
RP analysis on expression array data, of basal cell and putative stem cell markers 
identified from the literature. Genes have been included if present in 8 out of 16 NPC 
samples and/or present in 2 of 4 normal nasopharyngeal epithelium by GCOS 
analysis, or otherwise believed to be of key importance. 
Results 
115 
 
Chapter 3 
Epithelial basal cell markers upregulated in NPC included the β1 and α6 integrins, 
and ΔNp63 (designated as TP63). Integrins play a key role in establishing cell-matrix 
interactions but also facilitate cell-cell adhesion. A number of integrins are often 
overexpressed in carcinomas, where they increase cell survival and promote 
angiogenesis, invasion and metastasis (Jin and Varner, 2004, Orimoto et al., 2008). 
Additionally, high integrin levels, typically β1 and α6, have been used to isolate 
putative epidermal stem cells from normal squamous epithelium (Jones and Watt, 
1993, Seery and Watt, 2000). ΔNp63 is also required for cell adhesion and its 
expression in stratified epithelium modulates cell survival and stem cell maintenance 
(Carroll et al., 2006). Markers that have been used to identify putative stem cell 
populations in other epithelial cell types were also found to be highly expressed in 
NPC tumour biopsies compared to normal epithelium, along with proteins known to 
have a role in stem cell maintenance.  
 
SC markers upregulated in NPC include LRIG1; an inter-follicular stem cell marker 
with a role in maintaining quiescence (Jensen et al., 2009); SOX2, a transcription 
factor required to maintain self-renewal that has the capacity to induce pluripotent 
stem cells when combined with OCT4 (Huangfu et al., 2008), and EZH2 and BMI1; 
polycomb family members controlling proliferative potential and self-renewal 
(Ezhkova et al., 2009, Park et al., 2004). LRIG1, SOX2, EZH2 and BMI1 were found 
to be upregulated in 87.5%, 75%, 93.5% and 81.25% of NPC samples respectively, 
relative to control tissues, with fold changes of 2.79, 3.15, 5.05, and 2.12. In addition, 
two cell surface stem cell and/or CSC markers: CD44, a receptor for 
glycosaminoglycan hyaluronate with a role in tumour metastasis (Gunthert et al., 
1991), and p75NTR, an oesophageal and oral keratinocyte stem cell marker 
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(Okumura et al., 2003, Nakamura et al., 2007a), were found to be upregulated in 
81.25%, and 50% of NPC samples, relative to control tissues, by 2.50 and 1.98 fold 
respectively.  
 
A heat map showing the relative expression of basal cell and stem cell markers in the 
NPC tumours compared to control tissue (normal nasopharyngeal/tonsil epithelium) 
is shown in Figure 3. 1. From the heatmap it can be seen than no one tumour sample 
shows upregulation of all markers but there is a general consensus that NPC 
tumours are enriched for expression of various basal and stem cell markers 
compared to control epithelium. It can also be seen that the C666.1 cell line appears 
to correlate with the NPC tumours displaying a comparable stem cell marker 
expression profile. 
  
 
Table 3.1 Expression of basal cell and putative stem cell markers genes in micro-dissected NPC tumour tissue verses 
normal nasopharyngeal/tonsillar epithelium by microarray analysis 
Gene  
Accession 
Gene Symbol Name p value (t) 
FC 
(overall) 
Present 
In NPC 
(normal) 
up in 
(RMA) 
up in % 
(RMA) 
 
Basal cell marker 
 
1553678_a_at ITGB1 
Integrin, beta 1 (fibronectin receptor, beta polypeptide, 
antigen CD29 includes MDF2, MSK12) 
1.6E-06*** 9.37 16/16 (1/4) 16 100 
201656_at ITGA6 Integrin, alpha 6 0.0010** 3.17 16/16 (4/4) 15 93.75 
201983_s_at EGFR 
Epidermal growth factor receptor (erythroblastic leukaemia 
viral (v-erb-b) oncogene homolog, avian) 
NS 1.72 13/16 (3/4) 9 56.25 
212567_s_at MAP4 Microtubule-associated protein 4 NS 1.44 13/16 (0/4) 12 75 
207382_at TP73L Tumour protein p73-like NS 1.33 10/16 (0/4) 10 62.5 
203110_at PTK2B PTK2B protein tyrosine kinase 2 beta NS 1.32 8/16 (0/4) 13 81.25 
 
Stem cell markers 
 
203685_at BCL2 B-cell CLL/lymphoma 2 0.0035** 37.02 16/16 (2/4) 16 100 
213880_at LGR5 
Leucine-rich repeat-containing G protein-coupled receptor 
5 
3.2E-05*** 30.89 13/16 (0/4) 15 93.75 
212588_at PTPRC Protein tyrosine phosphatase, receptor type, C 0.0016** 13.14 15/16 (2/4) 14 87.5 
217901_at DSG2 Desmoglein 2 0.0039** 11.31 16/16 (2/4) 16 100 
208783_s_at CD46 CD46 molecule, complement regulatory protein 0.016* 6.33 16/16 (4/4) 15 93.75 
212097_at CAV1 Caveolin 1, caveolae protein, 22kDa 0.021* 5.79 14/16 (2/4) 14 87.5 
203358_s_at EZH2 Enhancer of zeste homolog 2 (Drosophila) 0.018* 5.05 15/16 (0/4) 15 93.75 
200999_s_at CKAP4 Cytoskeleton-associated protein 4 0.00015*** 4.40 16/16 (4/4) 16 100 
204457_s_at GAS1 Growth arrest-specific 1 0.18 3.34 6/16 (0/4) 9 56.25 
228038_at SOX2 SRY (sex determining region Y)-box 2 0.085 3.15 16/16 (0/4) 12 75 
208691_at TFRC Transferrin receptor (p90, CD71) 0.017* 2.97 16/16 (4/4) 15 93.75 
211596_s_at LRIG1 Leucine-rich repeats and immunoglobulin-like domains 1 0.137 2.79 15/16 (2/4) 14 87.5 
202935_s_at SOX9 
SRY (sex determining region Y)-box 9 (campomelic 
dysplasia, autosomal sex-reversal) 
0.112 2.76 12/16 (2/4) 12 75 
203196_at ABCC4 ATP-binding cassette sub-family C member 4 0.056 2.64 15/16 (1/4) 15 93.75 
208476_s_at FRMD4A FERM domain containing 4A 0.0024* 2.62 10/15 (4/4) 13 81.25 
212063_at CD44 CD44 molecule (Indian blood group) 0.013* 2.50 16/16 (4/4) 13 81.25 
204343_at ABCA3 ATP-binding cassette, sub-family A (ABC1), member 3 0.00016*** 2.48 9/16 (0/4) 16 100 
213353_at ABCA5 ATP-binding cassette, sub-family A (ABC1), member 5 NS 2.26 9/16 (0/4) 13 81.25 
226774_at FAM120B Family with sequence similarity 120B NS 2.19 11/16 (1/4) 12 75 
  
 
        
Gene  
Accession 
Gene Symbol Name p value (t) 
FC 
(overall) 
Present 
In NPC 
(normal) 
up in 
(RMA) 
up in % 
(RMA) 
202265_at BMI1 BMI1 polycomb ring finger oncogene 0.205 2.12 14/16 (4/4) 13 81.25 
204531_s_at BRCA1 Breast cancer 1, early onset 0.021* 2.06 16/16 (1/4) 16 100 
205858_at NGFR 
Nerve growth factor receptor (TNFR superfamily, member 
16) 
NS 1.98 7/16 (0/4) 8 50 
204405_x_at DIMT1L DIM1 dimethyladenosine transferase 1-like (S. cerevisiae) 0.259 1.92 14/16 (4/4) 14 87.5 
201278_at DAB2 
Disabled homolog 2, mitogen-responsive phosphoprotein 
(Drosophila) 
NS 1.81 4/16 (0/4) 9 56.25 
220184_at NANOG Nanog homeobox NS 1.79 3/16 (0/4) 5 31.25 
209439_s_at PHKA2 Phosphorylase kinase, alpha 2 (liver) NS 1.40 6/16 (0/4) 12 75 
 
EMT markers 
 
202351_at ITGAV 
Integrin, alpha V (vitronectin receptor, alpha polypeptide, 
antigen CD51) 
0.00029*** 21.97 16/16 (2/4) 16 100 
225664_at COL12A1 Collagen, type XII, alpha 1 0.0015** 15.74 10/16 (0/4) 12 75 
201852_x_at COL3A1 
Collagen, type III, alpha 1 (Ehlers-Danlos syndrome type 
IV, autosomal dominant) 
0.016* 14.37 14/16 (3/4) 13 81.25 
211980_at COL4A1 Collagen, type IV, alpha 1 0.0013** 13.66 16/16 (3/4) 16 100 
210495_x_at FN1 Fibronectin 1 0.016* 11.11 15/ 16 (0/4) 14 87.5 
202403_s_at COL1A2 Collagen, type I, alpha 2 0.0030** 8.49 14/16 (1/4) 14 87.5 
201426_s_at VIM Vimentin 0.019* 4.39 14/16 (3/4) 14 87.5 
208083_s_at ITGB6 Integrin, beta 6 0.164 3.93 12/16 (4/4) 11 68.75 
203936_s_at MMP9 
Matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 
92kDa type IV collagenase) 
0.0044** 2.79 16/16 (2/4) 13 81.25 
213425_at WNT5A Wingless-type MMTV integration site family, member 5A 0.067 2.51 15/16 (3/4) 11 68.75 
200606_at DSP Desmoplakin 0.0071** 2.29 16/16 (4/4) 13 81.25 
201131_s_at CDH1 Cadherin 1, type 1, E-cadherin (epithelial) NS 2.03 16/ 16 (4/4) 13 81.25 
213139_at SNAI2 Snail homolog 2 (Drosophila) NS 1.57 7/16 (2/4) 6 37.5 
213943_at TWIST1 
Twist homolog 1 (acrocephalosyndactyly 3; Saethre-
Chotzen syndrome) (Drosophila) 
NS 1.46 8/16 (0/4) 11 68.75 
211453_s_at AKT2 V-akt murine thymoma viral oncogene homolog 2 NS -1.83 8/16 (3/4) 2 12.5 
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Basal cell 
marker
Stem cell
marker 
EMT
 
Figure 3. 1. Microarray analysis demonstrating an enrichment of basal and 
stem cell marker expression in NPC tumours 
RP analysis of 4 normal epithelial tissue samples compared to 15 micro-dissected 
NPC biopsies and the C666.1 NPC cell line identified increased expression of basal 
and stem cell markers in the NPC tissue. This was accompanied by increased 
expression of epithelial to mesenchymal transition (EMT) markers. 
Normal NPC 
Results 
120 
 
Chapter 3 
3.2.2 IHC validation of microarray expression profiling on tumour biopsies 
Validation of the microarray expression data was performed on an NPC tissue array 
containing both NPC tumour and normal nasopharyngeal mucosa. Expression of 
proteins of interest was assessed using standard IHC staining protocols, on 
approximately 20 normal mucosa and 50 NPC biopsy specimens and scored using a 
semi quantitative system (Hu et al., 2012). Representative images are shown in 
Figure 3. 2. Additionally, GCOS graphs of microarray data showing normalised array 
intensities (i.e. relative expression) of the gene of interest in the 4 normal 
nasopharynx (grey), 15 NPC tumour biopsies (red) and the C666.1 cell line (yellow) 
have been included for comparison.  
 
IHC staining for BMI1, P75NTR, SOX2, EZH2 and CD44 demonstrated localised 
expression of stem cell markers in the basal cell layers of normal nasopharynx and 
higher, more uniform expression in the majority of NPC tumour cells. Expression of 
NANOG and NESTIN was very weak in both the NPC and normal samples and was 
positive in isolated cells of both the normal and NPC tissue. GCOS analysis of the 
highest expressing probe set for each gene of interest demonstrates upregulation of 
all these stem cell/CSC markers in the majority of NPC tumour biopsies compared to 
normal nasopharynx.  
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Figure 3. 2. IHC validation of microarray expression data demonstrates 
increased expression of stem cell markers in primary NPC tissue compared 
to normal nasopharynx 
Representative IHC staining of normal and NPC sections, and associated gene 
GCOS analysis, for a number of stem cell/CSC markers. GCOS graphs show 
gene expression in the 4 normal nasopharygeal samples (grey) compared to the 
16 NPC samples (red), with the C666.1 cell line highlighted in yellow.  
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A semi quantitative scoring system (0; negative, 9; positive in a high proportion of 
cells) was used to evaluate the IHC staining (see materials and methods, section 
2.13.2). Average scores, standard distribution and statistical probabilities for staining 
of interest on NPC biopsies compared to normal nasopharynx are presented in 
Figure 3. 3. Expression of BMI1, P75NTR and SOX2 was upregulated in 87%, 80%, 
and 94% respectively. Scoring the staining for NANOG and NESTIN demonstrated 
no significant difference between the NPC and normal tissue samples.  
 
Whilst representative staining was performed on both normal and NPC tissue, 
staining for EZH2 and CD44 has previously been scored on the tissue array and has 
not been repeated here (Hu et al., 2012). Hu et al., (2012) demonstrated upregulation 
of EZH2 and CD44 in 75% and 50% of NPC case respectively.  
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Figure 3. 3 Scoring for IHC staining for stem cell markers in NPC tissue 
compared to normal nasopharynx 
Staining was scored on a normalised scale of 0 to 9, where 0 represents no staining 
present. Average scores and are standard deviations presented for NPC tissue 
biopsies (dark grey) and normal nasopharyngeal samples (light grey). *; P<0.05, **; 
P<0.001, ***; P<0.001, ****, P<0.0001. 
**** **** **** 
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3.3 The C666.1 cell line shows increased expression of stem cell markers 
compared to normal primary oral keratinocytes 
Having confirmed increased expression of a number of putative stem cell markers in 
primary NPC tumour specimens, the expression of selected stem cell markers in the 
authentic EBV positive NPC cell line, C666.1, was explored. Expression profiling was 
preformed against primary human oral keratinocytes (HOK) and the OKF6 cell line, a 
hTert-immortalised normal human oral keratinocyte cell line. HOK have previously 
been established as a good model for normal nasopharynx and served as a valid 
reference to control for the effects of in vitro cultivation (Hu, 2010, Yanai et al., 2008). 
Further microarray analysis interrogated the expression of stem cell markers in total 
RNA samples isolated from C666.1 and normal HOK (Figure 3. 4A) (GSE39826). 
Many tissue dependant markers have previously been described as upregulated in 
putative stem cell populations; the markers seen to be upregulated in the C666.1 cell 
line relative to HOK included SOX2, BMI1, LRIG1, EZH2 and p75NTR. Other putative 
stem cell markers were found to be reduced in this cell line compared to HOK and 
OKF6, including the ABC transporter gene ABCG2, NANOG, a homeobox protein 
essential for ESC renewal, and CD44, of which the variant 6 is most often associated 
as a CSC marker. 
 
Whilst HOK are a valid model for normal nasopharyngeal epithelium, the lack of 
availability of primary tissue, coupled with the limited lifespan of primary oral 
keratinocytes in culture, prompted us to search for a suitable replacement. The 
hTert-immortalised oral keratinocyte cell line OKF6 was chosen as a normal control 
for C666.1 (Cheung et al., 1999). To establish that the OKF6 cell line was a valid 
replacement for HOK, RT-PCR analysis was performed to compare the expression of 
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a number of stem cell markers in OKF6, HOK and C666.1 (Figure 3. 4B). This also 
acted to validate the microarray work as the genes investigated by RT-PCR 
demonstrated the same upregulation in the C666.1 cell line compared to the normal 
epithelial counterparts as seen in the microarray analysis. In addition, RT-PCR 
analysis for the expression of CD44 variant 6 (CD44v6) showed that this gene 
appeared to be upregulated, whereas microarray analysis for the non-variant CD44 
demonstrated downregulation in the C666.1 cell line. 
 
The level of CD44v6, CD133 and SOX2 mRNA in the HOK and OKF6 cells were too 
low to be detected by RT-PCR; however, mRNA could be detected in the C666.1 cell 
line. The stem cell markers p75NTR, LRIG1 and BMI1 were expressed in the OKF6 
cell line and HOK cells, mRNA expression was similar between the primary and 
hTert-immortalised cells, however marker expression was significantly increased in 
the C666.1 cell line. This would suggest OKF6 cells are a suitable substitute for HOK 
in experiments where continued culture of the cell line would be preferable. 
 
Further investigation into the expression of cell surface marker expression in C666.1 
and OKF6 cells was performed by flow cytometric analysis (Figure 3. 4C). Staining 
was performed on viable cells with a rabbit polyclonal antibody specific for CD44v6 
and a mouse monoclonal antibody to CD133. C666.1 cells displayed a 4.6 fold 
increase in CD44v6 expression (P=0.039, n=3), and an 11.6 fold increase in CD133 
expression (P<0.05, n=3) compared to the OKF6 cell line. In addition, flow cytometric 
analysis demonstrated that this increased expression was observed in a subset of 
cells rather than as a population shift, indicating the C666.1 cell line possesses a sub 
population of cells which may possess stem cell like characteristics. This sub-
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population, had it been isolated, would be expected to possess increased 
tumourigenicity compared to an unsorted population of cells.  
 
This increased expression of stem cell markers in C666.1 cell line mirrors that 
observed in the NPC tumour biopsy microarray suggesting C666.1 can be used as a 
model to investigate the activity of cellular signalling implicated in the maintenance of 
a CSC-like phenotype. 
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Figure 3. 4 The C666.1 cell line expresses high levels of stem cell/CSC markers 
(A) Microarray analysis of 3 C666.1 total RNA samples compared to normal primary 
tonsil epithelium. (B) Validation of dysregulated HH signalling in the C666.1 cell line 
compared to normal tonsil epithelium. (C) FACS analysis showing increased 
expression of cell surface stem cell markers CD44v6 and CD133 in C666.1 cell line 
compared to OKF6. C666.1 displays a 4.6 fold increase (P=0.039, n=3) in expression 
of CD44v6 and an 11.4 fold increase (P=0.040, n=3) in CD133 expression. 
A. 
B. C. 
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3.4 Primary NPC tumours display aberrant HH signalling activity – the link to 
stemness 
To date, studies have identified dysregulation of a number of stem cell signalling 
pathways in NPC. These include the NOTCH, WNT, TGFβ, BMP and JAK/STAT 
pathways. Previous work in this laboratory supports published findings demonstrating 
that a number of these pathways are dysregulated in NPC (Hu, 2010, Yanai et al., 
2008). Studies into signalling dysregulation in NPC has thus far not been extended to 
interrogate the HH signalling pathway, a pathway commonly dysregulated in other 
carcinomas, such as BCC, which arise from stem cell or early progenitor cells. 
Subtypes of BCC maintain an undifferentiated “basal cell” phenotype and are 
dependent on sustained HH signalling for proliferation (Hutchin et al., 2005). 
Additional interest in the HH signalling pathway arose from finding that BMI1, a stem 
cell marker consistently upregulated in NPC tumours and the C666.1 cell line, is 
regulated by, and required for, HH pathway driven tumourgenesis in meduloblastoma 
and mammary gland carcinomas (Wang et al., 2012b, Michael et al., 2008). 
Furthermore BCL2, a downstream target of the GLI transcription factors (Regl et al., 
2004, Bigelow et al., 2004), is also known to be upregulated in NPC (Vera-Sempere 
et al., 1997). Previous studies analysing the expression of BCL2 in NPC tumours has 
identified overexpression, by IHC staining and QPCR, in the region of 80% of type I 
tumours (Low et al., 2012), and inhibition of the BCL2 family of proteins induces 
apoptosis and reduces tumour growth in NPC xenographs (Hu et al., 2008). 
 
The finding that a number of HH targets are consistently upregulated in NPC 
combined with the finding that other tumours displaying increased stem cell marker 
expression show aberrant HH signalling, such as that of the CD44+, CD24+, ESA+, 
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SHH ligand expressing CSC population of pancreatic tumours (Li et al., 2007), 
highlighted a plausible role for HH signalling dysregulation in NPC pathogenesis. 
 
3.4.1 Microarray analysis reveals perturbations in the expression of HH 
signalling pathway in nasopharyngeal carcinoma tumours 
Data obtained from the previous microarray analysis was interrogated to examine the 
status of the HH signalling pathway in this cohort of NPC samples. Table 3. 2 shows 
the fold changes and statistical significance, from RP analysis on expression array 
data, of individual genes of the HH pathway and downstream target genes. An 
extensive list of genes potentially involved in, or downstream of, the HH signalling 
pathway exists in the literature. Again, genes have been included if present in 8 out 
of 16 NPC samples or downregulated and present in at least 2 of 4 normal tonsil 
epithelium samples. However, some of key components of the pathway where 
absent from the microarray study by this criteria but have been included in table 3.2 
for completeness (HH ligands, GLI1 and PTCH2). Genes that are not present in this 
table include HhAT, HhIP, PTCHD1, PTCHD2, NPC1L1, DISP1, CDO1, BOC, LRP1, 
LRP2, OTX2, FKBP8, FGF9, CDON and BMP4. 
  
 
Table 3. 2 Expression of HH pathway associated genes in microdissected NPC tumour tissue verses normal tissue by 
microarray analysis 
 
Gene 
Accession 
Gene Symbol Name p value (t) 
FC 
(overall) 
Present in 
NPC 
(normal) 
up in 
(RMA) 
up in % 
(RMA) 
 
Hh ligand 
  
236263_at SHH Sonic hedgehog homolog (Drosophila) - - 1/16 (0/4) - - 
1552730_at DHH Desert hedgehog homolog (Drosophila) - - 0/20 - - 
215420_at IHH Indian hedgehog homolog (Drosophila) - - 0/20 - - 
 
Hh receptor 
  
209815_at PTCH1 Patched homolog 1 (Drosophila) 0.013* 3.79 16/16 (2/4) 14 87.5 
221292_at PTCH2 Patched homolog 2 (Drosophila) - - 0/20 - - 
218629_at SMO Smoothened homolog (Drosophila) NS - 5/16 (0/4) 2 12.5 
 
Hh antagonists 
  
224203_at SUFU Suppressor of fused homolog (Drosophila) NS -1.57 11/16 (3/4) 0 0 
209456_s_at FBXW11 F-box and WD-40 domain protein 11 NS -1.54 13/16 (4/4) 2 12.5 
 
Protein kinases 
  
202742_s_at PRKACB Protein kinase, cAMP-dependent, catalytic, beta 0.0046** 5.00 14/16 (2/4) 12 75 
200605_s_at PPKAR1A 
Protein kinase, cAMP-dependent, regulatory, type I, 
alpha (tissue specific extinguisher 1) 
0.059 3.10 15/16 (4/4) 13 81.25 
235464_at CSNK1A1 Casein kinase 1, alpha 1 0.049* 2.44 13/16 (1/4) 14 87.5 
213331_s_at NEK1 NIMA (never in mitosis gene a)-related kinase 1 0.142 2.29 14/16 (1/4) 11 68.75 
 
Signalling mediators 
  
212097_at CAV1 Caveolin 1, caveolae protein 0.021* 5.79 14/16 (3/4) 12 75 
223642_at ZIC2 Zic family member 2 (odd-paired homolog, Drosophila) 0.00024*** 3.90 11/16 (0/4) 13 81.25 
223463_at RAB23 RAB23, member RAS oncogene family 0.0011** 3.53 12/16 (1/4) 8 50 
204457_s_at GAS1 Growth arrest-specific 1 0.18 3.43 6/16 (0/4) 14 87.5 
226364_at HIP1 Huntingtin interacting protein 1 0.0004*** 2.36 15/16 (2/4) 15 93.75 
228680_at KIF3A Kinesin family member 3A NS 2.28 14/16 (4/4) 8 50 
226166_x_at STK36 Serine/threonine kinase 36, fused homolog (Drosophila) NS 1.34 13/16 (1/4) 10 62.5 
224471_s_at BTRC Beta-transducin repeat containing NS -1.38 12/16 (4/4) 0 0 
204522_at DZIP1 DAZ interacting protein 1 NS -1.43 13/16 (3/4) 10 62.5 
 
 
 
 
      
  
 
 
Gene 
Accession 
Gene 
Symbol 
Name p value (t) 
FC 
(overall) 
Present in 
NPC 
(normal)  
up in 
(RMA) 
up in 
% 
(RMA) 
 
Transcription factors 
  
206646_at GLI1 GLI-Kruppel family member GLI1 - - 0/20 - - 
228537_at GLI2 GLI-Kruppel family member GLI2 NS -1.36 6/16 (3/4) 1 6.25 
227376_at GLI3 GLI-Kruppel family member GLI3 0.025* 2.19 14/16 (2/4) 13 81.25 
 
HH targets 
  
203685_at BCL2 B-cell CLL/lymphoma 2 3.3E-06*** 37.02 16/16 (2/4) 16 100 
239629_at CFLAR CASP8 and FADD-like apoptosis regulator 0.0037** 5.94 14/16 (1/4) 13 81.25 
202037_s_at SFRP1 Secreted frizzled-related protein 1 0.199 5.68 14/16 (2/4) 8 50 
200951_s_at CCND2 Cyclin D2 0.00024*** 5.35 11/16 (0/4) 16 100 
209784_s_at JAG2 Jagged 2 0.0054** 4.81 16/16 (3/4) 16 100 
218469_at GREM1 
Gremlin 1, cysteine knot superfamily, homolog 
(Xenopus laevis) 
0.0030** 4.13 10/16 (0/4) 12 75 
203131_at PDGFRA 
Platelet-derived growth factor receptor, alpha 
polypeptide  
3.91 12/16 (1/4) 12 75 
228964_at PRDM1 PR domain containing 1, with ZNF domain 0.155 2.78 11/16 (2/4) 12 75 
202935_s_at SOX9 
SRY (sex determining region Y)-box 9 (campomelic 
dysplasia, autosomal sex-reversal) 
0.112 2.76 13/16 (2/4) 12 75 
213425_at WNT5A Wingless-type MMTV integration site family member 5A 0.067 2.51 15/16 (3/4) 11 68.75 
209757_s_at MYCN 
V-myc myelocytomatosis viral related oncogene, 
neuroblastoma derived (avian) 
NS 2.42 9/16 (1/4) 9 56.25 
202580_x_at FOXM1 Forkhead box M1 0.05 2.31 12/16 (1/4) 14 87.5 
206104_at ISL1 ISL1 transcription factor, LIM/homeodomain, (islet-1) NS 2.11 7/16 (2/4) 6 37.5 
208712_at CCND1 Cyclin D1 NS 1.28 16/16/ (4/4) 7 43.75 
208606_s_at WNT4 Wingless-type MMTV integration site family, member 4 NS -1.63 5/16 (1/4) 2 12.5 
 
HH EMT and stem cell targets 
  
213880_at LGR5 
Leucine-rich repeat-containing G protein-coupled 
receptor 5 
3.2E-05*** 30.89 13/16 (4/4) 15 93.75 
205290_s_at BMP2 Bone morphogenetic protein 2 0.0014** 3.42 11/16 (0/4) 12 75 
203603_s_at ZEB2 Zinc finger E-box binding homeobox 2 0.0076** 3.05 9/16 (0/4) 14 87.5 
212063_at CD44 CD44 molecule (Indian blood group) 0.013* 2.50 16/16 (4/4) 13 81.25 
202265_at BMI1 BMI1 polycomb ring finger oncogene 0.205 2.12 14/16 (4/4) 13 81.25 
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To illustrate the extent of HH pathway dysregulation in NPC, a KEGG map, Figure 3. 
5, is shown to highlight statistically significant upregulated and downregulated genes. 
Upregulated genes, represented in red, are defined here as genes that presented 
with a GCOS normalised expression level greater or equal to two times the mean of 
the normal samples, and were found to be significantly upregulated by RP analysis. 
Downregulated genes, none of which exist under this definition, would be defined as 
significantly downregulated by RP analysis and have a normalised expression of less 
than or equal to two times less than the mean of the normal samples. Genes that did 
not meet either of these definitions are unchanged and remain white. 
 
Dysregulation in the HH signalling pathway, presented in Table 3.2, can also be 
visualised as a heatmap illustrating the expression of HH pathway components in the 
4 normal control and 15 microdissected tumour samples, in addition to the C666.1 
cell line (Figure 3. 6). Expression of genes, such as DHH, IHH, PTCH2, SMO, GLI1, 
GLI2, and ISL1, was minimal; therefore, it is not possible to compare the expression 
of these genes in the NPC tumour biopsies and normal control tissue. SHH is also 
absent; its expression was so low as to be classified absent from all but one sample; 
the NPC biopsy XY3. Its absence may allude to a ligand independent mechanism for 
chronic HH signalling activation in NPC tumours or simply be due to a lack of 
sensitivity of the probe sets present in the Affymetryx gene chips. 
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Figure 3. 5 KEGG map of the HH pathway genes differentially expressed in NPC 
Here the differentially expressed HH genes are imposed on signalling pathway in the 
condition of activated SMO and the processing of GLI into its active form. Genes in 
red are significantly upregulated by microarray analysis in the tumour samples 
compared to the four normal epithelial samples with a fold change ≥ 2 and 
significantly increased by RP analysis. No components of the HH signalling pathway 
were found to be significantly downregulated (fold change ≥-2). 
GLI1 
GLI2 
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Figure 3. 6 Heat map showing dysregulated HH pathway genes in the 16 NPC 
samples compared to normal nasopharyngeal and tonsil epithelium 
HH pathway components and targets presented are either upregulated in NPC and 
present in ≥8/16 micro-dissected tumour samples, or downregulated in NPC and 
present in ≥2/4 normal tonsil tissue samples. 
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The microarray data identified a number of HH pathway genes that were significantly 
upregulated in NPC tumour specimens relative to normal control tissue. These 
included the HH receptor, and putative target gene PTCH1 (Marigo and Tabin, 1996), 
the HH transcription factor GLI3, and additional HH target genes (FOXM1, CCND2, 
WNT5A, SOX9, CFLAR, PDGFR, and BCL2) (Katoh and Katoh, 2009a). Other HH 
pathway signalling components were found to be significantly upregulated in NPC 
relative to normal epithelium, which included positive regulators of HH signalling 
CAV1, NPC1, and ZIC2, (Capozza et al., 2012, Bidet et al., 2011, Chan et al., 2011) 
and negative regulators such as PKA, GSK3B, HIP1, and RAB23 (Wen et al., 2010, 
Yang et al., 2010, Chuang and McMahon, 1999). ZIC2 acts to maintain activated GLI 
transcription factors in the nucleus facilitating downstream HH target transcription 
(Mizugishi et al., 2001, Chan et al., 2011), whereas HIP1 negatively regulates HH 
signalling by competing with PTCH to bind SHH (Chuang and McMahon, 1999). 
CAV1 is reportedly required for the intracellular transport of SHH ligand to the cell 
membrane and targeted deletion of CAV1 in zebrafish, who possess only one CAV 
protein compared to the three mammalian homologs, produces a SHH deficient-like 
phenotype (Mao et al., 2009). RAB23 acts downstream of SMO (Yang et al., 2010) 
and may have a role in inhibiting the production of the activated form of GLI2 (GLI2A) 
and promoting processing of GLI3 into repressor forms (GLI3R) (Eggenschwiler et 
al., 2006). Inhibitory protein kinases, PKA, CK1 and GSK3B, phosphorylate GLI2 and 
GLI3 in the absence of SHH facilitating the processing of GLI transcription factors 
into repressor forms (GLIR) (Wen et al., 2010). Other pathway components not 
significantly changed included SKT36, GAS1, DZIP1, SUFU, KIF3A and BTRC. 
Taken as a whole, the microarray analysis identified abundant but varied expression 
of a number of HH pathway components and targets in NPC specimens relative to 
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normal control tissue, revealing the general presence of aberrant or HH signalling in 
this tumour. 
 
3.4.2 IHC validation of microarray expression profiling on tumour biopsies. 
Validation of the microarray data was performed for HH pathway components and 
targets by IHC, as previously described for stem cell markers (Chapter 3, section 
3.2.2), using an NPC tissue array containing both NPC tumour and normal 
nasopharyngeal mucosa. IHC staining for HH pathway components (SHH, SMO, 
PTCH1, GLI1, GLI2, GLI3 and SUFU), downstream targets (FOXM1, CFLAR, BCL2 
and WNT5A) and the EBV latent gene EBNA1 was performed on approximately fifty 
primary NPC tumour sections and twenty normal nasopharyngeal epithelium 
biopsies, dependent on tumour array section quality. Representative IHC staining for 
individual proteins of interest are shown in Figure 3. 7A, and GCOS analysis of 
microarray data from the highest expressing probe set for each of these genes is 
also presented (Figure 3. 7B). GLI1, is absent from Figure 3. 8B as expression of this 
gene was not detected in any samples. 
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Figure 3. 7 IHC validation of microarray data confirms activation of the HH 
pathway in NPC 
(A) Representative staining of normal and NPC sections for these HH pathway 
components and targets. (B) Corresponding GCOS maps of gene expression in the 4 
normal nasopharyngeal samples (grey) compared to the 16 NPC samples (red), 
including the C666.1 cell line (yellow). Samples that were not present above 
background by RP analysis are presented as faded samples. 
B. 
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IHC staining revealed increased expression of pathway components SHH, SMO, 
PTCH, GLI1 and GLI2 in 60%, 96%, 96%, 90% and 84% of NPC cases compared to 
normal nasopharyngeal epithelium respectively, whilst GLI3 expression was reduced 
in 76% of NPC samples. Additionally, expression of the negative regulator SUFU 
(Kogerman et al., 1999, Jia et al., 2009) was reduced in 6/50 (12%) of tumour 
samples.  
 
A number of downstream targets of the HH pathway were also interrogated by IHC. 
Overexpression of the homeobox protein FOXM1 has been demonstrated in basal 
cell carcinoma as a downstream target of GLI1 (Teh et al., 2002). Homeobox 
proteins have roles in the regulation of genes involved in cellular proliferation, growth 
and differentiation. Activation of the HH target FOXM1 is implicated in the 
transformation of keratinocytes (Gemenetzidis et al., 2009, Teh et al., 2010). In this 
study, FOXM1 was found to be upregulated in 98% of NPC biopsies by IHC. Other 
downstream HH targets; BCL2 and CFLAR were found to be upregulated in 48/50 
96% and 82% of tumour samples respectively, while WNT5A was found to be 
upregulated in representative samples stained in this study. Quantitation of WNT5A 
expression has previously been presented by Hu (2012), a study which utilised the 
same tissue array and demonstrated upregulation of this protein in 39/50 (78%) of 
NPC samples. A summary of the IHC staining can is shown in Figure 3. 8; average 
scores and standard deviations for NPC (dark grey) and normal nasopharyngeal 
epithelium (light grey) are presented for each of the antibody columns. 
 
GCOS analysis is also presented here to allow a comparison of these genes at the 
RNA and protein level (Figure 3. 7B). Whilst SHH, SMO and GLI2 have been 
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included they were scored as absent in the majority of samples by microarray 
analysis as the levels of expression were very low. GCOS analysis demonstrated 
upregulation of pathway component PTCH in 69% of NPC biopsies compared with 
the average expression of this protein in the four control samples. Upregulation of 
downstream HH targets was also observed; FOXM1 was overexpressed in 87.5% of 
NPC tumours with a fold change of 2.3, whilst BCL2, CFLAR and WNT5A were 
upregulated in 100%, 63% and 75% of NPC biopsies respectively. 
 
Overall, the IHC study supports findings from the microarray analysis demonstrating 
differential expression of HH pathway components and upregulation of key 
downstream targets. In addition, SHH ligand and GLI1, which were absent from the 
microarray gene expression profile, were found to be upregulated in a significant 
number of primary NPC tumour specimens. This is significant as in meduloblastoma 
there is a link between the expression of SHH ligand, and the induction of the HH 
signalling pathway, and acquisition of “stemness”; in this disease SHH can induce 
the expression of  stem cell maintenance associated gene BMI1 through direct 
binding of GLI1 to the BMI1 promoter (Wang et al., 2012b). 
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Figure 3. 8 Scoring for IHC staining for HH pathway components and targets in 
primary NPC tissue specimens compared to normal nasopharynx 
Staining was scored on a normalised scale of 0 to 9 where 0 represents no staining 
present. Average scores and standard deviations presented for 50 NPC tissue 
biopsies (dark grey) and 20 normal nasopharynx samples (light grey). *; P<0.05, **; 
P<0.001, ***; P<0.001, ****, P<0.0001. 
** *** **** **** **** **** **** * ** * 
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3.5 Dysregulation of HH signalling in the C666.1 cell line 
3.5.1 Microarray analysis reveals an activated HH pathway in the C666.1 cell 
line compared to normal primary keratinocytes 
Having obtained evidence for HH pathway dysregulation in authentic primary NPC 
specimens, the extent of this dysregulation was examined in more detail by 
comparing C666.1 cells with HOK cultured in vitro. Total RNA isolated from C666.1 
and normal primary tonsillar epithelial cells was analysed for the expression of HH 
ligand, HH pathway components and HH target genes. 
 
Gene expression profiling revealed elevated HH pathway activity in C666.1 cells 
compared to HOK. This dysregulation is apparent when normalised array intensities 
for individual HH pathway components are shown in the form of a heatmap 
(Figure 3. 9A). Compared to HOK, C666.1 cells showed increased expression of 
pathway components and downstream targets including PTCH1, FOXM1 and BCL2, 
consistent with activated HH signalling in NPC. While a number of negative inhibitors 
of HH signalling (BTRC, DZIP and RAB23) were found to be downregulated in NPC, 
expression of positive regulator SKT36 (FUSED), was found to be upregulated. The 
expression of downstream targets including FOXM1, BCL2, CFLAR and WNT5A was 
seen to be increased in the C666.1 cell line, whilst the expression of other HH 
targets; CCND2 and SOX9, were found to be downregulated in NPC tumours by 
microarray analysis. 
 
The expression of all three GLI transcription factors in the microarray was highly 
variable. As a downstream target of HH signalling, GLI1 is used as an indicator of HH 
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activation. The GLI transcription factors influence the state of HH pathway activity 
and are subject to control by post translational modification into repressive or 
activator forms, and location of the resulting protein, which cannot be analysed by 
techniques looking at RNA levels. 
 
RT-PCR analysis was once again performed to confirm the predictions of the 
microarray analysis the expression of key pathway components. SHH ligand 
expression (Figure 3. 9B), whilst very low, could be detected in the C666.1 cell line 
by RT-PCR but was again not detected above background levels in the microarray 
analysis. All other genes shown were defined as present in the microarray analysis 
and showed the same directional change, except GLI2, which was found to be 
upregulated by RT-PCR but downregulated in authentic tumours relative to normal 
nasopharyngeal epithelium. 
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Figure 3. 9 The C666.1 cell line displays aberrant HH signalling compared to 
normal HOKs 
(A) Microarray analysis of 3 C666.1 total RNA samples compared to normal primary 
keratinocytes display significant differences in the expression of HH pathway 
components consistent with an activated HH signalling pathway. (B) Validation of 
microarray data by RT-PCR supports dysregulated HH signalling in the C666.1 cell 
line compared to normal tonsil epithelium. 
A. B. 
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3.5.2 Validation of HH expression in the C666.1 cell line, HOK and OKF6 cell 
lines 
The expression of HH pathway components and downstream targets was 
interrogated in C666.1, HOK and OKF6 cell lines to validate the OKF6 cells as a 
viable replacement for HOK (Figure 3. 10A). RT-PCR analysis confirmed increased 
expression of SHH, PTCH1, GLI1 and GLI2 in C666.1 cells compared to both HOK 
and OKF6. Discrepancies arose in the expression of SMO between HOK and OKF6. 
Expression of SMO was significantly greater in HOK compared to OKF6 or C666.1 
cells, while all other pathway components and downstream targets showed 
comparable expression between OKF6 and HOK cells and, more importantly, 
showed the same directional change with respect to C666.1. This analysis 
established the OKF6 cell line as a suitable model for normal nasopharyngeal 
epithelial cells. 
 
The expression of HH pathway components in the OKF6 and C666.1 cell lines was 
interrogated at the protein level by western blot analysis (Figure 3. 10B). Protein 
expression of all pathway components and targets closely resembled that observed 
by RT-PCR; SHH, PTCH, GLI1, GLI2 and FOXM1 were significantly upregulated 
whereas SUFU was highly expressed in OKF6 cells but much lower in the C666.1 
cell line. There was little difference in the expression of GLI3 between these two cell 
lines. Western blot analysis supported findings from the microarray analysis and 
RT-PCR demonstrating that C666.1 show activated HH signalling when compared to 
normal HOK and the hTert-immortalised oral keratinocyte cell line, OKF6. 
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Figure 3. 10 C666.1 cells express higher levels of HH pathway components and 
targets compared to normal HOK and OKF6 counterparts 
(A) Validation of OKF6 as a model for HOK. RT-PCR analysis comparing the 
expression of HH pathway components and downstream targets in HOK cells, the t 
hTert-immortalised normal human oral keratinocyte cell line (OKF6) and the C666.1 
NPC cell line. (B) Western analysis reveals increased expression of HH pathway 
components and downstream targets in the C666.1 cell line compared to OKF6, 
normal human keratinocyte cells. C666.1 cells display chronic activation of the HH 
pathway expression demonstrated by increased expression of PTCH, GLI1 
transcription factor and downstream HH targets. 
A. B. 
Results 
147 
 
Chapter 3 
3.5.3 Validation of the hTert-immortalised normal nasopharyngeal and oral 
cell lines, NP460 and OKF6, and comparison to C666.1 
Further validation of the OKF6 cell line became possible when an hTert-immortalised 
normal nasopharyngeal cell line, NP460, became available towards the end of this 
study. While HOK have previously been shown to be a suitable control for normal 
nasopharyngeal tissue by microarray analysis, the need for a cell line with a longer 
replicative lifespan necessitated the use of the hTert-immortalised oral and 
nasopharyngeal epithelial cell lines. RT-PCR analysis was performed to compare the 
status of the HH signalling pathway and the expression of stemness-associated 
markers in OKF6 and NP460 cell lines relative to C666.1 (Fig 3. 11). As predicted, 
both OKF6 and NP460 displayed similar expression profiles with regard to both the 
HH signalling pathway and putative stem cell marker expression. Expression of 
downstream HH targets GLI1, PTCH and FOXM1, and all stem cell markers, were 
found to be expressed at low levels in the OKF6 and NP460 cells relative to C666.1 
cells. However, there was variation in the expression of other GLI transcription 
factors between the OKF6 and NP460 cell lines; GLI3 was found to be expressed at 
higher levels in NP460 relative to OKF6, while expression of GLI2 was higher in the 
OKF6. Overall the expression profile was comparable between these two cell lines 
justifying use of OKF6 as a suitable model for normal nasopharynx in earlier 
experiments. 
 
Immunofluorescence staining (Figure 3. 12) was also performed to compare the 
expression of HH pathway components and downstream target FOXM1 in OKF6, the 
newly acquired NP460, and C666.1 cell lines at the single cell level. C666.1 shows 
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increased nuclear expression of GLI1, which correlates with the increased 
expression of ZIC2 (as seen in the C666.1 cell line by microarray analysis in Figure 
3. 6) that acts to maintain nuclear localisation of activated GLI transcription factors. 
Additionally, the NPC cell line demonstrates increased SMO and FOXM1 expression, 
and increased and redistributed PTCH expression compared to OKF6 cells  
 
OKF6 and NP460 display a similar HH expression pattern however subtle differences 
exist; NP460 cells display increased expression of GLI2 and SHH, and decreased 
expression of cytoplasmic GLI3 compared to the oral keratinocyte cell line. These 
data support the RT-PCR analysis and demonstrate the presence of a dysregulated 
HH signalling pathway in the C666.1 cell line at the protein level, and further validate 
the OKF6 cell line as an adequate model for normal nasopharyngeal cells. 
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Figure 3. 11 Expression of HH pathway components and stem cell markers in 
the hTert-immortalised OKF6 and NP460 cell lines compared to C666.1 
Expression of HH pathway components and targets (left), and stem cell/CSC markers 
(tight) was compared by RT-PCR in the NP460 and OKF6 normal cell lines compared 
to the C666.1 NPC cell line.  
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Figure 3. 12 Immunofluorescence staining of HH pathway components in C666.1, OKF6 and NP460 cell lines 
Overexpression and redistribution of HH pathway components (SHH, PTCH, SMO), increased nuclear expression of transcription 
factors GLI1 and GLI3, and increased FOXM1 HH target expression in the C666.1 cell line compared to the hTert-immortalised 
normal oral keratinocyte cell line OKF6 and normal Chinese nasopharyngeal cell line NP460. Bar = 20 µm. 
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1SHH PTCH SMO FOXM12 GLI3
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3.6 HH signalling pathway integrity in C666.1 and OKF6 cell lines 
It was important to establish the integrity of the HH signalling pathway in OKF6 and 
C666.1 cells, and to demonstrate that both cell lines were responsive to SHH 
pathway stimulation. 
 
3.6.1 The responsiveness of OKF6 and C666.1 cells to exogenous SHH ligand 
stimulation 
The responsiveness of OKF6 and C666.1 cells to SHH ligand was examined by 
transfecting pBABE SHH, or a control empty vector (pBABE puro), along with an 
8xGLI-BS-Luc, a reporter construct containing eight tandem copies of a consensus 
GLI responsive element upstream of the luciferase gene (Sasaki et al., 1997), to 
assay HH pathway activity (Figure 3. 15).  
 
A point two-fold stimulation in GLI-luciferase reporter activity was observed in 
response to 0.5 µg SHH plasmid transfection in both OKF6 and C666.1 cells. 5E1 is 
a rat monoclonal antibody that inhibits the HH pathway by binding HH ligand at a 
pseudo-active site (Peterson and Bogenmann, 2003). Treatment of the OKF6 and 
C666.1 cell lines with 5E1 conditioned media (used at a 1:1 ratio with full 
complement growth media and compared to 1:1 control conditioned media) was 
sufficient to inhibit increased 8xGLI-BS-Luc reporter activity in SHH stimulated cells. 
This demonstrates that both the C666.1 and OKF6 cells have an intact HH pathway 
and are capable of further stimulation with SHH plasmid over 48 hr. Whilst the 
C666.1 cell line demonstrated increased HH signalling, the basal level of reporter 
activity in this cell line was substantially lower than that of the OKF6 cells. This is 
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possibly due to the slow proliferative nature of the C666.1 cell line or a differential 
susceptibility of the cell line to the transfection protocol. 
 
3.6.2 Cell line responsiveness to HH pathway stimulation and inhibition 
The consequence of HH pathway stimulation was examined by measuring the 
expression of HH target genes: PTCH, GLI1 and FOXM1, in response to SHH 
plasmid transfection. The consequences of HH pathway inhibition was then 
examined using 5E1, a neutralising SHH antibody, and treatment with GANT58 
and/or GANT61, two chemical inhibitors that act on the GLI transcription factors 
(Lauth et al., 2007). Representative experiments for OKF6 and C666.1 are shown in 
Figure 3.16 and Figure 3.17 respectively. 
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Figure 3. 13 Transient transfection of a SHH expressing plasmid induces 
8xGLI-BS-Luc activity in both OKF6 and C666.1 cells 
(A) OKF6 and (B) C666.1 cell lines normalised to control transfection. Cells were 
transfected with SHH and grown in 1:1 conditioned control media or 1:1 5E1 
expressing media. SHH transfection induced a greater than 0.25 fold increase in 
8xGLI-BS-Luc activity in both cell lines (P=0.011 in both cell lines, n=3).Treatment 
with 5E1 containing media reduced 8xGLI-BS-Luc activation to 0.63 in the OKF6 and 
0.62 fold in the C666.1 cells (P=0.047 and 0.019 respectively, n=3). (C) Shows the 
average raw values normalised to pGL2 activity to demonstrate significantly reduced 
8xGLI-BS-Luc basal activity in the C666.1 cell line. *, p<0.05; ** p<0.01; *** p<0.001. 
A. 
B. 
C. 
OKF6 
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mRNA was collected at 0, 24, and 48 hr from OKF6 and C666.1 cells transfected 
with 0.5 µg of SHH expression vector, or treated with a 1:1 dilution of 5E1-
conditioned media, 25 µM GANT58 or 12.5 µM GANT61. GANT61 was used at half 
the concentration of GANT58 due to observations that it is toxic at higher 
concentrations possibly due to its nature to target both GLI1 and GLI2. Cells will 
proliferate readily in 12.5 µM of GANT 61 and 25 µM GANT58.  
 
Whilst OKF6 cells do not produce significant amounts of SHH ligand they are 
capable of responding to SHH ligand induction of the HH pathway. SHH ligand was 
seen to induce the expression of PTCH, GLI1 and FOXM1 at both the protein and 
RNA level in both cell lines after 24 hr. While both cell lines showed decreased 
expression of HH pathway components and targets upon 5E1 treatment, they 
demonstrated differential sensitivity to the GLI transcription factor inhibitors. GANT61 
inhibition decreased the expression of these HH targets significantly after 48 hr in the 
C666.1 cell line but only marginally in the OKF6. GANT58 also significantly inhibited 
the expression of PTCH and FOXM1 in the C666.1 cell line but had little effect on the 
OKF6 cells. Inhibition of the GLI1 transcription factor with GANT58 did not reduce the 
expression of GLI1 in either cell lines over 24 hr possibly due to the uninhibited GLI2 
transcription factor, which is known to induce GLI1 by binding to its promoter (Ikram 
et al., 2004). 
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Figure 3. 14 The effect of stimulation and inhibition of the HH signalling 
pathway in the OKF6 cell line 
The OKF6 cell line responds to stimulation with (A) SHH ligand (0.5μg), and inhibition 
of the HH pathway with (B) 5E1 (1:1 dilution of 5E1 conditioned media), (C) GANT58 
(25 µM), and (D) GANT61 (12.5 µM) over 48 hr. 
A. B. 
. D. 
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Figure 3. 15 The effect of stimulation and inhibition of the HH signalling 
pathway in the C666.1 cell line 
The C666.1 cell line responds to stimulation with (A) SHH ligand (0.5μg/ml), and 
inhibition of the HH pathway with (B) 5E1 (1:1 dilution of 5E1 conditioned media), (C) 
GANT58 (25 µM), and (D) GANT61 (12.5 µM) over 48 hr. 
 
 
 
 
. B. 
. D. 
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3.7 The expression of stem cell markers and the maintenance of a stem cell 
like phenotype are dependent on HH signalling 
3.7.1 Inhibition of the HH signalling pathway influences stem cell marker 
expression 
The requirement of HH signalling for stem cell marker expression in the C666.1 cell 
line was investigated by inhibiting the HH pathway. HH pathway inhibition, with the 
GLI1/2 inhibitors GANT58 and GANT61 over 48 hr, was found to reduce the 
expression of putative stem cell markers by RT-PCR (Figure 3. 18A). Significant 
downregulation of the stem cell markers: CD44v6, SOX2, BMI1, CD133, EZH2 and 
NESTIN, was observed in response to GANT61 treatment, which targets both GLI1 
and GLI2, whilst marginal effects were observed on p75NTR, CXCR4 and LRIG1 
expression. 
 
FACS analysis provided evidence for the dependence of CD133 expression on HH 
signalling as CD133 expression was decreased following GANT58 treatment in a 
dose dependant manner (Figure 3. 19). The CD133 positive sub population of 
C666.1 cells was decreased from 29% to 25% by 25 µM GANT58 treatment in low 
serum medium over 72 hr. 12.5 µM GANT61 treatment was sufficient to reduce the 
CD133 positive sub population from 29% to 23%. HH inhibition did not, however, 
alter cell surface CD44v6 expression (Figure 3. 20) despite evidence that HH 
inhibition can decrease cellular CD44v6 by RT-PCR and western analysis. 
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Figure 3. 16 Expression of stem cell markers in C666.1 on inhibition of the HH 
pathway with GANT58 and GANT61 
RT-PCR demonstrating inhibition of stem cell markers CD44v6, SOX2, BMI1, CD133, 
EZH2 and NESTIN upon treatment with 25μM GANT58 (G58) or 12.5μM GANT61 
(G61) over 48 hr. Expression of P75NTR, CXCR4 and LRIG was not significantly 
altered. 
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Figure 3. 17 FACS analysis of CD133 expression in the C666.1 cell line treated 
with HH inhibitors 
Representative FACS analysis demonstrating the expression of stem cell marker 
CD133 is dependent on HH signalling and responsive to hedgehog inhibition with 
GANT58 (12.5 µM and 25 µM) and GANT61 (12.5 µM). GANT58 (G58) treatment 
reduces cell surface CD133 marker expression in a dose dependent manner. 
GANT61 treatment produced more substantial inhibition of CD133 expression than 
GANT58. CD133 antibody = C24B9. 
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Figure 3. 18 FACS analysis of CD44v6 expression in the C666.1 cell line treated 
with HH inhibitor 
GANT58 (G58) treatment (0-25μM) does not significantly alter cell surface CD44v6 
expression. 
 
100 
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3.8 DISCUSSION 
Current theories regarding the origin of head and neck cancer (HNSCC) propose that 
these malignancies arise from populations of tumour-initiating CSCs.  As the origin 
and phenotype of CSCs in many tumours remains unclear, the molecular 
characteristics of CSCs are largely unknown. Although there is concern that stem 
cells and CSCs can only be defined operationally, and that a single marker may not 
be sufficient to identify true stem cells or CSCs, recent studies on oral, gastric and 
breast cancer-derived cell lines show that the hyaluronic receptor CD44 “marks” a 
heterogeneous population of cells which retain stem cell/CSC-like properties. Other 
studies have shown that cells expressing high levels of CD44 (CD44high) overlap 
phenotypically with SP-cells, identified on the basis of their ability to exclude the 
DNA-labelling dye Hoechst 33342. Interestingly, both CD44high and SP-cell 
populations display many characteristics ascribed to bona fide CSCs; they contain 
cells that are resistant to the cytotoxic effects of DNA-damaging drugs, have an 
ability to seed new tumours at low cell density in SCID mice, and are enriched for a 
variety of stem cell markers. As with HNSCC, previous studies have identified 
tumourigenic sub-populations of cells in NPC cell lines marked by the CSC marker 
CD44 (Su et al., 2011), or through increased Hoechst DNA binding dye exclusion 
(Wang et al., 2007).  We sought to use previously collected microarray data to 
identify markers of interest from the many putative stem cell/CSC markers that are 
proposed to identify CSC containing sub populations of cell in NPC, or other tumours 
of head and neck carcinoma origin, to determine if there was selective enrichment of 
CSCs in NPC tumours. 
 
Results 
162 
 
Chapter 3 
Analysis of microarray data comparing NPC tumour biopsies to normal 
nasopharyngeal epithelium revealed increased expression of basal cell markers and 
a number of putative stem cell/CSC markers, a select few of which were validated on 
a NPC tissue array by IHC.  
 
The cell surface receptor CD44 has been used to isolate subpopulations of tumour 
cells with stem cell-like characteristics from two EBV-negative NPC cell lines: CNE1 
and SUNE1 (Couve-Privat et al., 2004), and the authentic EBV-positive NPC cell line 
C666.1 (Cheung et al., 1999). Although CD44 and was not found to be significantly 
upregulated in the microarray analysis, it was found to be consistently over 
expressed in primary NPC tumours by IHC, and by RT-PCR and western blot 
analysis in the C666.1 cell line. This may highlight technical problems associated 
with the RNA amplification protocol used in the microarray analysis, or a fault in the 
probe sets which may have been unable to efficiently recognise CD44-derived 
transcripts. Unlike CD44, BMI1, a stem cell-associated marker and putative 
downstream target of HH signalling, along with EZH2 and SOX2, were found to be 
overexpressed in the NPC microarray. Additionally, these genes were found to be 
over expressed at the protein level in primary NPC relative to normal nasopharyngeal 
tissue and in C666.1 cells relative to HOK and OKF6. 
 
While a number of putative stem cell-associated markers were found to be 
upregulated in the microarray analysis, a few notable genes were absent. These 
included ABCG2 and CD133. ABCG2 is an ABC transporter gene that is reportedly 
upregulated in CSC populations isolated from a variety of tumours, including NPC 
(Hu et al., 2008, Wang et al., 2013), and CD133, a marker that has been used to 
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isolate stem cell populations from various tissues and malignant tumours including 
pancreatic, brain, liver, colorectal and lung (Singh et al., 2003, Suetsugu et al., 2006, 
Bertolini et al., 2009, Choi et al., 2009). The absence of putative stem cell markers 
may be due, in part, to the relatively small size of the sample population examined, 
as CSC populations expressing this marker may be localised or constitute too small a 
population to be detected by microarray analysis of total amplified RNA. However, 
additional research into the expression of CD133 suggests that expression is 
downregulated during metastatic progression such that tumour from a late stage 
biopsy would be expected to have low CD133 expression (Shmelkov et al., 2008). 
CD133 could not be detected on the array and was only upregulated in the C666.1 
cell line, which may allude to cell line specific expression of this marker or an 
expression profile that is an artefact of in vitro culture.  
 
Upregulation of p75NTR was also not observed by microarray analysis, again 
possibly due to problems associated with the RNA amplification protocol or probe 
sets used. However, IHC analysis revealed consistent overexpression of p75NTR in 
the majority of primary NPC biopsies. p75NTR was also expressed  at high levels in 
C666.1 cells in vitro, and may constitute a useful marker in the identification of NPC-
derived CSCs as it has been used to isolate both normal and squamous cell 
carcinoma stem cells from the head and neck (Okumura et al., 2003, Okumura et al., 
2006, Huang et al., 2009). 
 
With a key concern about the relative size of CSC populations in authentic NPC 
tumour hindering the identification of markers by microarray analysis it may be 
regarded as a bit of an oddity that IHC validation for the CD44, EZH2, BMI1 and 
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SOX2 demonstrated marker expression in the vast majority of tumour biopsies and 
the majority of the cells therein.  
 
Expression of CD44 and CD44 splice variants has been interrogated in HNSCC; 
Prince et al., showed CD44 positivity in fewer than 10% of HNSCC tumour cells 
which also demonstrated increased BMI1 expression (Ruat et al., 2012), whilst in 
another studies CD44 positivity in HNSCC reportedly ranges from  less than 5% to 
95%, with established cell lines all demonstrating over 90% positivity (Lauth et al., 
2007, Louvi and Grove, 2011). A study into the CD44 and CD44v6 expression of the 
epithelium of the head and neck demonstrated positivity of these two markers in 50-
80% of cells with only moderate increases in differentiated carcinomas, questioning 
the selectivity of these proteins as CSC markers (Liao et al., 2010). When CD44 was 
used to identify cells with CSC-like properties from NPC derived C666.1 and SUNE1 
cells the marker was seen to be expressed in a distinct subpopulation comprising 
45.3% and 52.5% of the cell lines respectively (Janisiewicz et al., 2012, Su et al., 
2011). CD44 positivity was also associated with poor clinical prognosis, increased 
clone forming ability and increased drug sensitivity in the SUNE1 cell line. 
Additionally a recent paper demonstrated that the CD44+ population constituted the 
tumour initiating population of C666.1 (Lun et al., 2012). Our findings identify a 
substantial increase in CD44 marker expression during NPC pathogenesis, 
highlighting a potential role of CSC expansion in disease progression. 
 
Another stem cell maker interrogated in this study was EZH2, which was found to be 
consistently upregulated in the tumour microarray and in primary NPC tumours 
analysed by IHC. Studies have found over expression of EZH2 in numerous cancers; 
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however, analysis of this polycomb group protein demonstrates varied expression in 
regard to the number of positive cells within different tumour types. In prostate 
cancer, EZH2 expression did not exceed 10% of the tumour cell population, with the 
majority of tumours (75%) demonstrating positivity in less than 1% of malignant cells 
(van Leenders et al., 2007). A study of GC detected positive EZH2 staining in greater 
than 10% of cells and reported this in 78.8% of cases (Mattioli et al., 2007). Staining 
of bronchiole SCC tissue demonstrates an increased expression of this marker 
compared to normal epithelium, where EZH2 staining is present in isolated cells near 
the basal layer. Positivity appears to be present in greater than 10% of cells, 
although percentages were not presented, and EZH2 did not correlate with BMI1 
expression which was widely expressed in normal tissue (Breuer et al., 2004). 
 
The expression of stem cell/CSC markers was further interrogated in the C666.1 cell 
line, the only available EBV positive NPC cell line that is amenable to growth in vitro. 
Normal oral keratinocytes were used as a model for normal nasopharyngeal 
keratinocytes, having previously been validated for this purpose by microarray 
analysis (Hu, 2010). 
 
While the microarray analysis of the C666.1 cell line showed increased expression of 
many stem cell/CSC markers of interest, a number of markers were seen to be 
downregulated relative to HOK. This downregulation is not surprising as analysis of 
stem cell marker expression in tissues and tumour biopsies demonstrate that stem 
cell marker expression is tumour dependent and, as such, not all of the putative 
markers would be expected to be upregulated in a single NPC cell line. Some 
markers may also be dependent on tumour grade, such as CD133 expression which 
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is proposed to decrease with tumour grade, and/ or mechanism of genetic 
modification, as it is clear from the heterogeneity of marker expression in the tumour 
biopsies that the mechanism by which pathogenesis may occur could vary between 
individual occurrences of NPC. The diversity of marker expressed highlights the need 
for multiple marker identification to distinguish between true CSCs and more 
differentiated progeny.  
 
FACS analysis of the C666.1 cells compared to OKF6, an hTert-immortalised oral 
keratinocyte cell line that was validated as a model for normal nasopharyngeal 
epithelial cells, demonstrated increased cell surface marker expression of CD133 
and CD44v6 in the NPC cell line. It is interesting to note the high proportions of cells 
within the cell line that show expression of these putative CSC marker; on average 
57% of C666.1 cells show CD44v6 positivity, which coincides with the expression 
seen in previous studies of NPC and HNSCC, and 48% show CD133 positivity 
 
These markers may identify CSCs in some tissue types; CD44v6 expression in 
p53/PTCH double heterogeneous mice tumours is found in less than 10% of cells 
and is induced upon GBM neurosphere formation (LaBarge and Bissell, 2008), and 
CD133 is reported to be expressed in only 3% of human laryngeal tumour cell line 
Hep-2, identifying cells with CSC-like properties (Zhang et al., 2003). However, other 
studies have shown the potential of these markers to widely identify non-CSC 
populations; CD44v6 was downregulated in poorly differentiated SSC tumours 
compared to normal tissue and only induced in the formation of some tumours 
following injection into SCID-mice (Shmelkov et al., 2005), and in the colon, the 
tumour initiating population is not restricted to a CD133+ population although this 
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population may give rise to a highly tumourigenic CD133-/ CD44+ population (Qazi et 
al., 2011). 
 
Microarray analysis and IHC staining also revealed aberrant expression of the HH 
pathway in NPC; pathway component and downstream target PTCH was found to be 
upregulated along with other positive regulators of the HH signalling pathway. 
Additionally, negative regulators of the pathway were found to be downregulated and 
a number of HH targets were induced in the NPC tumours compared to normal 
nasopharynx. Having pathway components such as PTCH and GLI1 as downstream 
targets allows for feedback into the pathway. Increased expression of GLI1 is 
reported to be an accurate measure of HH signalling activity and activation of the GLI 
transcription factors is known to influence cell differentiation, proliferation, motility and 
cause an EMT (Kasper et al., 2006, Kar et al., 2012). However key components, 
including SHH, GLI1 and GLI2, were scored as absent from the microarray analysis. 
SHH ligand was found to be expressed in only one of the NPC tumour biopsies by 
microarray analysis but was later found to be upregulated in 60% of NPC tumour 
samples by IHC. Similarly GLI1 and SMO could also be detected by IHC and were 
found to be upregulated in approximately 90% and 96% of NPC tumours respectively 
compared to normal tissue. The expression of these genes analysed by microarray 
analysis was too low to be perceived as present above background in the sample 
RNA and may reflect problems with the RNA amplification protocol or probe sets 
used for detection rather than low expression in the samples. 
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The third HH transcription factor, GLI3, was found to be overexpressed in the NPC 
tumours by microarray analysis. GLI3 is often referred to as a negative regulator of 
transcription having both a repressor and activator form (Wang et al., 2000). This is 
also true of GLI2; however, GLI2 is believed to exist primarily as a transcriptional 
activator (Simpson et al., 2009).  Microarray analysis does not identify the form of 
GLI3 expressed in NPC tumours; however, it is interesting to note that the production 
of the repressive form requires SUFU, whose expression appeared to be 
downregulated in a number of primary NPC tumours. In the absence of HH signalling 
SUFU is required to bind full length GLI3 in the cytoplasm where it is cleaved into its 
repressive form (Kise et al., 2009). When HH signalling is activated GLI3 is 
maintained in its activated form and allowed to translocate to the nucleus (Humke et 
al., 2010). In a situation where SUFU is absent, as is possibly the case in NPC, GLI3 
is not efficiently processed to its repressive form, therefore would not be 
phosphorylated by GSK3β and PKA, and could act primarily as a transcriptional 
activator.  
 
Analysis of the HH signalling pathway in primary NPC tumours revealed varying 
patterns of expression of HH ligand and HH pathway components, with no tumour 
displaying increased expression of all pathway components. However, expression of 
HH pathway targets appeared to be a consistent feature in this disease. This 
suggests that HH pathway dysregulation may be achieved through any one of a 
number of mechanisms that may involve mutations in PTCH1 or SMO, 
overexpression of SHH ligand, or decreased expression of SUFU. A dysregulated 
HH signalling pathway has been shown to be sufficient to induce tumourgenesis in 
neural precursor cells, and is suggestive of an undifferentiated cell origin in neural 
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tumours (Schüller et al., 2008, Yang et al., 2008b). Due to the undifferentiated nature 
of NPC and the abundant expression of putative stem cell markers, it is possible that 
the origin of the NPC tumour is an undifferentiated cell. EBV infection in an 
undifferentiated background may favour stable infection, and precedence for this 
theory exists in persistent stable HPV infection of undifferentiated cervical cells giving 
rise to cervical cancer (Martens et al., 2004, Bodily and Laimins, 2011). This theory, 
that the origin of epithelial carcinogenesis is a stem cell, was first proposed in 1974 
(Pierce, 1974, Potten and Loeffler, 1990) and has yet to be disproved, although 
evidence implicates more committed cells in a number of tumours such as unipotent 
progenitor cells in meduloblastoma, luminal progenitors in BRAC1-associated breast 
cancer and interfolicular epidermal progenitors in BCC (Visvader, 2011). 
Identification of the cellular origin of NPC may help identify high risk individuals and 
has implications for treatment. 
 
Microarray analysis allowed comparison of the C666.1 cell line to human primary 
keratinocytes and identified upregulation of HH pathway components consistent with 
activation of the HH pathway in this tumour cell line. Expression of GLI1 and FOXM1 
was confirmed by RT-PCR and immunofluorescence staining. PTCH2 and SMO 
expression were seen to be downregulated in the microarray of C666.1 and HOK, 
and SHH expression was so low as to be barely detectable above the background. 
Upon RT-PCR and western analysis SHH could once again be detected in the 
C666.1 cell line however the expression of SHH ligand was very low in the RNA 
samples.  
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Inconsistencies in HH downstream target expression by microarray analysis were 
seen; some HH targets were found to be upregulated (FOXM1 BCL2, CFLAR and 
WNT5A) others where downregulated (CCND2 and SOX9), this may be due to 
competing signalling pathways. For instance CCDN2 expression can also be 
regulated by other signalling pathway including a STAT5/BCL6-dependent 
mechanism, and the MYC/MAX/MAD network (Fernandez de Mattos et al., 2004, 
Bouchard et al., 2001), and SOX9 is regulated by WNT signalling in the intestinal 
crypt (Blache et al., 2004). Additionally, the decreased expression of cell surface 
receptors PTCH2 and SMO seen in this microarray, and the absence of SHH 
expression, may point towards ligand independent activation of the HH pathway 
downstream of these receptors, leading to increased PTCH1 and other downstream 
target expression. Ligand independent activation of the HH pathway can be 
demonstrated in a few cell lines in which the HH signalling pathway has become 
uncoupled. For instance, RPMI 8226 cells lack SMO expression and exhibit low GLI 
responsive luciferase activity in response to the addition of HH ligand (ShhNp) 
(Peacock et al., 2007). 
 
Activation of the HH pathway in NPC, in the absence of SHH ligand, could be 
achieved by inadequate repression of the pathway, through mechanisms including 
the epigenetic silencing of SUFU,  downregulation of HH receptor antagonists such 
as HHIP and GAS1 or through non-canonical signalling. Furthermore, crosstalk 
between the HH signalling pathway and other stem cell maintenance pathways has 
been proposed where the PI3K/ATK and KRAS pathways have been demonstrated 
to positively regulate HH signalling, and HH independent activation of GLI can occur 
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through the TGFβ and TNF-α signalling pathways (reviewed in Chung and Fu, 2013) 
and via mutant KRAS (Collins et al., 2012). 
 
Alternatively, as mentioned previously, activation of the HH signalling pathway could 
be due to activating mutations in proteins such as SMO or loss-of-function mutations 
in PTCH1. Oncogenic transformation of receptor proteins is seen in multiple 
carcinomas including BCC, where a constitutively active form of the SMO protein is 
sufficient to induce oncogenic transformation in transgenic mouse models when 
directed to the skin. Additional ligand–independent mechanisms of pathway 
activation also exist in carcinomas such as squamous cell carcinoma (SCC), where 
N-cadherin mediated cell-cell contacts and CD44 can activate EGFR signalling in the 
absence of EGF, leading to downstream MAPK pathway activation (Shen and 
Kramer, 2004).  
 
Immunofluorescence staining for HH pathway components and downstream targets 
identified a redistribution of the PTCH1 protein, possibly due to increased 
endocytosis of PTCH1 due to chronic HH pathway stimulation. Further studies are 
required to interrogate the function of PTCH1 in this system or if this redistribution is 
caused by some other factor which may impact on HH signalling activity. PTCH is 
normally localised in the primary cilium, maintaining SMO in vesicles and preventing 
its activation (Ruat et al., 2012). It would thus seem that the distribution of PTCH 
could have significant consequences on HH signalling; for instance redistribution of 
the receptor into vesicles away from the cilia could allow for activation of the pathway 
in a ligand independent manner. Additionally constitutive SMO expression has been 
shown to activate the HH pathway (Xie et al., 1998). Evidence from a variety of 
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techniques used to measure expression of HH pathway components and 
downstream target expression, at both the RNA and protein level, reveal an activated 
HH signalling pathway in the C666.1 cell line which, when combined with the 
evidence that NPC tumours demonstrate the same deregulation, highlights the 
importance of this pathway in the pathogenesis of EBV-positive NPC. 
 
Inhibition of the HH pathway with cyclopamine has been shown to impact on stem 
cell marker expression and limits the growth of CSC populations in pancreatic 
xenograph models (Jimeno et al., 2009). Work presented here shows that inhibition 
of the GLI transcription factors with GANT58 and GANT61 attenuates HH signalling 
and reduce expression of key stem cell/CSC markers in the C666.1 cell line. 
GANT61 was found to be effective at inhibiting stem cell marker expression, 
consistent with evidence that GANT61 is a more efficient HH inhibitor, targeting both 
GLI1 and GLI2 (Lauth et al., 2007).  
 
Whilst the expression of multiple stem cell markers, including CD44v6 and CD133, 
was found to be dependent on HH signalling, only cell surface CD133 expression 
was reduced in response to HH pathway inhibition, as there was no effect on cell 
surface CD44v6 expression in response to HH pathway inhibition. One could 
postulate that multiple cell signalling pathways are responsible for the expression of 
CD44; indeed the WNT and TGFβ signalling pathways have been shown to influence 
the expression of this stem cell marker among other canonical pathways (Wielenga 
et al., 1999, Shipitsin et al., 2007). As such, inhibition of the HH pathway alone may 
not be sufficient to reduce the expression of CD44v6. Further work is required to 
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better understand the interaction between these stem cell maintenance pathways in 
the background of signalling dysregulation present in the NPC tumour. 
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CHAPTER FOUR: EBV INDUCES THE EXPRESSION OF 
STEM CELL MARKERS BY DIRECTLY ENGAGING THE 
HEDGHOG SIGNALLING PATHWAY. 
 
 
 
 
 
 
 
 
 
 
“Truth in science can be defined as the working hypothesis best suited to open the 
way to the next better one.”  
— Konrad Lorenz 
In On Aggression (1966, 2002), 279.  
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4.1 Introduction 
In NPC, viral gene expression is restricted to EBNA1, the non-coding EBER1/2 
RNAs, the BamHI1A-derived miRNAs, BARF1, and variable expression of LMP1 and 
LMP2 (Raab-Traub, 2002, Port et al., 2013). These latent gene products influence 
epithelial cell behaviour, modulating the activity of various cell signalling pathways to 
effect changes in cell growth, differentiation, motility, invasion, apoptosis and 
angiogenesis (Young and Rickinson, 2004, Lung, 2012). In relation to stem cell 
maintenance in epithelial cells, LMP2A has been shown to transform epithelial cells, 
to block epithelial cell differentiation, and to enhance epithelial cell adhesion and 
motility. Key roles have been identified for Syk, PI3K/Akt and ERK-MAPK signalling 
in these responses (Fotheringham et al., 2012, Scholle et al., 2000, Dawson et al., 
2008). Similarly LMP2A has been shown to inhibit differentiation and to enhance 
colony formation and tumorigenic potential through activation of the WNT/β-catenin 
pathway, mediated in part through PI3K/Akt inactivation of GSK3 (Morrison et al., 
2003). Crosstalk between the HH and WNT signalling pathways is well documented 
and HH activation can induce the expression of a number of WNT proteins (Mullor et 
al., 2001, Cohen, 2003, Cohen, 2010). LMP2A induction of WNT/β-catenin signalling 
may impact on the HH signalling pathway; activation of β-catenin decreases SHH 
expression in ventral midbrain precursors and mouse embryonic stem cells (Tang et 
al., 2010) while in developing hair buds, WNT is proposed to precede and be 
required for a tumourigenic response to activated HH signalling (Yang et al., 2008a). 
The tissue dependent nature of the relationship between WNT and HH is further 
demonstrated in the developing tooth, which relies on a WNT/HH/FGF/BMP 
signalling network, where the HH and WNT signalling pathways are mutually 
inhibitory (Nakashima and Reddi, 2003, Ahn et al., 2010).  
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Like LMP2A, LMP1 also engages a plethora of cellular signalling pathways which 
exert a profound effect on epithelial cells. LMP1 has been shown to impact on mTOR 
signalling in the HONE1 and 6-10B NPC cell lines (Chen et al., 2010), and can also 
increase levels of nuclear β-catenin (You et al., 2011). Studies have reported variable 
expression and detection of LMP1 in NPC tissue, leading to discussion over its 
importance is NPC pathogenesis. However, LMP1 detection is associated with the 
sensitivity of the technique used. Whilst RT-PCR testing of NPC biopsies has 
demonstrated LMP1 expression in a higher percentage of tumours than previously 
described, when NPC cell lines are infected with type EBV LMP1 can only be 
detected on early passage and is often lost on establishment of a stable cell line (Jia, 
J and Dawson, C.D. unpublished observation). The low level LMP1 expression, 
which persists in the NPC tumour following the initial high level expression upon 
infection (Strong et al., 2013), may suggest that LMP1 dysregulation of the cellular 
signalling background occurs during initial infection. If LMP1 is responsible for the 
dysregulation of HH signalling seen in the C666.1 cell line, which does not express 
LMP1 but continues to display aberrant HH signalling, either LMP1 was important in 
the initial dysregulation of this signalling pathway, which is maintained without LMP1 
expression, or another latent protein is continuing to act on the pathway, or both. 
 
Latent EBV infection has also been shown to activate STAT3 and NFκB and to 
induce the expression of downstream targets such as c-Myc, VEGF and COX-2, 
whilst suppressing the p38-MAPK signalling pathway (Lo et al., 2006). More recently 
studies have interrogated the role of viral-encoded miRNAs on cell signalling 
pathway activity and their impact on cellular phenotype (Lung et al., 2013). While this 
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research is on-going it is likely that it will determine that these miRNAs have a 
significant role in modulating cell signalling and therefore cellular phenotype. 
 
In addition to influencing stem cell maintenance pathways, EBV latent proteins have 
previously been associated with the expression of stem cell markers in NPC. One 
study looked at the effect of LMP1 positivity on CD44v6 expression, a CD44 variant 
highly expressed in certain GCs and non-Hodgkin’s lymphoma, in tumour biopsies 
from NPC of various stages. CD44 variant expression correlated neither to LMP1 
expression or stage; however, it was not determined if other EBV latent genes could 
affect CD44 expression (Brooks et al., 1995). Whilst LMP1 was not found to influence 
CD44 variant expression in this study there is much evidence of the transforming 
ability of this oncoprotein in epithelial cells (Dawson et al., 2012). Indeed in the 
context of “stemness” LMP1 can induce the expression of TWIST and the transition 
of cells from an epithelial to mesenchymal phenotype (Horikawa et al., 2007). 
  
Prior to this study, EBV had not been shown to engage the HH pathway. However, a 
number of HH downstream targets had previously been demonstrated to be 
upregulated in EBV positive NPC. BCL2, a target of HH signalling that possesses the 
GACCACCCA motif to which active GLI transcription factors bind (Katoh and Katoh, 
2009a), is over expressed in EBV positive tumours, including NPC, compared to EBV 
negative counterparts (Yang et al., 2001, Yip et al., 2006). BCL2 expression in NPC 
is correlated with histological type and mean survival of patients, and has been 
proposed as a prognostic marker (Vera-Sempere et al., 1997). Studies investigating 
the role of EBV latent protein in the expression of this protein have found that LMP1 
silencing does not affect BCL2 expression, suggesting an LMP1 independent 
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mechanism for BCL2 upregulation (Mei et al., 2007). However both BCL2 and LMP1 
proteins have been demonstrated to act synergistically to promote cell growth (Sheu 
et al., 2004).  
 
BMI1 is another HH target found to be upregulated in NPC biopsies. BMI1 is a 
prognostic marker in NPC, where expression correlates with disease stage and can 
be used to predict survival (Song et al., 2006). Downregulation of BMI1 inhibits the 
growth of nasopharyngeal cells (Wu et al., 2011) and increases NPC cell sensitivity 
to cytotoxic drugs resulting in increased apoptosis (Qin et al., 2008). BMI1 
expression has also been shown to immortalise primary nasopharyngeal epithelial 
cells in vitro through the induction of telomerase and inactivation of p16INK4a (Song et 
al., 2006), and can induce an EMT via activation of the PI3K/Akt pathway and 
epigenetic silencing of PTEN (Song et al., 2009). Again EBV may have a role in the 
induction of this HH target protein as LMP1 has been shown to induce the expression 
of BMI1 in HL cells (Dutton et al., 2007). LMP2A has also been demonstrated to 
induce an EMT, and the dedifferentiation of cells towards a stem cell like phenotype, 
which could play a role in establishing the undifferentiated phenotype seen in NPC 
tumours (Kong et al., 2010). Further phenotypic consequences of an activated HH 
pathway, including increased motility, proliferation and survival can be also induced 
by individual EBV viral proteins LMP1 and LMP2A (Dawson et al., 2012).   
 
This chapter investigates the possible contribution of EBV infection to the activation 
of the HH signalling pathway, expression of putative stem cell markers and 
acquisition of a stem cell-like phenotype as observed in the C666.1 cell line. Finally, 
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some preliminary data as to the role of individual EBV latent genes in the activation 
of the HH signalling pathway will be presented. 
 
4.2 EBV infection drives the expression of putative stem cell markers in 
latently infected epithelial cells: the role of the HH pathway 
4.2.1 Authentic NPC and gastric cell lines derived from NPC or EBVa-GC 
express higher levels of putative stem cell markers than EBV negative 
cell lines 
To obtain an overall impression of stem cell marker gene expression in epithelial cell 
lines derived from EBV-positive and EBV-negative carcinomas, RT-PCR profiling was 
performed on EBV positive; C666.1 and gastric derived YCCEL1, and EBV negative 
cell lines; SUNE-1, A549, CNE2, and OKF6 (Figure 4. 1). This analysis identified 
differences in the expression of a number of putative stem cell markers between EBV 
positive and EBV negative epithelial cell lines. It was found that C666.1 and YCCEL1 
expressed significantly higher levels of the cell surface markers CD133 and CD44v6, 
and stem cell maintenance genes; SOX2, BMI1 and LRIG1. p75NTR was also 
expressed at higher levels in the C666.1 cell line but was not expressed in YCCEL1. 
Expression of epithelial cell adhesion marker (EPCAM), a cell surface receptor 
overexpressed in a variety of cancers, was expressed in OKF6 cells and the EBV 
negative carcinoma-derived cell lines and expressed at slightly higher levels in 
C666.1 and YCCEL1 cells.  
 
From these data it was postulated that EBV infection might induce the expression of 
a number of putative stem cell markers by activating cell signalling pathways involved 
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in stem cell maintenance. Although dysregulation of a number of stem cell signalling 
pathways has been described in NPC, for example TGFβ, WNT/β-catenin and 
NOTCH, the contribution of EBV infection to this phenomenon is currently unknown. 
Whilst NPC tumour biopsies and the authentic EBV positive C666.1 cell line display 
increased expression of HH pathway components, as demonstrated in Chapter 3 and 
by Yue et al., (2012), the contribution of this particular pathway to the induction of 
stem cell marker expression and the role EBV infection plays in this phenomenon is 
unknown.  
 
With this in mind, the effect of EBV infection on HH signalling and its contribution to 
stem cell marker expression and the acquisition of stem cell-like characteristics were 
investigated. 
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Figure 4. 1 Increased expression of stem cell markers in EBV positive C666.1 
and YCCEL1 cell lines compared to EBV negative cell lines 
Increased stem cell marker expression is seen in the EBV positive NPC cell line 
C666.1 compared to EBV negative NPC cell line CNE2, A549 and SUNE1, and the 
OKF6 normal nasopharynx model. Additionally, increased expression of the same 
markers is seen in the YCCEL1 EBV positive gastric carcinoma cell line. 
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4.2.2 The generation of rEBV infected epithelial cell lines 
 
EBV infected epithelial cell lines were generated after co-cultivation with Akata BL 
cells induced into lytic cycle as described in the Materials and Methods (section 2. 3) 
(Stewart et al., 2004). The NPC-derived cell lines: CNE1, CNE2, HONE1 and 
SUNE1, along with the non-small cell lung cancer (NSCLC) cell line, A549, were 
chosen for study; EBV-infected AGS cells had been developed in a previous study 
(Stewart et al., 2004). Stably infected clones were selected and maintained as 
polyclonal populations under neomycin selection.  
 
Once established, the pattern of EBV gene expression in stable rEBV infected cell 
lines was analysed by RT-PCR (Figure 4. 2). For comparison, the C666.1 cell line 
was included as a reference. The pattern of EBV gene expression in the C666.1 cell 
line was similar to that presented by Lo et al., 2006 (Lo et al., 2006) with detection of 
Qp-driven EBNA1, EBER1/2, BamH1A transcripts (1/2, 3/4) and BARF1, low level 
expression of LMP1 and BZFL1, and little if any LMP2A and LMP2B. An examination 
of the freshly derived rEBV-infected epithelial cell lines revealed patterns of EBV 
gene expression that were broadly similar to C666.1. All cell lines were found to 
express Qp-driven EBNA1 and the EBER1/2 RNAs; however, EBER2 expression in 
the AGS cell line was particularly low and may allude to the propensity for this cell 
line to lose EBV upon serial propagation (Feng et al., 2007). Low levels of LMP1 
expression were observed in all cell lines, and variable levels of LMP2A, LMP2B, 
BamH1A–derived transcripts and BARF1 were observed in seven of the eight EBV 
positive cell lines; in AGS all four of these EBV latent genes were undetectable. With 
the exception of ADAH and HONE1, the majority of cell lines displayed low or 
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undetectable levels of the immediate early (IE) gene BZLF1. Little correlation was 
observed between expression of BZLF1 and the other IE gene BHRF1, where 
expression was restricted to CNE2, CNE1, ADAH and HONE1.  
 
From the panel of EBV infected epithelial cell lines generated, two were chosen to 
further investigate the role of EBV infection on the induction of stem cell marker gene 
expression. RT-PCR analysis was performed to profile stable EBV infected A549 and 
CNE2 cell lines for EBV gene expression (Figure 4. 3). Both cell lines displayed an 
EBV gene expression profile that closely resembled that observed in the authentic 
EBV positive NPC cell line, C666.1. EBV gene expression profiling was repeated to 
include the EBV negative parental cell lines, an EBV transformed LCL, X50/7; the 
Akata BL cell line; and the EBV negative BL cell line, DG75 (Figure 4. 3). Again both 
rEBV-infected CNE2 and A549 cell lines displayed a viral gene expression profile 
that closely resembled the C666.1 and Akata BL cell lines, expressing EBNA1 from 
the Qp rather than the Cp/Wp promoters, high levels of EBER1/2 and BamH1A-
derived transcripts (BARTs), and BARF1. Whilst very low levels of LMP1 were 
observed, rEBV-infected CNE2 cells were found to express levels of LMP2A mRNA 
that closely approximated those observed in X50/7. The lack of BZFL1 expression 
established that both rEBV infected cell lines had adopted a latency type II infection 
programme. 
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Figure 4. 2 RT-PCR expression profiling of NPC cell lines stable infected with 
rEBV 
Multiple rEBV infected carcinoma cell lines were analysed for expression of latency II 
expression products; EBNA1 Qp, EBER1, EBER2, LMP1, LMP2A/2B, the BamH1 
transcripts and BARF1, as well as immediate-early genes BHRF1 and BZLF1. 
Expression profiles were compared to the EBV positive C666.1 prototype cell line. 
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Figure 4. 3 Generation of EBV positive CNE2 and A549 cell lines 
RT-PCR comparing the expression of EBV latent genes (EBNA1, EBERs, LMP1, 
LMP2A, LMP2B) and lytic genes (BZLF1 and BHRF1) demonstrates that the rEBV 
infected CNE2 and A549 cell lines display an expression pattern similar to that seen 
in the EBV positive C666.1 cell line. Additional comparison with EBV positive, X50-7, 
and EBV negative Burkitt’s lymphoma cell line, DG75, and EBV positive Akata B-cell 
line. 
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Further interrogation into the expression of EBV latent genes in the A549, CNE2 and 
C666.1 cell lines was achieved by QPCR analysis (acknowledgements go to Lauren 
Lupino for the LCL cell line data). Expression of EBNA1, LMP1 and LMP2A was 
analysed using RNA from a BL cell line (Rael BL) as a positive control to which all 
scores where normalised. Figure 4. 4 shows the relative expression of these EBV 
latent genes. EBNA1 was found to be expressed in all EBV positive cell lines but was 
substantially less than that observed in the BL cell line. LMP1 was not detected by 
QPCR in any of the carcinoma cell lines. However LMP2A was found to be 
expressed at higher levels in the CNE2 and A549 cell lines than in the BL sample but 
could not be detected in the C666.1 cell line. Interestingly, A549 demonstrated a six 
fold increase in LMP2A expression compared to BL, and the relative level of EBNA1 
in CNE2 was only half that found in the A549 cell line.  
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Figure 4. 4 QPCR analysis of the relative expression of EBNA1, LMP1 and 
LMP2A in C666.1 and EBV infected CNE2 and A549 cell lines 
QPCR analysis of the relative expression of EBNA1, LMP1 and LMP2A in BL, 
C666.1 and the A549 and CNE2 parental and EBV infected cell lines, normalised to 
the BL positive control. 
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Immunofluorescence staining of rEBV infected CNE2 and A549 cells for expression 
of the EBV genome maintenance protein EBNA1 was performed using an EBNA1 
specific polyclonal rabbit serum (R4), subsequently detected with Alexa-Fluor® 488-
conjugated goat anti-rabbit immunoglobulin. Counterstaining with DAPI was 
performed to identify cell nuclei. Representative fluorescence microscopy images, 
Figure 4.4, confirmed the presence of EBV in all viable cells in both rEBV infected 
CNE2 and A549 cell lines and demonstrated variability in the staining such that 
around 10% of cells in each cell line demonstrated higher EBNA1 expression. 
Immunofluorescence staining was repeated through the course of the experiments 
presented in this thesis to check the EBV status of stably infected cell lines; no 
change was seen in expression throughout. 
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Figure 4. 5 Immunofluorescence staining demonstrating EBNA1 antibody 
expression 
(A) CNE2 and (B) A549 parental and stable rEBV infected cell lines stained with 
EBNA1 antibody, R4 (green), demonstrates positivity in all 100% of cells of the rEBV 
infected cell lines. Positivity was not seen in the EBV negative parental counterparts. 
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4.2.3 Stable EBV infected CNE2 and A549 cells express higher levels of 
putative stem cell markers  
While a number of individual EBV latent genes, notably LMP1 and LMP2A, have 
been shown to activate signalling pathways which can impact on stem cell marker 
gene expression (described in Chapter 1. 9), it is unclear whether EBV infection, with 
biologically relevant levels of latent gene expression, can do the same. This is 
particularly relevant given that most studies have been performed on cell lines 
engineered to overexpress the EBV latent gene of interest, with levels of expression 
that far exceed those found in authentic NPC specimens (Kong et al., 2010, Kondo et 
al., 2011). As such, they have not taken into account potential cooperative or 
modulatory mechanisms that occur when epithelial cells are infected with whole virus, 
where expression of these latent genes occurs at physiological levels.  
 
Experimental infection of epithelial cells with rEBV in vitro has demonstrated an 
ability of the virus to alter epithelial cell behaviour. For example, EBV infection of the 
GC-derived cell line, AGS, resulted in anchorage-independent growth (Marquitz et 
al., 2012). In NPC-derived cell lines, EBV infection can induce cell growth through the 
induction of insulin-like growth factor 1 (Iwakiri et al., 2005), whilst  EBV infection of 
the hTert-immortalised normal nasopharyngeal cell line, NP460, induced anchorage 
independent growth, and increased invasive properties and survival in growth factor 
and nutrient deficient medium (Tsang et al., 2010).  
 
To explore the possibility that stable EBV infection is associated with the induction of 
stem cell/CSC marker genes, control uninfected and stable rEBV infected cell lines 
were analysed for the expression of a number of putative stem cell/CSC marker 
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genes, as it was hypothesised that the EBV-infected cells might show increased 
expression of stem cell/CSC markers. As a guide, expression of CD133, CD44v6, 
SOX2, BMI1 and others were chosen, as the expression of these had been found to 
be increased in the authentic EBV positive C666.1 and YCCEL1 cell lines.  
 
RT-PCR analysis demonstrated that rEBV infected CNE2 and A549 cell lines both 
displayed increased expression of the putative CSC markers: CD133, CD44v6 and 
p75NTR, and the stem cell maintenance genes: SOX2, LRIG1, NANOG and BMI1 
compared to their uninfected counterparts (Figure 4. 5A). Additionally, rEBV infected 
CNE2 cells also showed increased expression of EZH2 compared to their uninfected 
counterparts; however, this upregulation was not observed in rEBV infected A549 cell 
line. Expression of the genome maintenance protein EBNA1, confirmed that rEBV 
infected cell lines were latently infected with EBV. 
 
Western blot analysis confirmed findings made from the RT-PCR analysis, supporting 
EBV driven stem cell marker gene expression, with significant increases of CD44, 
NESTIN, BMI1 and EZH2 in the EBV infected CNE2 and A549 cell lines. Both CD44 
and NESTIN expression in the parental cell lines was very low prior to EBV infection, 
BMI1 and EZH2 showed increases expression above the basal level observed in 
parental cell lines (Figure 4. 5B). 
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Figure 4. 6 EBV expression induces the expression of a number of putative 
stem cell markers in both CNE2 and A549 cell lines 
(A) RT-PCR and (B) western analysis for putative stem cell markers in CNE2 and 
A549 cells and rEBV infected counterparts. 
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FACS analysis of the CNE2 (Figure 4. 7) and A549 (Figure. 4. 8) cell lines 
demonstrated increased expression of cell surface stem cell markers CD133 and 
CD44v6 on rEBV infected cell lines. During the course of these experiments the 
CD133 antibody (Cat. No. CS24B9) from Cell Signalling Technology, Danvers, USA, 
was discontinued and data for this antibody can only be presented on the CNE2 cell 
line.  
 
Like the C666.1 cell line, CNE2 cells contained a subpopulation displaying high 
levels of CD133 expression, which was increased in response to EBV infection 
(FC=3.6, P=0.041, n=3). Similarly CD44v6 was also found to be increased in a 
subpopulation of cells (FC=2.2, P=0.021, n=3). However, the replacement CD133 
MACS (293C3) antibody displayed a population shift demonstrating increased 
expression of this marker in the EBV positive CNE2 cells as an increase in cell 
surface marker rather than an increase in a sub-population of positive cells (FC=1.6, 
P=0.041, n=3). The increase in expression of CD133 MACS in the A549 EBV 
infected cell line was greater than that seen in the CNE2 cell line (FC=3.1, P=0.007, 
n=3). Basal CD44v6 expression in the parental A549 cell lines was greater than that 
of the CNE2 parental cell lines, and EBV infection of the A549 cells produced a fold 
change of 1.8 (P=0.015, n=3). An additional cell surface marker was used to replace 
CD133 (C24B9) to analyse marker expression in the A549 cell line; p75NTR was 
seen to increase 4.6 fold on EBV infection (P=0.048, n=3) and produced a separate 
population peak.  
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Figure 4. 7 FACS analysis for stem cell markers in CNE2 cells stably infected 
with EBV compared to their uninfected counterparts 
(A) CNE2 EBV cell line (red) displays a 2.2 fold induction of cell surface CD44v6 
(P=0.021, n=3), (B) 3.6 fold induction of cell surface CD133 (P=0.041, n=3), and (C) 
1.6 fold induction of cell surface CD133 (MACS antibody) (P=0.041, n=3) compared 
to CNE2 parental cell line (blue). 
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Figure 4. 8 FACS analysis from stem cell markers in A549 cell line stably 
infected with EBV compared to their uninfected counterparts 
(A) A549 EBV cell line (red) displays a 1.8 fold induction of cell surface CD44v6 
(P=0.015, n=3), (B) 4.6 fold induction of cell surface p75NTR (P=0.048, n=3), and (C) 
3.1 fold induction of cell surface CD133 (MACS antibody) (P=0.007, n=3) compared 
to A549 parental cell line (blue). 
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The average positivity for the CD44v6 and CD133 MACS markers, and standard 
deviation over multiple experiments, are shown in Figure 4. 9. The basal percentage 
positivity for both antibodies was highest in the A549 cell line, at CD133macs; 58.5%, 
and CD44v6; 55.2%, and lowest in the OKF6 cell line CD133macs; 13.0%, CD44v6; 
13.9%. All three cell lines demonstrated significant increases in percentage positivity, 
with greatest fold changes being recorded in the C666.1 cell line; CD133 MACS; 
FC=3.8 (P=0.042, n=3), CD44v6; FC=4.6 (P=0.039, n=3). These data demonstrate 
that EBV infection induces an increase in putative stem cell/CSC marker expression 
in accordance with the enhanced marker expression demonstrated in naturally EBV 
positive carcinoma cell lines.  
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Figure 4. 9 Expression of (A) CD133 and (B) CD44v6 cell surface markers in 
OKF6, CD133, CNE2, CNE2 + EBV, A549 and A549 + EBV cell lines  
Average expression and standard deviation of CD133 (MACS) and CD44v6 by FACS 
analysis. Fold changes for CD133 in the C666.1, CNE2 EBV and A549 EBV to 
respective control was 3.8 (0.042), 1.6 (P=0.041), 3.1 (P=0.007). Fold change for 
CD44v6 in the C666.1, CNE2 EBV and A549 EBV to respective control was 4.6 
(P=0.039), 2.2 (P=0.021), 1.8 (P=0.015). All n=3, *, p<0.05; ** p<0.01; *** p<0.001. 
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4.3 EBV infection engages the HH pathway 
EBV latency programs have been shown to influence a number of cell signalling 
pathways that could alter stem cell marker expression; however, whilst aberrant HH 
signalling has been demonstrated in NPC (Yue et al., 2012) the role of EBV in the 
dysregulation of this pathway is unknown. Following findings that HH signalling can 
directly influence the expression of stem cell markers in the C666.1 cell line, it was 
hypothesised that EBV infection may directly influence the status of HH signalling in 
NPC cell lines resulting in increased stem cell marker expression in EBV positive 
carcinomas.  
 
4.3.1 rEBV infection induces SHH ligand expression in multiple carcinoma 
cell lines. 
Induction of hedgehog ligand SHH due to mutation is rare, and is seen in less than 
2% of cases of BCC (Daya-Grosjean and Couve-Privat, 2005, Couve-Privat et al., 
2002). The vast majority of BCC cases are caused by mutations in the PTCH or SMO 
membrane proteins, these “common” basal cell carcinomas do not display increased 
SHH expression (Rubin and de Sauvage, 2006). Whilst most HH driven cancers 
appear to be regulated by mutations downstream of SHH ligand, SHH is found to be 
overexpressed in a subset of gliomas where its expression is associated with tumour 
grade (Becher et al., 2008); in breast cancer, SHH ligand expression is correlated 
with increased risk of metastasis, and SHH is upregulated in 70% of primary 
pancreatic adenocarcinomas (Thayer et al., 2003). Additionally, whilst direct gene 
mutation may not be responsible for its induction, SHH overexpression has a clear 
role in HH pathway dysregulation and tumour formation in BCC (Fan et al., 1997). 
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The expression of SHH ligand in multiple rEBV-infected NPC cell lines, the NSCLC-
derived A549 cell line and the AGS gastric carcinoma cell line, was interrogated by 
RT-PCR (Figure 4. 10A) and western blot analysis (Figure 4. 10B). The highest basal 
level of SHH expression was observed in the HONE1 and CNE1 cell lines, and the 
lowest in the CNE2 and AGS cell lines. Increased expression of SHH ligand was 
demonstrated at both the RNA and protein level in all rEBV infected cell lines 
compared to their uninfected counterparts. 
 
The expression of SHH in the rEBV infected cells was further interrogated in the 
CNE2 and A549 cell lines. Immunofluorescence staining was performed to examine 
the expression of SHH ligand at the single cell level, using an antiserum specific for 
SHH, subsequently detected with Alexa-Fluor® 488-conjugated goat anti-rabbit 
immunoglobulin, and the DAPI nuclear stain (Figure 4. 11A). Representative staining 
shows CNE2 parental cells demonstrate lower basal SHH expression than A549 cell 
lines, whilst EBV infected cell lines show similar levels of expression. Additionally, 
immunofluorescence staining highlighted variable SHH expression between different 
cells; overall more cells of the rEBV-infected cell lines showed positivity and, in those 
SHH positive cells, expression was greater. Supporting densitometry readings from 
RT-PCR data recorded a 14.8 fold relative increased in the rEBV-infected CNE2 cells 
and a 5.7 fold increase in the rEBV-infected A549 cells which, on average, 
demonstrated higher basal SHH expression (Figure 4. 11B). 
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Figure 4. 10 Stable EBV infection induces the expression of HH ligand in 
multiple carcinoma cell lines 
(A) RT-PCR and (B) western blot analysis demonstrates EBV infection in multiple 
carcinoma cell lines of NPC, EBV-aGC and NSCLC origin increases the expression 
of SHH ligand at both the RNA and protein level. 
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Figure 4. 11 Stable EBV infection induces SHH ligand expression in the CNE2 
and A549 NPC cell lines 
(A) Immunofluorescence and (B) RT PCR demonstrates EBV infection of CNE2 cells 
induces SHH expression. Densitometry of RT-PCR data shows EBV infection 
increases relative SHH gene expression 14.8 fold in CNE2 cells (P=0.0033) and 5.7 
fold in A549 cells (P= 0.0040) (n=3). Bar =20 µm. 
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4.3.2 Activation of the HH pathway in rEBV-infected NPC cell lines is 
mediated through autocrine induction of SHH ligand 
The induction of SHH ligand is sufficient to activate the HH pathway and to promote 
cell proliferation in NSCLC, pancreatic, prostate, colorectal and ovarian cancers, 
which require pathway activity for tumour growth (Kasper et al., 2006, Teglund and 
Toftgard, 2010). Constitutive activation of the HH pathway promotes tumourgenesis 
through the induction of a number of proteins that influence cellular phenotype (Kar 
et al., 2012) as outlined in Chapter 1.  
 
To investigate the impact of EBV infection, and associated increase in SHH ligand 
expression on the activity of the HH signalling pathway, RT-PCR and western blot 
analysis were enlisted to interrogate the relative expression of HH pathway 
components and downstream targets in control uninfected and rEBV infected CNE2 
and A549 cell lines (Figure 4. 12). Both cell lines showed increased expression of 
GLI1 and PTCH1 in response to stable rEBV infection, indicative of an activated HH 
signalling pathway and highlighting the stimulation of this stem cell maintenance 
pathway by EBV infection. Furthermore, stably infected CNE2 cells also 
demonstrated upregulation of GLI2 and downstream HH pathway targets FOXM1, 
WNT5A and BMP2; however, similar downstream target induction was not observed 
in the A549 cell line.  
 
 
 
  
 
 
 
 
Figure 4. 12 Stable EBV infection activates the HH pathway in CNE2 and A549 cells 
(A) RT-PCR and (B) western analysis demonstrates increased expression of HH ligands; SHH and IHH, effectors; PTCH1 and GLI1, and 
targets; FOXM1, BMP2, and WNT5A in CNE2 and A549 cells stable infected with rEBV. 
A. B. 
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Immunofluorescence staining further supported RT-PCR and western blot analysis, 
confirming activation of the HH signalling pathway in response to EBV infection. 
rEBV infected CNE2 and A549 cells showed increased expression of SHH ligand, 
pathway components, SMO and PTCH, and downstream targets: GLI1, and FOXM1 
(Figure 4. 13). Additionally, the expression of GLI1 in the rEBV infected A549 cell line 
was found to be more nuclear, suggesting the presence of an active form of this 
transcription factor. Increased expression of GLI1 in the CNE2 cell line appeared to 
occur in a subset of cells that demonstrated increased nuclear and cytoplasmic 
staining. Increased nuclear expression of GLI2 was observed in the rEBV infected 
CNE2 cell line; however, GLI2 expression in the A549 cell line remained low 
following EBV infection. In the CNE2 cell line redistribution of the SMO and PTCH 
proteins towards the cell membrane occurred upon EBV infection, which, as 
highlighted in the discussion of Chapter 3, may impact on HH signalling. This 
redistribution in PTCH and SMO is less apparent in the A549 cell line, which showed 
significantly increased expression of these membrane proteins. 
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Figure 4. 13 Immunofluorescence staining demonstrating increased expression 
of a number of HH signalling pathway components and FOXM1, a downstream 
target, in CNE2 cells stably infected with wild type recombinant EBV 
Representative immunofluorescence staining for SHH ligand, pathway components 
(PTCH1, GLI1, GLI2) and downstream target FOXM1 in uninfected and stable EBV-
infected CNE2 (A) and A549 (B) cell lines. Bar =10 µm. 
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4.4 The integrity of the HH signalling pathway in CNE2 and A549 epithelial cell 
lines 
It was important to ascertain the nature of HH pathway activation in response to 
rEBV infection. HH signalling can be activated in both a ligand dependent and 
independent manner. Ligand independent activation occurs upon chronic activation 
of the pathway through SMO and PTCH mutation as previously described as the 
main mutations driving basal cell carcinoma (Rubin and de Sauvage, 2006), and can 
also occur through non-canonical pathway activation and the loss of negative 
pathway regulators. For instance, loss of function of SUFU accounted for 5% of 
sporadic basal cell carcinomas in a study by Reifenberger et al., (2005), and has also 
been implicated in the development of meduloblastoma (Wildeman et al., 2012, Mei 
et al., 2007, Yue et al., 2012). 
 
Ligand dependent activation can occur through both autocrine and paracrine 
mechanisms; the latter of which involves stromal cells which can either produce HH 
ligand or react to ligand produced by the tumour. Stromal cells that react to tumour 
produced HH ligand activate the tumour cell through VEGF, IGF and WNT signalling. 
The various mechanisms involved in HH pathway activation are reviewed by Scales 
and Sauvage (Scales and de Sauvage, 2009). 
 
Whilst SHH expression is induced in EBV infected cells lines the activity of this 
ligand, and therefore its ability to stimulate the HH pathway, has yet to be verified. It 
was first established that the CNE2 and A549 cell lines possessed an intact HH 
pathway and are able to respond to ligand stimulation.  
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4.4.1 Transfection of CNE2 and A549 cell lines with SHH expression plasmid. 
To examine the responsiveness of CNE2 and A549 cells to SHH ligand, and to 
establish the integrity of the HH pathway in these cell lines, transient luciferase 
reporter assays were performed using the 8xGLI-BS-Luc reporter construct. CNE2 
and A549 cell were cotransfected with a SHH expression plasmid (see material and 
methods, section 2. 5) and a Renilla plasmid to control for transfection efficiency 
(Figure 4. 14). 8xGLI-BS-Luc activity, normalised to pGL2, was seen to increase in a 
dose dependant manner upon SHH plasmid transfection. Both cell lines responded to 
transfection with 0.5 µM SHH plasmid inducing a 2 fold increase in basal 8xGLI-BS-
Luc activity in the A549 cell line, and 1.2 fold increase in the CNE2 cell line. As such, 
both cell lines appear to have an intact HH signalling pathway and are likely to 
respond to increased SHH ligand expression induced by EBV infection.  
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Figure 4. 14 Relative fold induction 8xGLI-BS-Luc activity in A549 and CNE2 
cell lines 
Induction of 8xGLI-BS-Luc activity, relative to pGL2, upon co-transfection with 
increasing concentrations (µg) of SHH plasmid in the A549 and CNE2 parental cell 
lines (n=3).  
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4.4.2 The effect of HH stimulation and HH pathway inhibition on the 
expression of HH pathway components and downstream targets. 
RT-PCR and western blotting analysis showed increased expression of HH pathway 
components and targets in CNE2 cells in response to 48 hr treatment with SHH 
ligand, and a reduction in expression in response to cyclopamine treatment (Figure 4. 
15). The expression of HH pathway components and targets could also be inhibited 
in response to 5E1 and GANT58 treatment in the rEBV infected CNE2 (Figure 4. 16) 
and A549 cell lines (Figure 4. 17). A 1:1 ratio of 5E1 containing supernatant-to-serum 
free medium was used for both the CNE2 and A549 cell lines, with conditioned media 
being used as a control. While a concentration of 50 µM GANT58 in conditioned 
media was tolerated by CNE2 cells, this concentration resulted in noticeable cell 
death in the A549 cell line after 48 hr. A concentration of 25 µM GANT58 was 
therefore chosen to treat the A549 cell line in this assay. The CNE2 cell line seemed 
more responsive to 5E1 inhibition than the A549 cell line, with more significant 
reduction in the expression of GLI1 and FOXM1, whilst treatment with GANT58 was 
roughly comparable. 
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Figure 4. 15 The expression of HH pathway components and target genes in 
the CNE2 cell line is responsive to SHH ligand stimulation and cyclopamine 
inhibition 
The CNE2 parental cell line was stimulated with 25 µM SHH ligand and inhibited with 
25 µM cyclopamine (CYCLO) over 48 hr. (A) RT-PCR and (B) western analysis 
demonstrates the CNE2 cell line possess an intact, responsive HH signalling 
pathway. 
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Figure 4. 16 HH pathway component and target expression in CNE2 rEBV 
infected cell line is responsive to HH signalling pathway inhibitors 5E1 and G58 
(A) RT-PCR, (B) western analysis and (C) semi-quantitative RT-PCR (n=3) 
demonstrates inhibition of the HH pathway, with 10µl/ml 5E1 (Developmental Studies 
Hybridoma Bank, University of Iowa) and 50 µM GANT58 (G58) impacts on the 
expression of pathway components and downstream targets. *, p<0.05; ** p<0.01; *** 
p<0.001 
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Figure 4. 17 HH pathway component and target expression in A549 rEBV 
infected cell line is responsive to HH signalling pathway inhibitors 5E1 and G58 
(A) RT-PCR, (B) Western analysis and (C) semi-quantitative RT-PCR (n=3) 
demonstrates inhibition of the HH pathway, with 10µl/ml 5E1 (Developmental Studies 
Hybridoma Bank, University of Iowa) and 25 µM GANT58 (G58) impacts on the 
expression of pathway components and downstream targets. *, p<0.05; ** p<0.01; *** 
p<0.001 
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4.4.3 The expression of stem cell/CSC markers in rEBV infected cell lines is 
dependent on HH signalling 
The established CSC markers: CD133, CD44v6, BMI1, and LRIG1 were found to be 
upregulated in response to stable EBV infection (Figure 4. 18A). The effect of HH 
pathway inhibition on the expression of these stem cell/CSC markers was 
subsequently investigated using the GLI1 inhibitor GANT58. Treatment of cells with 
GANT58 for 48 hr was found to inhibit the expression of these markers to varying 
extents in both the rEBV infected CNE2 and A549 cell lines. 
 
RT-PCR analysis established that the levels of CD133, BMI1, NANOG and LRIG1 
expression were significantly reduced upon treatment of rEBV infected CNE2 cells 
with 25 µM GANT58. Whilst expression of CD44v6 and CXCR4 were also reduced, 
the change was not as marked. A similar inhibition of these stem cell/CSC markers 
was observed in the A549 cell line, although the reduction in marker gene expression 
was not as substantial as that observed in the CNE2 cell line. Expression of LRIG1 in 
the A549 cell line was reduced only marginally by GANT58 treatment. Western blot 
analysis supported findings that GANT58 treatment is sufficient to inhibit the 
expression of stem cell markers (Figure 4. 18B). In both the A549 and CNE2 cell 
lines expression of CD44, BMI1 and NESTIN were reduced after 48 hr treatment with 
GANT58. 
 
 
 
 
Results 
215 
 
Chapter 4 
 
 
 
 
 
CNE2 + EBV A549 + EBV
-v
e
G
5
8
-v
e
G
5
8
-v
e
G
5
8
-v
e
G
5
8
CNE2 + EBV A549  + EBV
ACTIN
CD44
BMI1
NESTIN
CD133
CD44v6
BMI1
CXCR4
GAPDH
LRIG1
NANOG
 
Figure 4. 18 Expression of stem cell markers in rEBV infected epithelial cells is 
dependent on HH signalling  
CNE2 and A549 rEBV Cell lines were cultured in the presence or absence of 
GANT58 (G58; CNE5 50 µM, A549 25 µM, 48 hr). (A) RT-PCR and (B) western 
analysis demonstrates that inhibition of the HH signalling pathway decreases the 
expression of stem cell marker genes. 
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4.5 Identification of EBV genes required for SHH ligand induction, 
engagement of the Hedgehog pathway, and induction of a stem cell like 
phenotype. 
Following the identification of dysregulated HH signalling in rEBV infected CNE2 and 
A549 cell lines, the HH pathway was interrogated further using the authentic EBV 
negative HONE1 cell line; HONE1 cells were originally infected with EBV but lost the 
virus after propagation in vitro (Yao et al., 1990). The availability of stable transfected 
cell lines expressing a number of individual EBV genes provided an opportunity to 
identify the EBV latent gene(s) responsible for HH pathway activation.  
 
4.5.1 The generation of HONE1 cell lines expressing individual EBV latent 
genes 
HONE1 cells engineered to express EBNA1, LMP1, LMP2A and a neomycin 
resistant gene, together with a stable rEBV infected cell line were made available for 
study. RT-PCR, western blotting and immunofluorescence staining confirmed 
expression of individual EBV genes in the respective cell lines (Figure 4. 19).  
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Figure 4. 19 Expression profiling of HONE1 single gene transfectant cell lines 
The expression of EBV latent genes was interrogated in the single gene transfectant 
cell lines by (A) RT-PCR analysis, (B) western analysis and (C) immunofluorescence. 
Bar = 20 µm. 
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4.5.2 The role of EBNA1, LMP1 and LMP2 in the expression of HH pathway 
components. 
To examine the contribution of individual EBV latent genes to the expression and 
activity of the HH pathway in epithelial cells, RT-PCR analysis was performed to 
examine the expression of key HH pathway components, effectors and validated 
target genes. As shown in Figure 4. 19, all three viral genes (EBNA1, LMP1 and 
LMP2A) induced expression of SHH and IHH ligand to levels that were comparable 
to rEBV infected cells. Expression of the HH receptor and putative HH target gene 
PTCH1 was also increased in all three cell lines, as was expression of the key HH 
effector proteins GLI1 and GLI2. However, whilst GLI1 and GLI2 were increased to 
variable levels in all three cell lines, they were more strongly induced in LMP1 
expressing cells. The expression of SMO appeared unaltered in all cell lines. 
Expression of the HH effector protein GLI1 was also induced in all three cell lines, but 
more strongly so in the LMP1 expressing cell line. Similar results were found for 
GLI2, although expression was increased in EBNA1 and LMP1 expressing cell lines 
but not in LMP2A expressing cells. Expression of the HH target genes BCL2 and 
FOXM1 were also increased to varying extents in all three cell lines. 
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Figure 4. 20 Expression of HH pathway components in the single latent gene 
HONE1 cell line transfectants.  
The state of the HH signalling pathway was investigated by RT-PCR in the HONE1 
EBNA1, LMP1, and LMP2 cell lines compared with HONE1 parental and rEBV 
counterparts. 
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4.5.3 The role of EBNA1, LMP1 and LMP2 in the expression of stem cell 
markers 
The EBV-encoded latent proteins LMP1 and LMP2A have previously been found to 
induce the expression of stem cell markers and to impose stem-like characteristics 
on NPC derived cell lines in vitro (Kong et al., 2010, Kondo et al., 2011). LMP2A has 
been shown to increase the expression of stem cell markers (ABCG2, BMI1, NANOG 
and SOX2) in the CNE2 and SUNE1 cell lines, an effect that was linked to the 
induction of an EMT, and an increase in the number of cells displaying a side 
population (SP)-like phenotype, a state associated with increased proliferative and 
tumour initiating potential. In addition, LMP2A infected cells demonstrated increased 
activity of the Akt pathway, which when inhibited, significantly decreased the size of 
cell populations with SP-like features (Kong et al., 2010). However, this work failed to 
establish levels of LMP2A expression that were representative to that observed in 
NPC, relying on the over expression of LMP2A in cell lines to achieve cellular 
consequences. As such, it does not extend to establish the effect of whole viral 
infection on stem cell marker expression or the establishment of a side population of 
cells. In addition, LMP1 has been shown to induce and EMT and to induce a stem-
like phenotype in nasopharyngeal epithelial cells (Horikawa et al., 2011). Individual 
EBV genes were seen to induce the expression of stem cell markers in the HONE1 
cell line (Figure 4. 20). A number of markers were seen to be responsive to a single 
EBV latent gene; CD44v6 and P75NTR were upregulated in response to LMP1 
expression, whereas CXCR4 and weak induction of CD133 was seen in the LMP2A 
expressing HONE1 cell line.  
 
Results 
221 
 
Chapter 4 
Little change was observed in BMI1 and OCT4 expression upon either rEBV infection 
or expression of individual EBV latent genes, whereas SOX2 was strongly induced 
by rEBV and found to be upregulated in the EBNA1, LMP1 and LMP2A expressing 
HONE1 cell lines compared to the parental control. LRIG1 appeared to be 
responsive to both LMP1 and LMP2A expression, and EZH2 was down regulated in 
the rEBV infected cell line and most strongly upregulated in the LMP2A expressing 
cell line. These finding demonstrate the different ability for these viral proteins to 
engage stem cell marker expression. While LMP1 appears to most strongly engage 
the HH signalling pathway, both LMP1 and LMP2A can induce stem cell marker 
expression.  
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Figure 4. 21 Expression of putative stem cell markers in HONE1 cells 
expressing individual EBV latent genes 
The state of the HH signalling pathway was investigated by RT-PCR in the HONE1 
EBNA1, LMP1, and LMP2 cell lines compared with HONE1 parental rEBV 
counterparts. 
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4.6 DISCUSSION 
The rationale for investigating the effect of EBV infection on the induction of stem 
cell/CSC marker genes and activation of stem cell maintenance pathways in 
epithelial cells stemmed from the observation that the authentic EBV positive cell 
lines, C666.1 and YCCEL1, were found to express higher levels of stem cell/CSC 
markers compared to their EBV negative counterparts. Using two EBV infected 
epithelial cell lines, which displayed an EBV gene expression profile closely 
resembling that of the authentic EBV positive C666.1 cell line: CNE2-EBV and A549-
EBV, the role of rEBV infection on the induction of stem cell/CSC markers and stem 
cell maintenance pathways was investigated.  
 
Stable EBV infection was associated with the induction of a number of established 
stem cell/CSC markers (CD44v6, BMI1 and EZH2) that were also found to be 
overexpressed in the authentic EBV-positive NPC cell line C666.1 and a high 
proportion of primary NPC tumour biopsies. Whilst the induction of these genes may 
have widespread effects on epithelial cell biology, their involvement in promoting a 
“stem-cell-like” phenotype was of particular interest. Previous studies investigating 
the role of CD44 in CSC formation and maintenance have identified a role for this 
protein in mediating intercellular reactive oxygen species that promote the aggressive 
phenotype observed in NPC tumours (Lin et al., 2013). Furthermore, in a study 
looking at polymorphisms in this gene a CD44 rs13347C>T polymorphism was found 
to affect NPC development by increasing CD44 expression (Xiao et al., 2013), while 
CD44 shRNA gene therapy has been demonstrated to suppress breast cancer 
tumours in NOD/SCID mice (Van Pham et al., 2012).  
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While both epithelial cell lines demonstrated a clear increase in expression of a 
number of stem cell/CSC markers in response to EBV infection, differential 
upregulation of NANOG, p75NTR and EZH2 was observed between the CNE2 and 
A549 cell lines. Additionally, the induction of stem cell/CSC marker gene expression 
was more substantial in the CNE2 cell line. Although the reasons for this are 
presently unclear, it may reflect inherent differences in the plasticity of this cell line to 
respond to signalling pathway modulation, and/or the ability of EBV to modulate cell 
signalling on the background of pre-existing signalling pathway dysregulation. EBV 
may have a role in reprogramming the cell in which it resided such that it becomes 
more compatible with continued latent infection, which does not normally occur in 
normal non-transformed epithelial cells. Expression of these proteins, that either 
maintain an undifferentiated cell or reprogram a more committed cell to 
dedifferentiate, may have a role in the establishment of stable latent infection and, 
therefore, initiation of NPC. 
 
Additional investigations into EBV induced expression of stem cell markers CD133 
and CD44v6 were performed by FACS analysis. It was observed that, in some 
instances, increased stem cell/CSC marker gene expression occurred as a 
population shift demonstrating an increase in marker expression in all cells causing a 
rightward shift of the FACS curve, whilst others demonstrated an increase in the 
positive population, without a shift in the remaining negative population. Perhaps 
more surprising is that detecting the same protein with different antibodies might 
produce two very different results as was the case with CD133. EBV infection of 
epithelial cell lines was found to increase the expression of the CD133 MACS 
antibody (C293C3) whereas the cell signalling CD133 antibody (CS24B9) displayed 
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an increase in the positive population, in the CNE2 cell line. Similarly, the same 
antibody, CD44v6, in different cell lines produced more of a population shift 
demonstrating an increased expression of this marker in the A549 cell line that was 
not observed in the CNE2 cell line.  
 
Further refinement of the molecular marker expression of CSC populations in NPC 
may isolate subpopulations of cells demonstrating marker positivity, when using 
antibodies with subpopulation peaks, or the gating of cells demonstrating the highest 
levels of stem cell/CSC marker expression. For instance, the CD44 positive fraction 
of cells isolated from NPC cell lines has been reported to contain the CSC population 
(Su et al., 2011), whereas integrin β1 positive human epidermal stem cells are 
contained in the highest integrin expressing sub-population (Watt, 2002). Many 
different markers have been utilised to isolate sub-populations of NPC cells which 
display “stem cell-like” properties and increased tumourigenic potential, it is likely that 
a combination of markers is required to isolate a true CSC population. 
 
In addition to inducing stem cell marker expression, findings presented in this study 
show that stable latent infection of epithelial cells with EBV is associated with the 
induction of SHH ligand. EBV induced SHH ligand expression was found in six cell 
lines of NPC, GC and NSCLC origin, demonstrating that this ability is not cell type 
specific. Furthermore, in vitro studies utilising the CNE2 and A549 cell lines 
demonstrated that rEBV induces SHH ligand, and activates the HH pathway through 
autocrine signalling as demonstrated by increased expression of HH pathway 
components and downstream targets by RT-PCR, western blot analysis and 
immunofluorescence staining. While these observations are not supported by data 
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obtained from the microarray analysis of NPC tumours described in Chapter 3, the 
IHC based study did confirm overexpression of SHH ligand in primary NPC tumours. 
These data highlight technical difficulties associated with RNA amplification or the 
probes used to detect SHH ligand, which may be inadequate for the detection of this 
gene. Taken together, results presented here demonstrate the aberrant HH signature 
displayed in NPC tumours is likely due to an autocrine mechanism for EBV 
engagement of the HH signalling pathway but does not rule out additional paracrine 
mechanisms to this aberrant HH activity.  
 
Previous studies have shown that both the CNE2 and the A549 cell lines display 
elevated HH signalling activity and are dependent on HH signalling for survival and 
proliferation (Yue et al., 2012, Bermudez et al., 2013). Furthermore a study by Yuan 
et al., (2006) demonstrates the A549 cell line harbours a constitutively active HH 
signalling pathway due to the overexpression of GLI1, and reports that this cell line is 
refractory to cyclopamine-mediated SMO inhibition. This highlights possible intrinsic 
differences in the HH signalling pathway between these two cell lines which could 
explain the differences in the level of pathway activation in the CNE2 and A549 cell 
line upon EBV induced SHH induction and supports findings demonstrating that the 
CNE2 cell line is more responsive to HH activation upon induction with SHH ligand. 
Results presented here demonstrate that HH signalling in the A549 cell line can be 
inhibited by the 5E1 anti-SHH ligand antibody and can respond to SHH plasmid 
induction of the 8xGLI-BS-Luc reporter demonstrating that the A549 cell line, whilst 
displaying aberrant HH signalling, is still responsive to SHH ligand stimulation. A 
more recent study by Ali et al., (2011) demonstrates that TGFβ can induce the 
expression of SHH and induction of the HH signalling pathway in this cell line. This 
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activation was responsible for the induction of an EMT and an aggressive CSC 
phenotype demonstrating increased growth, motility and invasion. Similarly 
Bermudez et al., (2013) demonstrated that A549 cells do respond to cyclopamine but 
that exogenous SHH only induced modest increases in GLI1 and PTCH1 expression. 
While this work does not extend to investigate the differences in activation of the HH 
signalling pathway between cell lines it does demonstrate the ability for EBV to 
induce SHH expression which can impact on HH signalling activation in responsive 
cell lines. Future studies may wish to investigate the ligand responsiveness of EBV-
associated tumours and cell lines to assess possible paracrine involvement of other 
pathways. 
 
While a number of tumour types are dependent on HH-mediated paracrine signalling, 
both the A549 and CNE2 cell lines appear to show autocrine responsiveness to SHH 
production, as inhibition of SHH ligand with 5E1 attenuated HH pathway activity. This 
does not rule out a paracrine mechanism for HH signalling in the tumour where EBV 
would function to activate HH signalling in a subset of tumour cells that are then 
responsible for inducing cell signalling in the bulk of the tumour. Additionally, HH 
signalling may act in a paracrine manner to influence surrounding stroma or the 
lymphoid infiltrate which assist in the maintenance of NPC tumours. Further work 
should investigate the contribution of the stroma to tumour growth and interrogate HH 
activity in the stromal cells compared to tumour cells. Understanding the implications 
of tumour micro-environment have significant implications for therapy, as such animal 
models should be utilised to investigate the adequacy of cell line models which 
cannot replicate this micro-environment.  
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The discovery that EBV infected cell lines expressed higher levels of stem cell 
markers than their uninfected counterparts invited an investigation into which EBV-
encoded gene(s) was responsible for stimulating their expression. Previous work 
investigating the EBV gene responsible for the induction of “CSC-like” characteristics 
has failed to establish biologically relevant expression of latent proteins. 
 
This study set out to establish the effect of viral infection on stem cell marker 
expression, and the relationship between pathway activity and the expression of 
these markers. Characterisation of rEBV infected cell lines for EBV latent gene 
expression revealed that EBNA1 was expressed in all EBV positive cell lines; the low 
level of expression in the EBV infected AGS cell line is likely due to the lytic nature of 
this cell line and loss of EBV upon serial passage. Very low levels of LMP1 were 
detected in all EBV-infected cell lines, apart from SUNE1, which were of an earlier 
passage, possibly demonstrating an inverse correlation with passage number 
following EBV infection and LMP1 expression. The expression of LMP2A was also 
low in all cell lines with the exception of CNE2, which showed high levels of 
expression.  
 
Zhang et al., (2010) demonstrated that overexpression of LMP2A in the CNE2 and 
SUNE1 cell lines increased the size of cell populations displaying a 
“side population”-like phenotype, which express the ABCG2 drug transporter protein 
and hence export Hoechst dye. This study also found that tumours could be initiated 
by smaller numbers of LMP2A expressing cells, indicating increased tumourigenic 
potential of these cells. These results may explain the undifferentiated phenotype of 
EBV positive NPC and GC tumours and points towards the possibility that stable 
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latent EBV infection of a differentiated cell induces cellular reprogramming, with cells 
acquiring a less differentiated or CSC-like phenotype. However, it does not rule out 
the possibility that infection of undifferentiated stem progenitor cells occurs, and 
stable infection drives the proliferation of these cells. Whether the EMT phenomenon 
will remain true upon the expression of physiological levels of LMP2A, and in the 
presence of other viral latent proteins, remains to be assessed. Indeed, Kong et al., 
(2010) did note that in the C666.1 cell line, which expresses low levels of LMP2A, no 
Hoechst dye effluxing putative stem cells where found. This could indicate that 
Hoechst dye efflux is not sufficient to identify a side population of cells, at least in this 
cell line, and would support the characterisation of other markers of “stemness” in 
NPC and the characterization of cell isolated from side population studies.  
 
In addition to inducing an EMT, LMP2A has also been reported to drive stem cell 
marker expression inducing the expression of stem cell markers including BMI1, 
SOX2, NANOG and ABC transporter ABCG2 in CNE2 and SUNE1 cell lines over-
expressing LMP2A (Kong et a., 2010). In this study, increased expression of NANOG 
was not readily observed in rEBV infected CNE2 cells, which, of all cell lines 
examined, expressed the highest levels of LMP2A. The effects observed may occur 
as a result of over-expression, with high levels of LMP2A forcing a phenotypic 
change in the CNE2 cell line that is not demonstrative of a natural stable infection in 
this epithelial background. Furthermore the effect of other EBV viral proteins, which 
may act in concert with or counter LMP2A-mediated effects, was not addressed. The 
ability of LMP2A to establish a stem cell phenotype may be restricted to cells 
possessing very high LMP2 expression, which might make up a sub-population of a 
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cell line or indeed a tumour, or occur in cell lines that are more sensitive to cellular 
reprogramming.  
 
Work presented here also investigated the expression of individual EBV latent 
proteins in the HONE1 cell line and demonstrated that different stem cell markers 
were induced in response to the expression of individual EBV genes. SOX2 was 
found to be upregulated in response to EBNA1, LMP1 and LMP2A expression, 
whereas LRIG1 was upregulated by LMP1 and LMP2A. Interestingly, LMP1 alone 
was found to strongly induce the expression of CD44 and p75NTR, whereas LMP2A 
alone induced the expression of CD133 and CXCR4. SHH ligand and HH targets 
were found to be induced by all three individual EBV latent genes, suggesting each 
of these viral proteins can modulate HH signalling, but HH activation was most 
noticeable in the LMP1 expressing cell line. This may suggest that LMP1 induced 
markers may be HH dependent while the expression of markers such as CD133 and 
CXCR4 may be related to other cell signalling pathways that may act in concert with 
the HH signalling pathway to induce a CSC phenotype in EBV infected epithelial 
cells. The role that EBV plays in the growth and maintenance of stem cell/CSCs and 
the viral gene products required for this effect is still under investigation and further 
interrogation is required to tease out the complexities relating to multiple signalling 
pathway interactions. 
 
Aberrant activation of a number of stem cell/CSC maintenance pathways (WNT, 
NOTCH, FGF and HH), have been identified in many cancers. While this may lead to 
the aberrant induction of stem cell/CSC markers and the acquisition of stem-like 
properties in more committed or differentiated cells, in most instances it is associated 
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with the growth of CSC subpopulations, which are responsible for generating the bulk 
of the tumour. Dysregulation of a number of stem cell maintenance pathways 
(WNT/β-catenin, TGFβ, and NOTCH) have been identified in NPC, the role that these 
pathways play in the growth and maintenance of stem cell/CSC populations in this 
cancer is unclear. A recent study has not only shown that NOTCH3 is overexpressed 
in primary NPC tumours, but that tumour initiating subpopulations marked by the 
CD44 antigen require NOTCH signalling for maintenance (Man et al, 2012). Although 
still preliminary, these findings suggest that NPC may arise from an EBV infected 
stem cell or CSC populations.  
 
With regard to the origin of NPC-derived CSCs at least two possibilities are 
proposed. In the first scenario, EBV infects an undifferentiated early progenitor cell or 
a stem cell which already display high levels of stem cell markers and heightened HH 
signalling and drives the proliferation of these cells through sustained HH pathway 
activation. Alternatively, EBV infects a precancerous cell of unknown differentiation 
status that is amenable to latent infection, and imposes a CSC-like phenotype 
through sustained engagement of the HH pathway. In this scenario, EBV becomes 
“trapped” in a latency program due to a mistake in cell programming or an inability to 
alter cell signalling in a mutated or undifferentiated background.  
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CHAPTER FIVE: THE CONSEQUENCES OF 
DYSREGULATED HEDGEHOG SIGNALLING PATHWAY IN 
EBV-INFECTED EPITHELIAL CELLS. 
 
 
 
 
 
 
“It is often claimed that knowledge multiplies so rapidly that nobody can follow it. I 
believe this is incorrect. At least in science it is not true. The main purpose of science 
is simplicity and as we understand more things, everything is becoming simpler. This, 
of course, goes contrary to what everyone accepts.”  
— Edward Teller 
Edward Teller, Wendy Teller, Wilson Talley, Conversations on the Dark Secrets of 
Physics (1991, 2002), 2.
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5.1 Introduction 
Dysregulation of the HH pathway is frequently associated with oncogenic 
transformation. As outlined in Chapter 1 section 1.12, loss of function mutations in 
PTCH or gain of function mutations in SMO, that cause constitutive activation of the 
HH pathway, are sufficient to induce basal cell carcinomas in mouse models (Rubin 
and de Sauvage, 2006). Whilst aberrant activation of the HH pathway plays an 
essential role in the renweal and maintenance of CSC populations, the HH pathway 
also impacts on other aspects of cell behaviour, influencing cell proliferation, 
invasion, metastasis, angiogenesis and differentiation (see Chapter 1, Figure 1. 8). It 
is estimated that dysregulated HH signalling is implicated in the aetiology of 
approximately 20-25% of all cancers (Briscoe and Therond, 2005). As such, it has 
become apparent that this pathway constitutes a viable therapeutic target in many 
cancers, particularly those whose aetiology is linked to the presence of CSC 
populations. For example, in hepatocellular carcinoma, HH pathway component 
overexpression is correlated with migration and invasion (Chen et al., 2013). 
Similarly, ectopic overexpression of GLI1 in ovarian cells has been shown to promote 
migration, proliferation and invasion, whilst inhibition of this pathway with 
cyclopamine, suppressed growth, migration, invasion and motility, and induced 
apoptosis (Liao et al., 2009).  
 
In recent years, the HH pathway has been identified as a viable therapeutic target in 
a range of solid and lymphoid tumours. In pancreatic cancer, which also displays 
dysregulated HH signalling, transient GLI1 overexpression can induce proliferation, 
and cyclopamine treatment reduced anchorage independent growth in soft agarose 
and inhibited cancer invasion and metastasis (Feldmann et al., 2007). Cyclopamine 
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treatment was also able to inhibit anchorage-independent growth and proliferation in 
both ER+ and ER- breast cancer cell lines (Zhang et al., 2009b), and reduced the 
growth of gastric cancer cells in vitro (Yanai et al., 2007). HH may even have a role in 
the transition of breast cancer towards estrogen-independent growth, as stable GLI1 
expression was seen to induce estrogen-independent growth, promote G1/S phase 
transition and downregulate estrogen receptor α (Zhao et al., 2010). Whilst cellular 
consequences of dysregulated HH signalling have been demonstrated in numerous 
cancers of epithelial origin including those of the head and neck, its role in the 
pathogenesis of NPC remains uncertain. A recent study by Yue et al., (2012) 
demonstrated that HH pathways component PTCH was seen to be upregulated by 
RT-QPCR in NPC tissue compared to inflamed nasopharyngeal tissue and normal 
tissue, whilst GLI1 was seen to be upregulated in NPC by both PCR and IHC 
compared to these control. Additionally, they found that inhibition of the HH pathway 
was sufficient to decrease proliferation and induce apoptosis in three NPC derived 
cell lines including CNE2 and this was accompanied by decreased GLI1 and PTCH, 
and altered cyclin D and E expression, which may impact on cell cycle regulation 
(Yue et al., 2012).  
 
The HH signalling pathway can influence differentiation and self-renewal by 
activating a variety of downstream target genes. For instance, GLI2 is able to inhibit 
the differentiation of squamous epithelial cells, a necessary requirement for the 
maintenance of an undifferentiated stem cell, through negative regulation of 
differentiation-associated genes: Keratin 1 and 10 (KRT1/10), involucrin (IVL) and 
loricrin (LOR), and additionally cooperates with GLI1 in the promotion of cell 
proliferation though upregulation of cyclin-dependent kinase 1 (CDK1) and CCND2 
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(Regl et al., 2003). GLI2 is also able to influence cell survival through transcription of 
BCL2 (Regl et al., 2004).  
 
HH activation is known induce cellular migration and invasion through an epithelial to 
mesenchymal transition (EMT), and it has been shown that GLI1 can upregulate the 
expression of EMT markers such as SNAI1 and SIP1 (Li et al., 2005, Katoh and 
Katoh, 2009a). It has previously been noted that EBV can induce an EMT through 
expression of EBV latent protein LMP1 and LMP2A (Dawson et al., 2012), indeed 
previous studies using rEBV infected CNE2 cell lines have documented the 
morphological transition that accompanies an EMT upon EBV infection (Kong et al., 
2010). 
 
EMT describes the process by which differentiated epithelial cells lose their 
differentiated characteristic, such as cellular adhesion and polarity, and adopt a more 
mesenchymal phenotype displaying increased motility, invasiveness and apoptosis 
resistance (Thiery and Sleeman, 2006). It has been demonstrated that, in a number 
of cellular backgrounds, an EMT can lead to the acquisition of stem cell and 
malignant traits (Brabletz et al., 2005, Blick et al., 2008). EMT occurs in 
embryogenesis as a transient state, being required for development past the blastula 
stage (Thiery and Sleeman, 2006) and is followed by the reverse process, an 
mesenchymal to epithelial transition (MET) (Duband et al., 1995). MET allows 
somatogenesis and is essential for the development of epithelial organs such as the 
kidneys, coelomic-cavity, gastrointestinal tract, lungs, skin and neural crest (Christ 
and Ordahl, 1995, Duband et al., 1995, Davies, 1996, Funayama et al., 1999, 
Locascio and Nieto, 2001, Gonzalez-Mariscal et al., 2007). During the EMT process 
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epithelial cells show decreased expression of junctional proteins (epithelial (E)-
cadherin, tight junction and desmosomal proteins) and cytokeratin-rich intermediate 
filaments, and gain motility and mesenchymal markers such as mesenchymal (N)-
cadherins and vimentin-rich intermediate filaments (Thiery and Sleeman, 2006). 
 
As well as an essential function in embryogenesis, EMT has a role in the 
maintenance of adult tissues during tissue regeneration and wound healing (Kalluri, 
2009). Signalling pathways are critical in the control of EMT and disruption has been 
associated with disease including cancer (Thiery and Sleeman, 2006, Hugo et al., 
2007, Baum et al., 2008, Yang and Weinberg, 2008), where induction of an EMT is 
associated with poor prognosis (Sabbah et al., 2008). Reduced cellular adhesion, 
induced by E-cadherin disruption, has been demonstrated to be involved in the 
malignant transformation of non-invasive tumours (Birchmeier and Behrens, 1994, 
Perl et al., 1998). 
 
During tumour metastasis cells acquire the ability for self-renewal, allowing tumour 
initiation. As EMT is required for the dissemination process, it has been hypothesised 
that an EMT could also bestow cells with a CSC-like phenotype (Kondo et al., 2003, 
Mani et al., 2008). Mani et al., (2008) isolated cells on the basis of CD44high/CD24low 
expression, which characterises the stem cell population of normal and cancerous 
mammary tissue, and demonstrated that these cells displayed an EMT phenotype. 
Additionally, this population displayed enhanced cell survival, and resistance to 
anoikis and chemotherapeutic drugs. They also demonstrated that human mammary 
cells induced to undergo EMT acquire these stem cell characteristics and display 
increased malignant potential. Similarly, in colon cancer, loss of epithelial features 
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accompanied by downregulation of E-cadherin and increased vimentin expression is 
seen at the invasive front (Brabletz et al., 2005). Recently, a study by Luo et al., 
(2013) demonstrated increased expression of a SOX2 and OCT4 stem cell markers 
at the invasive front of NPC tumours and found a correlation between high levels of 
OCT4, and high N-cadherin/low E-cadherin expression. Expression of SOX2 and 
OCT4 at the invasive front was also associated with poor overall survival. 
 
Progress has been made into defining the embryonic transcription factors critical for 
embryogenesis due to the induction of an EMT. These transcription factors, when 
expressed in neoplastic cells, confer a malignant phenotype by inducing motility, 
invasiveness, and resistance to apoptosis (reviewed by Sánchez-Tilló, et al., 2012). 
Transcription factors that inhibit E-cadherin through the E-box promoter element act 
to induce an EMT. These same transcription factors are often commandeered during 
cancer progression. For instance, SLUG and SNAIL transcription factors are 
regulators of EMT and may contribute to ovarian and pancreatic cancer progression 
(Elloul et al., 2005, Yoshida et al., 2009, Hotz et al., 2007). 
 
Within the stem cell niche the microenvironment is believed to play a large part in the 
maintenance and regulation of the stem cell population. Stromal interactions play an 
important role in the maintenance of cellular phenotype in regard to characteristics 
such as tumour initiation. Furthermore, stromal interactions may regulate an EMT as 
the tumour microenvironment is implicated in the induction of dysregulated cellular 
signalling. Studies have shown an induction of EMT at the tumour stromal interface in 
both human and animal models (Brabletz et al., 2001, Franci et al., 2006, Sheehan et 
al., 2007). In this regard the tumour microenvironment may have a role in maintaining 
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the cancer stem cell population and tumour characteristics much in the same way 
that the adult stem cell niche is responsible for the maintenance of this sub 
population of cells. 
 
A mesenchymal to epithelial transition, the reverse of an EMT, also has a role in 
cancer progression as it is involved in metastasis, possibly acting to re-establish the 
epithelial characteristics of distant metastases in the absence of EMT-inducing 
signals (Polyak and Weinberg, 2009). MET may also be dependent on tumour micro 
environment as a study by Yates et al., (2007) showed that epithelial marker E-
cadherin was upregulated when prostate cancers were co-cultivated with 
hepatocytes. However it has been unresolved whether an epithelial state is the 
default phenotype in the absence of an EMT inducing signal, such that tumours 
without activated stromal influences will reverse back to an epithelial phenotype via 
an MET. 
 
Following the identification of a dysregulated HH signalling pathway in NPC the 
phenotypic consequences of HH signalling activation on the proliferation, anchorage 
independent growth and induction of “stemness”, were investigated in the authentic 
EBV positive C666.1 cell line. Given that EBV infection is capable of inducing HH 
dependent stem cell marker expression, the phenotypic consequences of stable 
latent infection on EMT, cell proliferation, anchorage independent growth and sphere 
formation, and the role of HH signalling in these responses were investigated. 
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5.1.1 Authentic EBV positive carcinoma cell lines require sustained HH 
signaling for cell proliferation  
The incorporation of 5-bromodeoxyuridine (BrdU) into DNA is used to assess cell 
proliferation both in vivo and in vitro. Transient pulsing of cells or tissues with BrdU 
results in incorporation of the label in cells undergoing DNA replication.  Cells 
replicating DNA demonstrate nuclear staining when probed with antibodies specific 
for BrdU, allowing quantitation of cells undergoing DNA synthesis. BrdU label 
retention has also been used to identify putative stem cell populations; in the 
intestine staining over 24 hr is sufficient to stain all the crypt base columnar cells 
where BrdU is retained in the slow cycling cells but rapidly lost from actively 
proliferating cells (Barker et al., 2007, Barker et al., 2008). In other populations 
staining is required for significantly longer periods to ensure all cells are labelled prior 
to wash out; for instance breast cancer cell lines are pulsed with BrdU for 10 days 
(Fillmore and Kuperwasser, 2008). However the use of this assay for the 
identification of stem cells/CSC has been questioned as not all label retaining cells 
are true stem cells/CSC, indeed terminally differentiated cells retain BrdU (Barker et 
al., 2007), and this assay has been shown to be non-specific in the identification of 
haematopoietic stem cells (Kiel et al., 2007). More recently label retaining cells have 
been identified by the expression of histone 2B-green fluorescent protein (H2B-GFP) 
transgene under the control of a tetracycline-regulatable enhancer element (Fuchs, 
2009b). 
 
While stem cells are usually regarded as slow cycling label retaining cells, increased 
BrdU incorporation following transient pulsing, which measures proliferation, has 
been associated with stem cell properties such as self-renewal and the expression of 
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CSC markers. For instance, in the central nervous system stem cells, neural 
progenitors derived from BMI1-/- mice display decreased BrdU incorporation 
compared to WT cells, an effect that was associated with the inability of these cells to 
undergo self-renewal (Molofsky et al., 2003). In another study Ki-67, a marker of 
proliferation, was increased in CD133 positive, tumour sphere forming populations of 
glioblastoma cells. Proliferation of this CD133 positive population of cells was 
demonstrated to be more sensitive to NOTCH inhibition than the CD133 negative 
population (Fan et al., 2010). 
 
The requirement of HH signalling for sustained cell growth in authentic EBV positive 
cell lines was investigated using an ELISA-based assay which measures BrdU 
incorporation. The effects of GANT58 and GANT61 treatment on BrdU incorporation 
in the C666.1 and EBV positive gastric carcinoma cell line YCCEL1 were 
investigated. Inhibition of the HH signalling pathway was shown to impact on the 
proliferation of C666.1 and YCCEL1 cells in a dose dependant manner (Figure 5. 1). 
GANT61 was used at half the concentration of GANT58 due to inherent toxicity when 
used at higher concentrations, perhaps reflecting the fact that GANT61 targets both 
GLI1 and GLI2. Proliferation was significantly inhibited by 25 µM GANT61 and 50 µM 
GANT58 in both cell lines highlighting the potential importance of sustained HH 
signalling for cell proliferation in these unsorted EBV positive carcinoma-derived cell 
lines.  
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Figure 5. 1 Normalised BrdU incorporation in C666.1 (A, B) and YCCEL1 (C, D) 
cell lines.  
Cells were plated at 2.5 x104 and allowed to settle for 24 hr prior to treatment with 
either 25 µM GANT58 (A, C) or 12.5 µM GANT61 (B, D) for 48 hr. BrdU incorporation 
was performed in accordance with the manufactures' instructions. BrdU was pulsed 
for 6-8 hr. 
 
A. B. 
C.  
Results 
242 
 
Chapter 5 
5.1.2 Inhibition of the HH pathway impacts on anchorage-independent 
growth in the C666.1 cell line 
A uniform characteristic of transformed cells is their ability to proliferate in the 
absence of substrate attachment; so called “anchorage-independent growth” 
(reviewed by Wang, 2004). The ability of cells to proliferate in suspension differs from 
the formation of tumourspheres, which utilises special culture conditions which favour 
the growth of CSCs or cells with SC-like properties.  
 
To examine the “transformed” properties of C666.1 cells in vitro, and to identify a role 
for HH signalling in this response, C666.1 cells were plated out in normal growth 
media containing 0.3% agarose and overlaid on a base of 1% LMP agarose. Cells, 
cultured in the presence or absence of GAN58 or GANT61 were allowed to form 
colonies over a 3-4 week period, after which time they were photographed and 
scored for colony number and size. As shown in Figure 5. 2 and Figure 5. 3, both 
GANT 58 (Figure 5. 2) and GANT61 (Figure 5. 3) significantly reduced the ability of 
C666.1 cells to form colonies, and reduced the size of those spheres that formed, in 
a dose dependent manner. Significant inhibition of both colony size and number 
(P<0.005) was achieved with 25 µM of GANT58 or GANT61. 
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Figure 5. 2 Colony formation assay in the presence of HH inhibitor GANT58 
C666.1 cells plated out in triplicate at 5 x103 cells per well in a 12 well plate in 0.33% 
agarose solution containing 10% FCS and 1% RPMI, on a base of 1% agarose/ 1% 
RPM1/ 10% FCS. GANT58 used at increasing concentrations per total well volume, 
in 10% B-cell serum RPMI. Cells were allowed to form colonies for 2-3 weeks, or until 
around 100 colonies/well were present in the control wells. Four, non-overlapping, 
images were taken per well with an x10 objective. (A) Representative image of each 
treatment. (B) Number of colonies (P relative to control, n=3). All colonies of >25 µm 
were counted for each treatment. (C) The maximum diameter of all colonies within 
each photographed field of view were measured and plotted using a box and whisker 
plot (P relative to control, n=3). Bar = 100 µm. Statistical analysis of colony number 
and size using T-test and one-way ANOVA followed by a Tukey’s multiple 
comparison respectively, where *, p<0.05; ** p<0.01; *** p<0.001 
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Figure 5. 3 C666.1 colony formation in the presence of HH inhibitor GANT61  
C666.1 cells plated out in triplicate at 5 x103 cells per well in a 12 well plate in 0.33% 
agarose solution containing 10% FCS and 1% RPMI, on a base of 1% agarose/ 1% 
RPM1/ 10% FCS. GANT61 used at an increasing concentrations per total well 
volume, in 10% B-cell serum RPMI. Cells were allowed to form colonies for 2-3 
weeks, or until around 100 colonies/well were present in the control wells. Four, 
non-overlapping, images were taken per well with an x10 objective. (A) 
Representative image of each treatment. (B) Number of colonies (P relative to 
control, n=3). All colonies of >25 µm were counted for each treatment. (C) The 
maximum diameter of all colonies within each photographed field of view were 
measured and plotted using a box and whisker plot (P relative to control, n=3). Bar = 
100 µm. Statistical analysis of colony number and size using T-test and one-way 
ANOVA followed by a Tukey’s multiple comparison respectively, where *, p<0.05; ** 
p<0.01; *** p<0.001 
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5.1.3 Inhibition of the Hedgehog pathway impacts on sphere formation 
capacity in the C666.1 cell line 
It is now widely appreciated that CSCs, isolated on the basis of unique cell surface 
marker signatures, express higher levels of stemness-associated transcription factors 
and display a higher tumour-initiating potential than the bulk tumour population. 
Whilst the gold standard for the identification of a CSC is to use a limiting dilution 
study to assay for tumour formation in nude mice, a number of in vitro assays have 
been developed which select for cells with CSC-like properties. These assays are 
based on the ability of SC/CSCs to undergo self-renewal under highly selective 
culture conditions (Pastrana et al., 2011). Since its first use in the isolation of 
neuronal progenitor cells, allowing characterisation of these “neurosphere” 
populations in vitro (reviewed in Pastrana et al., 2011), sphere formation has been 
used to isolate and characterise CSC populations from a wide variety of cancers, 
including those of head and neck, prostate, pancreatic, neuronal and gastric origin 
(Dyall et al., 2011).  
 
In this study the ability of NPC-derived CSC populations to form spheres was 
examined using specialised culture conditions. C666.1, OKF6 and NP460 cells were 
plated at low cell density onto ultra-low attachment plates in serum free media (RPMI 
1640) supplemented with epidermal growth factor (EGF), fibroblast growth factor 
(FGF) and the N2 and B27 growth supplements in the presence or absence of 
GANT58 and GANT61. The C666.1 cell line formed colonies, defined as 3D spherical 
structures obtaining a diameter of at least 25 microns after 21 days. Both GANT58 
and GANT61 were found to significantly reduce the ability of C666.1 derived CSCs to 
form colonies and the size of the colonies that formed, Figure 5. 4. Importantly, it was 
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found that the hTert-immortalised OKF6 and NP460 cell lines were unable to form 
colonies under these highly selective conditions (Figure 5. 5). 
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Figure 5. 4 GANT treatment inhibits sphere formation in the C666.1 cell line  
Cells were plated in triplicate at 1x103 cells per well of a 12 well plate in 0.33% 
agarose solution containing 1%RPM1 and growth supplements. GANT58 (G58) and 
GANT61 (G61) used at a concentration of 25 µM and 12.5 µM total well volume 
respectively. Cells were allowed to form colonies for 3 weeks. Four, non-overlapping, 
images were taken per well with an x10 objective. (A) Representative image of each 
treatment. (B) Number of colonies (P relative to control, n=3). All colonies of >25 µm 
were counted for each treatment. (C) The maximum diameter of all colonies within 
each photographed field of view were measured and plotted using a box and whisker 
plot (P relative to control, n=3). Bar = 100 µm. Statistical analysis of colony number 
and size using T-test and one-way ANOVA followed by a Tukey’s multiple 
comparison respectively, where *, p<0.05; ** p<0.01; *** p<0.001 
A. 
B. C. 
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Figure 5. 5 OKF6 and NP460 cell lines were incapable of forming the same 
spheres seen in the C666.1 cell line 
After 3 weeks of incubation, the C666.1 cell line produced spheres with an average 
diameter of 74 µM. In the absence of any HH inhibitors OKF6 and NP460 did not 
produce sphere after 3 weeks of incubation. Bar = 100 µm. 
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5.1.4 EBV infection induces EMT marker expression and a morphological 
transition in CNE2 but not A549 cells. 
In a number of epithelial cell types, EMT is associated with the induction of stem cell 
markers and the acquisition of stem cell-like characteristics (reviewed by Singh and 
Settleman, 2010).  The status of EMT marker expression in rEBV infected CNE2 and 
A549 cell lines were investigated. EBV infection was found to induce a morphological 
transformation, with cells adopting a more mesenchymal or “fibroblastoid” state 
(Figure 5. 6) in the CNE2 cell line only. RT-PCR analysis confirmed that the 
morphological transition in rEBV infected CNE2 cell line was accompanied by the 
expression of mesenchymal markers, such as SIP1, SNAI1 and WNT5A by RT-PCR 
(Figure 5. 6A), which were not seen to be upregulated in A549 cells (Figure 5. 6B). 
This was confirmed at the protein level by western blot analysis. 
 
To investigate the contribution of HH signalling to the induction of an EMT, HH 
signalling was inhibited. Treatment of CNE2 cells with HH inhibitors was unable to 
revert the mesenchymal phenotype induced by EBV suggesting that other cell 
signalling pathways may be responsible for the EMT in this cellular background. 
However, the expression of EMT markers SIP1, SLUG and SNAIL were responsive 
to HH signalling and seen to be induced upon SHH ligand stimulation and decreased 
upon treatment with HH inhibitors cyclopamine and GANT58 (Figure 5. 7). 
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Figure 5. 6 EBV induces an EMT in the CNE2 cell line but not A549 cell line  
(A) CNE2 stably infected with rEBV demonstrates a morphological transition to a 
more mesenchymal state accompanied by increased expression of EMT markers by 
RT-PCR and western analysis. (B) Stable EBV infection of A549 cells does not 
induce and EMT. Bar = 50 µm. 
A. 
B. 
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Figure 5. 7 Expression of EMT markers is dependent on HH signalling in CNE2 
cells stably infected with EBV 
(A) RT-PCR and western analysis demonstrating the expression of EMT markers 
SMUG, SNAIL and SIP is dependent on HH signalling, following SHH and 
cyclopamine treatment. (B) Semi quantitative RT-PCR data for the same markers 
using ImageJ to generate densitometry readings (n=3), SHH (0.5µg/ml) and 
cyclopamine (25 µM) treatment significantly impact the expression of EMT markers. 
(C) 5E1 (1:1 with conditioned media) and G58 (25 µM) treatment inhibit EMT markers 
SLUG and SNAIL expression after 48 hr. 
A. B. 
C. 
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5.2 Phenotypic consequences of an activated HH signalling pathway in CNE2 
and A549 cell lines. 
5.2.1 EBV-infected CNE2 and A549 cell require sustained HH signaling for 
cell proliferation. 
The role of HH signalling in the proliferation of parental and rEBV-infected CNE2 and 
A549 cells was investigated by inhibiting the HH signalling pathway with GANT58 
and GANT61. As with the C666.1 cell line (Section 5.1.1), HH pathway inhibition 
resulted in decreased BrdU incorporation in both the A549 and CNE2 cell lines in a 
dose dependant manner (Figure 5. 8). Again A549, being more sensitive to HH 
inhibitors, was treated with half the concentration of inhibitors used on the CNE2 cell 
lines. Despite this both cell lines showed comparable levels of inhibition. 
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Figure 5. 8 GANT treatment inhibits BrdU proliferation assay 
Normalised BrdU incorporation in CNE2 parental (left) and rEBV (right) infected 
CNE2 (top) and A549 (bottom) cell lines. Cells were plated at 2.5 x104 and allowed to 
settle for 24 hr prior to treatment with either GANT 58 (light grey) or GANT 61 (dark 
grey) for 48 hr compared to a negative control. BrdU incorporation was performed in 
accordance with the manufactures' instructions. BrdU was pulsed for 6 hr.*, P<0.05; 
**, P<0.01; ***, P<0.001. 
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5.2.2 Anchorage independent growth is enhanced by rEBV infection and 
dependent on Hedgehog signalling 
Having demonstrated an effect of HH pathway inhibition on cell proliferation, the 
effects of HH pathway inhibition on anchorage-independent growth was investigated 
in uninfected control and rEBV infected CNE2 (Figure 5. 9) and A549 (Figure 5. 10) 
cells. Cells were plated out in complete growth medium in the presence of increasing 
concentrations of GANT58 or GANT61. Compared to control uninfected cells, rEBV 
infected cell lines formed fewer colonies; however, the colonies that did form were 
substantially larger. Both GANT58 and GANT61 were found to significantly reduce 
the ability of both cell lines to form colonies and the size of the colonies that formed. 
Interestingly, both rEBV infected CNE2 and A549 cell lines were more sensitive to 
HH pathway inhibition than their uninfected counterparts. The CNE2 cell line was 
most sensitive to GANT61 treatment, which caused a six fold reduction in the number 
of colonies that formed. However, the A549 cell lines appeared to be more sensitive 
to GANT58. 
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Figure 5. 9 Inhibition of the HH signalling pathway impacts on CNE2 cell 
anchorage independent growth 
Cells plated out in triplicate at 5 x103 cells per well in a 12 well plate in 0.33% 
agarose solution containing 10% FCS and 1% RPMI, on a base of 1% agarose/ 1% 
RPM1/ 10% FCS. Inhibitors were added to a final concentration of 50 µM of GANT58 
(G58) and 25 µM GANT61 (G61). Cells were allowed to form colonies for 2 weeks. 
Three, non-overlapping, images were taken per well with an x4 objective lens. (A) 
Representative image of each treatment. (B) Number of colonies (P relative to 
control, n=3). All colonies of >25 µm were counted for each treatment. (C) The 
maximum diameter of all colonies within each photographed field of view were 
measured and plotted (P relative to control, n=3). Bars= 100 µm. Statistical analysis 
of colony number and size using T-test and one-way ANOVA followed by a Tukey’s 
multiple comparison respectively, where *, p<0.05; ** p<0.01; *** p<0.001 
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Figure 5. 10 Inhibition of the HH signalling pathway impacts on A549 cell 
anchorage independent growth 
Cells plated out in triplicate at 5 x103 cells per well in a 12 well plate in 0.33% 
agarose solution containing 10% FCS and 1% RPMI, on a base of 1% agarose/ 1% 
RPM1/ 10% FCS. Inhibitors were added to a final concentration of 25 µM of GANT58 
(G58) and 12.5 µM GANT61 (G61). Cells were allowed to form colonies for 2 weeks. 
Three, non-overlapping, images were taken per well with an x4 objective lens. (A) 
Representative image of each treatment. (B) Number of colonies (P relative to 
control, n=3). All colonies of >25 µm were counted for each treatment. (C) The 
maximum diameter of all colonies within each photographed field of view were 
measured and plotted (P relative to control, n=3). Bars= 100 µm. Statistical analysis 
of colony number and size using T-test and one-way ANOVA followed by a Tukey’s 
multiple comparison respectively, where *, p<0.05; ** p<0.01; *** p<0.001 
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m
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5.2.3 The ability to form spheres is enhanced by rEBV infection and 
dependent on HH signalling 
As with the C666.1 cell line, it was important to show that EBV induced HH signalling 
and CSC marker expression correlated with an induction of stem cell-like 
characteristics. Again the sphere-forming assay was used to assess the 
tumoursphere forming potential of rEBV infected and control uninfected CNE2 and 
A549 cells. Both rEBV infected CNE2 (Figure 5. 11) and A549 (Figure 5. 12) cell 
lines displayed an increased ability to form spheres in this assay, and the spheres 
that formed were larger than those produced by the parental cell lines demonstrating 
that these cells, like C666.1, contain cells with CSC-like properties. Furthermore, 
inhibition of the HH pathway with either GANT58 or GANT61 was sufficient to inhibit 
tumoursphere formation and growth. Again the CNE2 cell line was highly sensitive to 
GANT61 treatment, which completely obliterated sphere formation at a concentration 
of 25 µM, whereas the A549 cell line was more sensitive to GANT58 treatment. 
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Figure 5. 11 Inhibition of the HH signalling pathway inhibits sphere formation in 
the CNE2 cell line 
Cells were plated in triplicate at 1000 cells per well in 0.33% agarose solution 
containing 1%RPM1 and growth supplements. GANT58 (G58) and GANT61 (G61) 
used at a concentration of 50 µM and 25 µM total well volume respectively. Cells 
were allowed to form colonies for 3 weeks. Four, non-overlapping, images were 
taken per well with an x10 objective. (A) Representative image of each treatment. (B) 
Number of colonies (P relative to control, n=3). All colonies of >25 µm were counted 
for each treatment. (C) The maximum diameter of all colonies within each 
photographed field of view were measured and plotted using a box and whisker plot 
(P relative to control, n=3). Bar = 100 µm. Statistical analysis of colony number and 
size using T-test and one-way ANOVA followed by a Tukey’s multiple comparison 
respectively, where *, p<0.05; ** p<0.01; *** p<0.001 
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Figure 5. 12 Inhibition of the HH signalling pathway inhibits sphere formation in 
the A549 cell line 
Cells were plated in triplicate at 1000 cells per well in 0.33% agarose solution 
containing 1%RPM1 and growth supplements. GANT58 (G58) and GANT61 (G61) 
used at a concentration of 25 µM and 12.5 µM total well volume respectively. Cells 
were allowed to form colonies for 3 weeks. Four, non-overlapping, images were 
taken per well with an x10 objective. (A) Representative image of each treatment. (B) 
Number of colonies (P relative to control, n=3). All colonies of >25 µm were counted 
for each treatment. (C) The maximum diameter of all colonies within each 
photographed field of view were measured and plotted using a box and whisker plot 
(P relative to control, n=3). Bar = 100 µm. Statistical analysis of colony number and 
size using T-test and one-way ANOVA followed by a Tukey’s multiple comparison 
respectively, where *, p<0.05; ** p<0.01; *** p<0.001 
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5.3 Hedgehog signalling is required for stable latent infection in the C666.1 
cell line 
Whilst most of the studies outlined this far focus on the impact of HH signalling on 
various phenotypic effects in rEBV infected epithelial cells, it was decided to 
investigate the consequences of HH pathway inhibition on the behaviour of EBV in 
latently infected epithelial cells. C666.1 cells were cultured in the presence or 
absence of GANT58 or GANT61, used at 25 µM and 12.5 µM respectively, in 
combination with 50 µM 12-O-tetradecanoylphorbol-13-acetate (TPA) for 48 hr. RT-
PCR and western blot analysis Figure 5. 13A confirmed increased expression of the 
immediate early (IE) protein, BZLF1, upon treatment with both GANT58 and GANT61 
when combined with TPA. BZFL1 was not found to be induced in TPA treated cells; 
however some induction was seen in the GANT58 and GANT61 treated cells in the 
absence of TPA. These results indicate the requirement of HH signalling in the 
maintenance of stable latent infection. 
 
Further interrogation utilised immunofluorescence staining (Figure 5. 13B); treatment 
of cells with TPA and GANT inhibitors was found to induce the expression of BZLF1 
in approximately 5% of cells. This combined effect was greater than the BZLF1 
induced by either GANT58 or GANT61 treatment alone, or TPA treatment. 
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Figure 5. 13 GANT treatment sensitises the C666.1 cell lines to TPA induced 
lytic cycle 
(A) RT-PCR and western analysis, and (B) immunofluorescence demonstrating 
immediate early antigen BZLF1 induction upon GANT58 or GANT61 treatment in 
combination with a chemical inducer of differentiation, TPA. Bar = 50 µm. 
 
 
 
A. 
B. 
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5.3.1 Hedgehog signalling is required for stable latent infection in the EBV 
infected epithelial cell lines 
The effect of inhibiting the HH signalling pathway on the expression of EBV latent 
protein expression was investigated. GANT58 and GANT61 inhibitors, used at 25 µM 
and 12.5 µM respectively, were applied to CNE2 and A549 cell lines stably infected 
with rEBV for 48 hr. Protein and RNA was collected for analysis by RT-PCR and 
western analysis (Figure 5. 14). 
 
Induction of BZFL1 was found in the TPA and GANT double treated cells, particularly 
upon GANT58 and TPA treatment. GANT61 and TPA did not stimulate BZLF1 above 
the levels seen in the TPA only treated cells suggesting that 12.5 µM of GANT61 was 
insufficient to inhibit the pathway in this experiment. However, 25 µM GANT58 alone 
was sufficient to induce BZFL1 in both cell lines. 
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Figure 5. 14 HH inhibition sensitises CNE2 and A549 rEBV infected cell lines to 
TPA induced lytic cycle 
RT-PCR and western analysis of (A) CNE2 rEBV and (B) A549 rEBV cells upon 
GANT58 (25 µM) or GANT61 (12.5 µM) treatment in combination with a chemical 
inducer of differentiation, TPA (25 µM) 
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Figure 5. 15 Immunofluorescence staining for BZLF1 in CNE2 and A549 rEBV 
infected cell lines treated with TPA and HH inhibitors 
Immunofluorescence staining demonstrates HH inhibition, using 25 µM GANT58 or 
12.5 µM GANT61, sensitises (A) CNE2 rEBV and (B) A549 rEBV cells to TPA 
induced lytic cycle. Bar = 50 µm. 
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5.4 DISCUSSION 
HH signalling is required for the proliferation of CSC populations in a number of 
tissue types (Clement et al., 2007, Samarzija and Beard, 2012). Studies on colon 
cancer epithelial cells have demonstrated that down regulation of both GLI1 and 
GLI2 expression by RNA interference impacts on BrdU incorporation; supporting 
findings that GANT61, which targets both GLI1 and GLI2, is more effective at 
inhibiting proliferation in C666.1 cells than GANT58, which targets GLI1 only (Varnat 
et al., 2009). HH signalling is also known to influence cell proliferation through 
CCND1 and CCND2, which have previously been found to be upregulated in NPC 
gene expression arrays (Shi et al., 2006, Zeng et al., 2007b). Whilst CCND1 
expression was present in all tissue samples by microarray analysis, there was no 
significant upregulation in the NPC tumour samples, and inhibition of the HH 
signalling pathway in C666.1 produced only marginal effects on CCND1 expression 
by RT-PCR. This suggests that the HH dependent nature of cell proliferation does 
not require, or is not solely dependent on, the expression of CCND1. Additionally 
crosstalk between HH and other stem cell maintenance pathways may be 
responsible for the maintenance of cell proliferation; for instance NOTCH 
(VanDussen et al., 2012) and WNT (Kuhnert et al., 2004) can both modulate 
proliferation in epithelial cells. 
 
Whilst HH inhibition was shown to impact on SC/CSC marker expression in EBV 
positive carcinoma and rEBV infected epithelial cell lines in vitro, as reported in 
Chapter 4, it was necessary to show that this coincided with an inhibition of CSC-like 
characteristics in these cells. Stemness in vitro can be assessed by the ability of 
progenitor cells to form colonies in specialised serum-free medium supplemented 
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with defined growth factors (Song et al., 2011). While so-called “tumourspheres” 
could be propagated from the C666.1 cell line, indicating the existence of CSC-like 
cells in this cell line, tumourspheres could not be grown from the hTert immortalised 
OKTF6 or NP460 cell lines. Importantly, propagation of spheres from the C666.1 cell 
line was significantly reduced in the presence of GANT58 and GANT61, 
demonstrating that HH signalling is required for the CSC-like cells residing in the bulk 
population to proliferate. It is interesting to note that around 300 of 1000 cells formed 
tumourspheres, which may suggest around 30% of cells have sphere forming 
capacity. While CSCs are normally considered to represent a minor subpopulation of 
tumour cells, and exist as a small subpopulation in cancer derived cell lines, stem 
cell/ CSC profiling of the C666.1 cell line revealed expression of CD133 and CD44v6 
in 48% and 57% of cells respectively. This may suggest a role in the dysregulation of 
cell signalling pathways, including HH, in the expansion of the CSC population in 
NPC. However, this percentage of sphere forming cells may not provide a true 
representation of the number of CSC-like cells in a cell line, due to the diffusion of 
CSC growth factors from true stem cells which may stimulate the growth of 
surrounding cells. 
 
It is now widely accepted that whilst slow cycling, stem cells and CSCs display 
increased resistance to chemotherapy or genotoxic agents, anchorage independent 
growth, cell migration, and self-renewal. The HH dependent nature of anchorage 
independent growth and cell proliferation were investigated. The C666.1 cell line 
demonstrated a dose dependent inhibition of both anchorage independent growth 
and cell proliferation, as assessed by BrdU incorporation, following treatment with 
GANT58 and GANT61. Whilst the proliferation of CSC-like cells was not interrogated 
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directly, as these cells were not isolated from the bulk population, this study found 
that HH signalling is required for the growth of both the C666.1 cell line and parental 
and rEBV infected A549 and CNE2 cells. This HH dependent proliferation is also 
demonstrated in BCC; clinical trials targeting the HH signalling pathway have 
demonstrated that drugs such as Vismodegib can decrease tumour size (Cirrone and 
Harris, 2012) suggesting these inhibitors may target CSC and non-CSC populations. 
 
Anchorage independent growth is viewed as an important property of CSCs, allowing 
the migration and metastasis of cells that no longer require attachment to the 
extracellular matrix to survive, and is correlated with cell tumourigenicity (Shin et al., 
1975). In this respect, the targeting of CSC populations within a tumour is an 
attractive idea and, in the case of NPC, may be achieved through the selective 
targeting of the HH pathway. Indeed, inhibition of the HH pathway has been shown to 
impact on metastasis and invasion of pancreatic cancer, which like NPC 
demonstrates aberrant activation of the HH signalling pathway. Treatment of a 
metastatic pancreatic cancer cell line with the SMO inhibitor cyclopamine not only 
decreased cell proliferation, but also induced apoptosis and reduced 
migration/invasion. Furthermore, whilst HH inhibition did not reduce primary tumour 
growth in orthotropic xenograft mice models, it significantly reduced the rate of 
tumour metastasis, an effect that would impact positively on patient survival 
(Feldmann et al., 2007). NPC is a highly invasive and metastatic disease (Hsu and 
Tu, 1983), partly due to the late stage of prognosis due to tumour growth in a “silent” 
anatomical site (Wang et al., 2012a). Distant metastasis is the most important factor 
impacting on disease survival (Teo et al., 1996) and as such treatment that 
specifically targets cancer cell metastasis by inhibiting anchorage independent 
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growth and survival would likely improve prognosis. Anchorage independent growth 
is also induced in gastric carcinoma tumoursphere cells compared to adherent cells, 
and these proposed CSC containing tumoursphere cells also demonstrate increased 
expression of CD44 and CD133, and increased activity of the HH signalling pathway 
(Song et al., 2011). In this study by Song et al., (2011) blocking the HH pathway was 
seen to reduce the ability of gastric carcinoma cell lines to form tumourspheres.  
 
The work of Mani et al., (2008) introduced the notion that the induction of an EMT in 
mammary epithelial cells could result in the acquisition of mesenchymal traits and the 
upregulation of stem cell-associated markers. Whilst an EMT functions during 
development to facilitate the migration of stem and early progenitor cells regulating 
tissue patterning, the aberrant reprogramming of cells and the generation of an EMT 
endows CSC-like cells with invasive and metastatic properties. rEBV infection of 
CNE2 cells was associated with the induction of an EMT and the expression of EMT 
associated markers, the same was not true for A549 cells. However, the fact that 
stem cell marker expression and the acquisition of CSC-like characteristics was 
observed in both CNE2 and A549 cells demonstrates that the induction of these 
characteristics is not dependent on the induction of an EMT in rEBV-infected 
epithelial cells. Preliminary investigations failed to confirm if the induction of EMT in 
rEBV infected CNE2 cells was HH pathway dependent, the possibility exists that 
other onco-developmental pathways may cooperate with HH in this cell line to induce 
an EMT.  
 
EMT can be induced by numerous cell signalling pathways. As such, it is possible 
that dysregulation of a single pathway may not be sufficient to induce an EMT and 
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multiple pathways must act in concert. Members of the TGFβ family of proteins are 
known to induce an EMT in both normal differentiation and cancer progression (Yang 
and Weinberg, 2008, Massagué, 2008). It is also known that TGFβ has a role in stem 
cell maintenance and can act in concert with other signalling pathways, such as the 
NOTCH, WNT and integrin pathways, to induce an EMT (Polyak and Weinberg, 
2009). Furthermore in NSCLC, SHH expression has been found to be regulated by 
TGFβ, and is associated with the induction of an EMT and acquisition of a highly 
motile and invasive phenotype (Ali et al., 2011). 
 
Bone morphogenic proteins (BMPs) are members of the TGFβ family of proteins and 
are expressed in many adult tissues. BMPs have a role in maintenance and renewal 
(Balemans and Van Hul, 2002, Hogan, 1996, Chen et al., 2004) and disruption of 
BMP signalling has been observed in a number of cancers leading to decreased 
apoptosis, increased proliferation and metastasis (Alarmo et al., 2007, Miyazaki et 
al., 2004, Dai et al., 2008). Additionally, BMP has been associated with an EMT; in 
ovarian cancer SLUG and SNAIL are induced by BMP4 and the accompanying EMT 
was found to be dependent on BMP4 as inhibition with Noggin blocked the transition 
(Thériault et al., 2007). 
 
The WNT signalling pathway, as mentioned above, may act in concert with TGFβ in 
the induction of EMT and can itself induce this transition. Inhibition of β-catenin 
degradation, by reduced phosphorylation by glycogen synthase kinase-3β (GSK-3β), 
allows increased nuclear translocation of β-catenin where it acts to increase the 
expression of EMT inducing transcription factors. β-catenin overexpression is not 
sufficient to induce EMT as colorectal carcinomas harbouring an APC mutation, and 
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so displays increased levels of β-catenin, do not usually display a mesenchymal 
phenotype.  
 
Recently, a study by Kong et al., (2010) has identified a role for LMP2A in the 
epithelial mesenchymal transition (EMT). Here overexpression of LMP2A in the 
CNE2 and SUNE1 cell lines resulted in down regulation of epithelial markers and 
upregulation of mesenchymal markers. In addition, Kong et al., (2010) also 
demonstrated a link between EMT transition and the expression of markers 
expressed by embryonic and adult stem cell populations suggesting that the 
expression of LMP2A increases the percentage of side population-like and/or CSCs 
in these epithelial cell lines.   
 
Finally, this study suggests that inhibition of HH signalling may facilitate the 
reactivation of lytic cycle in C666.1 cells, as demonstrated by increased expression 
of BZLF1 in approximately 5% of cells. Further studies may wish to investigate lytic 
reactivation of EBV in cells treated with HH pathway inhibitors, and characterise the 
expression of other EBV lytic genes and proteins in response to different HH 
inhibitors. However, the C666.1 cell line may prove to be a flawed model as it is 
known to carry mutations in genes that are required for efficient virus replication; like 
the non-producing Raji EBV strain (Polack et al., 1984), it has a BALF2 deletion and 
cannot replicate its DNA during lytic cycle. Whilst further interrogation into the 
replication status of EBV in cells treated with HH pathway inhibitors was not 
undertaken, we postulate that a HH targeted therapy in NPC may not only decrease 
proliferation, migration/invasion, and induce apoptosis of HH dependent cancer cells, 
it may have a role in inducing lytic reactivation to assist antiviral therapy. 
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CHAPTER SIX: GENERAL DISCUSSION 
 
 
 
 
 
 
 
 
 
 “Nothing in science has any value to society if it is not communicated, and scientists 
are beginning to learn their social obligations.”  
— Anne Roe 
The Making of a Scientist (1953), 17.  
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6.1 Summary of the findings of this thesis 
Recent investigations into the aetiology of NPC have identified dysregulation of a 
number of stem cell maintenance signalling pathways (WNT, NOTCH, TGFβ, 
ACTIVIN and BMP) implicated in stem cell maintenance. This study, along with the 
work of Yue et al., (2012), has now identified dysregulation of the HH signalling 
pathway in this disease. While HH signalling pathway genes have previously been 
reported to be over expressed in NPC (Yang et al., 2001, Yip et al., 2006, Vera-
Sempere et al., 1997, Song et al., 2006), the contribution of this signalling pathway to 
NPC pathogenesis is unknown. Work outlined in this thesis builds upon recent 
findings and demonstrates the frequent dysregulation of the HH signalling pathway in 
primary NPC tumours and the authentic EBV positive NPC cell line C666.1. Whilst 
work presented here point toward a role for EBV-driven SHH ligand induction as a 
key factor in HH pathway activation, further work may wish to interrogate NPC 
tumours for the presence of mutations in pathway proteins such as PTCH, SMO and 
SUFU. These genes are frequently mutated in cancers that display aberrant HH 
signalling such as BCC which, like NPC, is characterised by an undifferentiated 
epithelial phenotype, and mutations would implicate multiple mechanisms of HH 
dysregulation in NPC. 
 
Activation of the HH signalling pathway was associated with the induction of putative 
stem cell markers, a number of which have previously been identified in NPC (Alajez 
et al., 2010, Song et al., 2009, Su et al., 2011, Lun et al., 2012). These included 
SC/CSC marker genes known to be induced by EBV latent gene expression in EBV 
negative nasopharyngeal epithelial cells (Kong et al., 2010, Kondo et al., 2011). Work 
outlined here reveals the HH dependent nature of stem cell marker expression in 
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EBV-infected carcinoma cell lines in vitro, and are supported by the studies of Lun et 
al., (2012) who demonstrated increased expression of stemness-associated genes 
and transcription factors in the cancer stem cell populations isolated from the C666.1 
cell line.  
 
Data presented in Chapter 4 demonstrate the ability of EBV to directly engage and 
activate HH signalling through the autocrine induction of SHH ligand and goes on to 
demonstrate that this activation is associated with the induction of stem cell marker 
gene expression and acquisition of CSC-like characteristics. Furthermore, preliminary 
experiments allude to the role of a number of EBV latent genes in the establishment 
of an activated HH signalling pathway and the expression of these stem cell markers. 
Interestingly, while EBNA1, LMP1 and LMP2A were all found to induce SHH ligand 
and activate the HH pathway, only LMP1 and LMP2A were able to induce the 
expression of stem cell marker genes. However, the fact that LMP1 and LMP2A, 
unlike EBNA1, were found to induce different stemness-associated marker genes 
suggests that these oncogenic membrane proteins may engage additional stem cell 
maintenance programmes that cooperate with the HH pathway to induce stem 
cell/CSC marker expression and induce CSC-like characteristics. These findings 
support previous studies showing that the EBV-encoded latent proteins LMP1 and 
LMP2A can induce the expression of stemness-related genes and impose CSC-like 
characteristics on NPC-derived cell lines in vitro (Kong et al., 2010, Kondo et al., 
2011).  
 
The expression of EBV latent protein LMP1 is induced upon the establishment of 
latency but is detected at low levels in established tumours (Strong et al., 2013). 
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Whilst only hypothetical, the finding that multiple EBV latent proteins can activate the 
HH signalling pathway may reflect different functions of these proteins. LMP1 may 
act to initially dysregulate the HH signalling pathway in premalignant cells, allowing 
stable latent EBV infection prior to clonal expansion, whereas LMP2A may 
subsequently maintain this signalling dysregulation. Indeed, LMP1’s ability to induce 
the initial dysregulation of this pathway is supported by the finding that, compared to 
EBNA1 and LMP2A, this viral protein could most strongly activate HH signalling. This 
effect may be linked to activation of NFB and mTOR, which are known to stimulate 
HH ligand expression and activate GLI1 activity respectively (Kasperczyk et al., 
2009, Wang et al., 2012c). Furthermore, activated HH signalling appears to be 
required for latent infection as HH pathway inhibition, in combination with TPA 
treatment, an inducer of differentiation, induces the expression of the immediate early 
lytic protein, BZFL1. The discovery that TPA inhibits HH signalling further supports 
the importance of HH signalling in the maintenance of EBV latency, presumably by 
maintaining an undifferentiated cellular phenotype. 
 
Finally, work presented demonstrated the importance of a dysregulated HH signalling 
pathway on the expression of stem cell/CSC marker expression and the acquisition 
of stem cell/CSC characteristics. EBV induced upregulation of stem cell marker 
expression was found to have phenotypic consequences that impacted on epithelial 
cell proliferation and ability of cells to form tumourspheres. Studies, which have 
utilised this assay, have relied on the previous demonstration that isolated putative 
stem cell populations from tumours in nude mice. NPC derived “side population” 
cells, isolated by their increased Hoechst dye effluxing ability, have been shown to 
have increased tumour-initiating capacity (Wang et al., 2007). This side population 
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phenotype was later found to be induced by LMP2A expression, with a concomitant 
induction of an EMT, upregulation of a number of putative stem cell markers and 
increased tumoursphere forming capacity (Kong et al., 2010). Similarly, expression of 
LMP1 has previously been found to increase CD44high/CD24low expression, a 
phenotype that is dependent on HH signalling in breast cancer (Tanaka et al., 2009), 
and induce tumour sphere formation and tumour initiation in nude mice (Kondo et al., 
2011). While an increased expression of CD44 and other stem cell/CSC markers, 
and enhanced tumoursphere formation in response to EBV infection has been 
presented here, further work is required to demonstrate that this translates to 
increased tumour initiation in animal models and investigate if HH inhibition can 
reduce tumour burden. These studies may demonstrate that HH is a potential 
therapeutic target for the treatment of EBV associated tumours. 
 
6.2 Targeting the HH signalling pathway in NPC treatment 
The role of HH signalling in the pathogenesis of NPC appears to be highly significant 
owing to the fact that dysregulation of this pathway may involve multiple 
mechanisms, rather than centralising around a single driving mutation or the 
overexpression of SHH ligand. Microarray analysis highlights overexpression of a 
number of different HH pathway components in different NPC tumours which can 
lead to the activation of downstream targets. Increasingly cancers are being 
characterised and divided into subtypes that respond differently to therapeutic 
intervention. As such future work may wish to categorise this HH dysregulation in 
NPC into distinct subtypes. Furthermore, interrogation into the driving mutation 
behind different NPC tumours may find that, whilst there is interaction and co-
operation between multiple signalling pathways in tumour development, tumours may 
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be dependent on one pathway at the expense of another. This has been the case in 
meduloblastoma for which transcriptome analysis have identified four distinct tumour 
subgroups: WNT, SHH, Group C and Group D, where the WNT and HH signalling 
pathways are believed to play the predominant role in pathogenesis of distinct 
tumour subtypes (Northcott et al., 2011). This is the age of personalised medicine, 
and NPC should be regarded not as a single disease but as an overriding 
classification of a carcinoma that can be caused by a number of distinct mutations; 
further interrogation will likely distinguish different subtypes of tumour that have 
different responses to different treatments. 
 
This thesis identifies, for the first time, the role of EBV in the dysregulation of the HH 
signalling pathway not only in NPC cell lines but in epithelial carcinoma cell lines of 
other origin. Furthermore, activation the HH signalling pathway was seen to induce 
proliferation, anchorage independent growth and the induction of a cancer stem cell-
like phenotype, which may contribute to the tumourigenic potential of these cells.  
 
Further work would likely investigate the ability of HH inhibitors to impede tumour cell 
growth in animal models to demonstrate the dependence of NPC growth on the HH 
signalling pathway in vivo, highlighting the potential use for HH inhibitors in 
therapeutic intervention. The transition of this work toward a therapeutic intervention 
is particularly exciting as HH inhibitors have already been successfully implemented 
in the treatment of a number of human cancers which demonstrate deregulated HH 
signalling (Von Hoff et al., 2009, Rudin et al., 2009, Irvine and Copland, 2012), and 
Vismodegib, a SMO inhibitor, has shown positive results in phase I trials (LoRusso et 
al., 2011, Sekulic et al., 2012) and achieved FDA approval (Von Hoff et al., 2009). 
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Recently Vismodegib has progressed to phase II clinical trials for the treatment of a 
diverse range of cancers; including BCC, ovarian, pancreatic, and gastric cancer, 
and basal-cell nevus syndrome (Cirrone and Harris, 2012, Catenacci et al., 2012, 
Tang et al., 2012, Kaye et al., 2012, Berlin et al., 2013). As such, studies may wish to 
investigate the anti-tumour effects of a number of different HH inhibitors, including 
those with FDA approval, on pre-established NPC tumour burden by measuring 
tumour growth and metastasis.  
 
Whilst EBV has been demonstrated to have a causative role in the pathogenesis of 
NPC our understanding of how the virus alters cell signalling and associated 
characteristics leading to oncogenic progression, and the stage during NPC 
pathogenesis that this dysregulation occurs, is still incomplete. Whilst inhibitors of the 
HH signalling pathway may prove a useful tool in the treatment of NPC, the induction 
of latently EBV infected epithelial cells into lytic cycle may provide a viable 
therapeutic strategy. In NPC, the latent EBV viral protein expression pattern is 
restricted to gene products (both RNA, miRNAs and proteins) that are necessary for 
tumour growth but, in addition, may allow evasion of the host immune system 
(Middeldorp et al., 2003). The induction of lytic cycle activates the expression of 
immediate early, early and late viral antigens that are known to be immunogenic 
(Hislop et al., 2007) and allows tumour cells to be targeted by the host immune 
system and antiviral therapy (Wildeman et al., 2012). Indeed, Wildeman et al., (2012) 
demonstrated that lytic induction by gemcitabine (GCB) and valproic acid (VPA), as 
measured by the increased expression of ZEBRA (BZFL1), as well as other EBV lytic 
genes, increased the cytotoxicity of valganciclovir (GCV) treatment in the C666.1 cell 
line. They went on to demonstrate that a combined therapy of GCB, VPA and GCV; 
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cytolytic virus activation therapy, demonstrated a biological response in three 
patients with end-stage NPC and even reduced tumour size. Additionally, an 
increase in viral DNA load in the blood during recovery periods between therapies 
was postulated to represent a recovering immune system with increased clearance of 
lytic reactivated cells; however, no increase in anti-EBV immune reactivity was 
observed (Wildeman et al., 2012). This work demonstrates that HH may have a role 
in maintaining viral latency and as such inhibition of the pathway may have a dual 
effect to target both tumour cell proliferation and assist in the immune detection of 
EBV infected tumour cells. 
 
Finally, we cannot overlook the case for a prophylactic EBV vaccine in the prevention 
of this disease, a top down approach to NPC treatment which would bypass the need 
for more the more complete comprehension of how cell signalling pathways are 
dysregulated in human cancer; an area of research which over the next few decades 
is likely to shed light on the mechanisms of oncogenic transformation. 
 
6.3 Implications of this work on our understanding of the origin of NPC  
Finding presented in this thesis, along with recent developments by other research 
groups, impact on our understanding on the aetiology of NPC by supporting the 
existence of CSC populations within NPC tumours. A number of groups have 
identified sub-populations of cells in NPC that express stem cell/CSC markers or 
have CSC-like characteristics (Wang et al., 2007, Kong et al., 2010, Zhang et al., 
2010, Lun et al., 2012); however, the origin of these cells is currently under debate. 
While work presented in this thesis suggest that EBV is involved in the expansion of 
this population, through aberrant activation on HH and/or other stem cell 
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maintenance pathways, a number of possibilities exist. Firstly, EBV may preferentially 
infect and subsequently expand an undifferentiated early progenitor cell, such as a 
stem cell, which already expresses stem cell markers. Alternatively, EBV 
engagement of stem cell maintenance pathways may promote the dedifferentiation of 
a more committed cell inducing the expression of stem cell/CSC-markers and the 
acquisition of CSC-like characteristics. Whilst findings from in vitro studies suggest 
that EBV may induce epithelial cell de-differentiation, it cannot rule out the possibility 
that stable latently infected epithelial cells are generated from CSC-like populations 
resident in the cell lines used in this study. Future studies should aim to purify these 
resident populations, based on stem cell or SP-like properties, and examine the 
efficiency with which stable EBV infected cell lines can be generated from sorted and 
unsorted populations. 
 
The fact that NPC is a relatively rare tumour which displays distinct geographical and 
ethnic prevalence is interesting given that EBV is a ubiquitous virus that infects 
greater than 95% of the population worldwide. Although still speculative, it suggests 
that EBV infection must occur in cells which harbour some genetic mutations, which 
promote the establishment stable latent infection in an epithelial background. Data in 
support of this idea come from the recent finding that hTert-immortalised 
nasopharyngeal epithelial cells, engineered to overexpress cyclin D1, are permissive 
for stable latent infection with EBV (Tsang et al., 2012), highlighting the importance of 
specific genetic and/or environmental factors in the initiation of this disease. 
 
In summary, findings presented in this thesis demonstrate that dysregulation of the 
HH signalling pathway is important for stable latent infection of epithelial cells and, 
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moreover, contributes to the proliferation and anchorage independent growth of EBV 
infected epithelial cells in vitro. As such, these findings may lead to a novel target for 
the treatment of NPC and other EBV-associated diseases.  
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